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ABSTRACT 
 
Comparison of the Prevalence and Genotypic Characteristics of Clostridium difficile in a 
Closed and Integrated Human and Swine Population in Texas. (August 2010) 
Keri Noelle Norman, B.S., Miami University 
Co-Chairs of Advisory Committee: Dr. H. Morgan Scott  
                                    Dr. Bo Norby 
 
 Clostridium difficile has been recognized as one of the leading causes of 
nosocomial diarrhea and pseudomembranous colitis in human hospitals and nursing 
homes since the 1970s; however, recent occurrences of community-acquired cases have 
led researchers to search for additional sources of these infections.  Some of the possible 
sources being investigated include food animals and retail meat.  The objective of this 
study was to compare the prevalence and genotypic characteristics of C. difficile isolated 
from a closed population in Texas consisting of both humans and swine.  Implicit in this 
objective, we seek to investigate the possible food safety and occupational risks 
associated with swine and C. difficile.   
Isolation of C. difficile was performed utilizing an enrichment technique and 
restrictive media.  Polymerase chain reaction (PCR) was used to test for the presence of 
the toxin A and B genes, the tcdC gene deletion, and the binary toxin gene.  Genotypic 
characteristics were compared using PCR toxinotyping and pulsed-field gel 
electrophoresis (PFGE).  Antimicrobial susceptibility was tested using commercially 
available tests (ETest®) for 11 different antibiotics.  Statistical comparisons (both 
 iv 
parametric and non-parametric, and appropriate to the data) were performed both 
between and among host species.  
We tested 2,292 aggregated human wastewater samples and 2,936 swine fecal 
samples from 2004 to 2006 and found 271 (11.8%) and 252 (8.6%) to be positive for C. 
difficile, respectively.  The prevalence of C. difficile among swine production groups 
differed significantly (p<0.05); however, prevalence in the human occupational group 
cohorts (swine workers and non-workers) did not differ (p=0.81).  The majority of the 
human and swine isolates were a PFGE NAP7 (a variant pattern with 90.5% similarity) 
toxinotype V strain.  Antimicrobial resistance levels and multi-resistance patterns were 
generally similar between host species; however, there was decreased susceptibility 
(p<0.05) to ampicillin, clindamycin, and imipenem observed in swine isolates, whereas 
there was decreased susceptibility (p<0.05) to ciprofloxacin in the human isolates. 
The similarity in C. difficile prevalence between swine workers and non-workers 
suggests a low occupational hazard of working with swine as it relates to C. difficile 
source.  We also found that there is a decreased prevalence of C. difficile in late 
production groups in swine suggesting a lowered risk of food-borne exposure.  However, 
the majority of the isolates derived from the human wastewater and swine appeared to be 
of very similar strain types, suggesting that a common environmental point source 
predominates for both hosts. 
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MIC  Minimum inhibitory concentration 
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NAP North American pulsed-field type 
PCR Polymerase chain reaction  
PFGE Pulsed-field gel electrophoresis 
PYG Peptone yeast glucose 
RO Reverse osmosis 
TCDMNB Sodium taurocholate Clostridium difficile moxalactam norfloxacin 
broth  
 
TCCFB Sodium taurocholate cycloserine cefoxitin fructose broth  
VL Viande-Levure broth  
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1. INTRODUCTION 
 
1.1. Background 
Clostridium difficile is one of the most common causes of nosocomial, or 
hospital-acquired infections (1).  Clostridium difficile primarily affects individuals with 
an altered gut flora; this occurs predominately through antibiotic use.  This anaerobic, 
Gram-positive bacterium produces spores that are both heat- and alcohol-resistant and is, 
therefore, easily transferred between patients and equipment in hospitals.  Clostridium 
difficile has been found to colonize approximately 20% of hospitalized patients versus 
3% of healthy adults (2).  Clostridium difficile was originally discovered in the gut flora 
of infants; however, since infants lack the toxin binding receptors in the colon for C. 
difficile, it does not readily cause disease in that age group (3, 4).  As an infant matures, 
C. difficile is replaced by other bacteria (commensals) found in the normal gut flora of 
healthy adults. 
1.1.1 Description 
Vegetative C. difficile cells are shed along with spores in the feces of patients 
infected with the bacterium.  It has been shown that vegetative cells survive in an 
aerobic environment for 15 minutes, whereas, spores can survive for a minimum of 24 
hours and often survive for much longer periods of time.  Vegetative cells grown on 
nutrient-rich agar can survive under aerobic conditions for approximately 3 hours (5).  
Clostridium difficile agar-cultured colonies are large, flat, and have a broken-glass   
_____________ 
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appearance.  Gram staining reveals straight rods with subterminal spores ranging in 
length from 3 to 7 µm and 0.5 to 2 µm in width.  One of the few specific biochemical 
tests for C. difficile is the production of the enzyme L-proline-aminopeptidase.  The 
bacterium is typically grown on selective media containing cycloserine, cefoxitin, 
fructose, and neutral red (6).  Clostridium difficile is resistant to cycloserine and 
cefoxitin at concentrations of 250 mg/L and 8 mg/L, respectively (7).  Clostridium 
difficile ferments fructose and when used in conjunction with neutral red as a pH 
indicator the colonies have a yellow appearance on the plates (6). 
 Clostridium difficile contains two large proteins, toxin A and toxin B, that are the 
major pathogenicity factors.  Toxin A is described as a weak cytotoxin and an 
enterotoxin and toxin B is a cytotoxin.  A cytotoxin has toxic or destructive effects on 
certain cells and the toxins in C. difficile work on several different types of cells.  
Enterotoxins are protein toxins released in the gastrointestinal tract that cause vomiting, 
diarrhea, and abdominal pain (8).  The genes that encode for these proteins (tcdA and 
tcdB) are closely linked and transcribed in a similar manner (9).  The negative regulation 
of the toxin genes is controlled by the tcdC gene.  This gene prohibits the production of 
toxin genes until the cell is in the log growth phase (10).  There have been several 
common deletions found in the tcdC gene of some strains of C. difficile.  Some of the 
common deletions include an 18-bp deletion found in toxinotype III strains and a 39-bp 
deletion found in toxinotype V isolates.  Several researchers have found that deletions in 
the tcdC gene caused strains to become more virulent due to increased toxin production 
(11).  Pathogenic strains of C. difficile also contain a binary toxin gene (cdt).  The roles 
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and importance of this gene in the pathogenicity of C. difficile are not yet known (12). 
The pathogenicity locus (PaLoc), where these genes are located, also contains tcdD and 
tcdE genes.  The roles and importance of these genes are still under investigation (10). 
1.1.2 History  
 Clostridium difficile was first isolated from the stools of infants by Ivan C. Hall 
and Elizabeth O‟Toole in 1935 and was found to be part of the normal gut flora of 
infants.  They called the bacterium Bacillus difficilis, because it grew slowly in culture 
and was difficult to isolate (4).  Isolation of Clostridium difficile from humans was not 
reported again until 1943.  From 1943 to 1961 there were eight reported isolations of C. 
difficile from hospitalized patients.  The bacterium was isolated from a variety of sources 
and patients with varying demographic characteristics.  In 1943, C. difficile was found in 
the muscle tissue of a soldier who died from gas gangrene; in 1957 from an abscessed 
fracture in an adult male; in 1957 from the blood of a male infant; in 1959 from the 
pleural fluid of an elderly male; in 1959 from peritoneal fluid of an adolescent girl; in 
1959 from pleural fluid of an elderly male; in 1959 from an elderly woman with fatal 
peritonitis; and in 1961 from an abscess in an adult woman (13). 
In 1977, C. difficile was found to be the cause of antibiotic-associated 
pseudomembranous colitis (14).  Pseudomembranous colitis is manifested as severe 
inflammation with copious inflammatory byproducts in the colon that are produced by 
the disruption of the normal gut flora following the administration of antibiotics (15).  
Since its discovery as the cause of pseudomembranous colitis, C. difficile has been 
identified as a common problem in hospitals and nursing homes.   
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1.1.3  Taxonomy 
 The association between C. difficile and pseudomembranous colitis, antibiotic-
associated diarrhea, and inflammatory bowel disease led researchers to study more 
carefully C. difficile throughout the late 1970‟s and 1980‟s.  In the early 1980‟s, 
scientists began to experiment with different typing schemes to differentiate between 
strains of C. difficile.  The first typing scheme involved bacteriophages (16-18).  Another 
typing method that was used in the late 1980‟s was sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) of sulphur-35-methionine-labeled 
proteins (19, 20).  Researchers found the method to be simple, rapid, and reproducible; 
however, there were strains that they were not able to type (19).   
In 1987, a correlation was found between groups of C. difficile typed by SDS-
PAGE and toxin production.  Researchers found that isolates that did not produce toxin 
were in a different group from those strains that produced toxin (21).  At the same time, 
a study was published comparing restriction endonuclease DNA analysis (REA) with 
SDS-PAGE as a typing method (20).  This method was used to type isolates that 
previously could not be typed using bacteriophage or SDS-PAGE and the researchers 
found that the HindIII restriction enzyme was the most suitable for REA (22).  The first 
paper describing a ribotyping technique was published in 1993 (21).  This typing method 
used polymerase chain reaction (PCR) to look at variable lengths in the 16S and 23S 
rRNA intergenic spacer regions.  This method was used to type more isolates than the 
bacteriophage or SDS-PAGE methods and the results were easier to read than REA, 
because fewer bands were produced (23).  By the mid-1990‟s, pulsed-field gel 
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electrophoresis (PFGE) was also used and compared to other typing methods for C. 
difficile.  PFGE uses restriction enzymes to cut DNA into large fragments that are then 
run through a gel where the voltage is periodically switched between three directions 
(24-26).  In 1998, a new typing method was introduced that looked at the differences in 
the genes coding for the toxin A and toxin B genes.  In this method, referred to as 
toxinotyping, PCR was used to amplify the toxin genes and then restriction enzymes 
were used to observe restriction fragment length polymorphisms (RFLP‟s) (27).   
 Currently, the three most widely reported typing methods are toxinotyping, 
ribotyping, and PFGE.  PFGE is more commonly used in the United States, whereas 
ribotyping is more commonly used in Europe (28).  Toxinotyping is a relatively easy 
way to subtype isolates, because it uses well-published and standardized PCR and REA 
techniques (27).  Several different toxinotypes can fall into the same PFGE or ribotype 
group; however, the number of PFGE and ribotyping patterns found exceeds the number 
of toxinotypes.  Isolates in the same toxinotype have many identical characteristics such 
as presence or absence of the toxin genes, presence or absence of the binary toxin gene, 
and size of the tcdC gene deletion, and yet this often provides little information 
regarding the relatedness of the strains (29).  PFGE and ribotyping produce visual 
banding results that are more readily comparable using dendrograms than toxinotyping, 
but also have their disadvantages.  PFGE is requires expensive equipment and is time 
consuming; however, it produces banding patterns that are easily interpreted.  
Ribotyping does not require expensive equipment; however, banding patterns are more 
difficult to interpret (30).  There are no worldwide standardized typing protocols for C. 
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difficile and new typing methods, such as multilocus variable-number tandem-repeat 
analysis (MLVA) and multilocus sequence typing (MLST), are still in early stages of 
investigation (31).  MLVA exhibits a high level of discrimination; however, some 
researchers have ironically found it to be too discriminatory with similarities between 
strains that were seen with PFGE no longer apparent in a MLVA dendrogram (29).  
MLST is more labor intensive than the other techniques, because it sequences multiple 
loci and a limited number of researchers have access to sequencing equipment; however, 
the data produced is consistent between laboratories and can reveal genetic lineage 
between strains (29, 32).  The field molecular microbiology is very “fluid” and likely to 
change in the near future as costs decrease exponentially, making it important to report 
and compare as many typing methods as is practicable, along with conserving isolated 
strains for future analysis. 
1.1.4 Clinical significance 
Clostridium difficile is a major problem in hospitals and nursing homes and costs 
the United States health care system nearly $1.1 billion per year.  Patients infected with 
C. difficile experience symptoms ranging from diarrhea to severe cases of colitis that 
may result in death (33).  Patients testing positive for presence of C. difficile in stool 
samples and also experiencing symptoms such as diarrhea are presumptively diagnosed 
as having C. difficile-associated disease (CDAD).  Treatment of CDAD is difficult 
because of its direct causal relationship with antibiotic use.  Initial treatment of C. 
difficile usually involves immediate discontinuation of antibiotic treatment followed by 
fluid replacement.  If this treatment is ineffective, the most common antibiotics 
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prescribed are metronidazole and vancomycin.  However, resistance of C. difficile to 
metronidazole and vancomycin sometimes leads to treatment failure or relapses of 
infection (34).  The risk of C. difficile infection is increased if the bacteria are resistant to 
antimicrobials drugs (35). 
1.1.5 Study significance 
Recently, attention has been given to a new strain of C. difficile (PFGE type 
NAP1, REA group B1, ribotype 027, toxinotype III) that is believed to be more virulent 
than previously cultured strains (36, 37).  Outbreaks of this hyper-virulent strain have 
been seen both in North America and Europe (36, 38).   This strain contains an 18-bp 
deletion in the tcdC gene, which is a negative regulatory gene for the production of 
toxins A and B (11, 39, 40).  It is believed that a deletion in this gene leads to increased 
toxin production, because of decreased inhibition of toxin production (41).  This strain 
also contains a binary toxin gene that was rarely found in previously reported strains 
(42).  The role of the binary toxin in the pathogenicity of the bacteria is not yet known; 
however, it is believed to be partially responsible for the increased virulence of 
toxinotype III isolates (43, 44).   
The emergence of community-acquired C. difficile infections in the last few 
years has completely changed the previous perception that C. difficile was primarily a 
hospital or antibiotic-treatment related acquired infection.  Community-acquired cases 
are classified as patients with no history of hospitalization and many of them also have 
no history of antibiotic use (45).  In the past, patients infected with C. difficile were 
easily identified as having one or several well known risk factors, including 
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hospitalization, antibiotic use, and were often elderly individuals.  The risk factors for 
and source of community-acquired infections is not known; however, there are several 
hypotheses that are currently being investigated (46).  Some of the hypotheses being 
investigated include food-borne exposure, companion and food animal exposure, 
environmental exposure, use of proton pump inhibitors, and microbiological laboratory 
exposure (47-60).   
Clostridium difficile has been isolated from food animals including swine, 
chicken, and cattle.  Some strains isolated from swine have shown as much as an 80% 
similarity to those isolated from humans (54).  Clostridium difficile has also been 
isolated from retail meat (48, 56).  The finding of C. difficile in food animals and retail 
meat raises concern for the potential for both food-borne and occupational exposures. 
1.2  Study objectives 
The objectives of this study were to compare the prevalence and genotypic 
characteristics of C. difficile isolated from closed and integrated human and swine 
populations in Texas from 2004-2006.  We compared the prevalence of C. difficile in the 
various swine production groups to explore the potential for food-borne exposure in 
market-aged pigs.  The prevalence in a swine worker cohort was compared to a non-
worker cohort to explore possible occupational exposure.  The isolates from the swine 
and human samples in this closed population were compared to determine genotypic 
similarity of isolate carriage among the two host species. Finally, we compared both 
within and between the host species the antimicrobial susceptibility of isolates arising 
from this closed population
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2. LITERATURE REVIEW 
 
 
2.1 Background  
 Clostridium difficile is one of the most common causes of nosocomial diarrhea 
(61).  Many studies have been conducted looking at the risk factors for C. difficile-
associated disease (CDAD) in hospitals and nursing homes (62-66) and ways to both 
prevent (67-73) and treat the disease (74-80).  Recently, cases of CDAD have been 
found in populations previously considered to be low-risk, and the focus of C. difficile 
studies has shifted to understanding community-acquired cases of CDAD (36, 44, 81-
82).  Community-acquired CDAD (CA-CDAD) has been discussed in the literature since 
the 1990‟s (81); however, the studies themselves were not designed to investigate the 
fraction of community-acquired cases among the overall total (including nosocomials), 
and it is arguable as to whether or not these cases are truly community-acquired.   
As these community-acquired cases began to be recognized, studies were 
conducted to evaluate risk factors associated with these cases.  Factors including 
antibiotic use, age, and underlying conditions that are typically associated with hospital-
acquired CDAD were also found to be associated with CA-CDAD (82-84).  However, 
there remained cases of CA-CDAD that were not associated with any of these common 
risk factors (85).  Recently, the two most commonly investigated risks for CA-CDAD 
have been the use of gastric acid suppressants (86) and exposure to food animals and 
their products (51-54, 58, 87, 88).   
Researchers hypothesize that changes in the digestive tract from gastric acid 
suppressants may facilitate the colonization of C. difficile or promote the survival of 
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spores (89).  There have been studies both supporting (59, 90-92) and refuting (93, 94) 
gastric acid suppressants as a risk factor for hospital-acquired CDAD and this is a 
hypothesis currently being heavily investigated for CA-CDAD. 
 Clostridium difficile has been isolated from a variety of food animals including 
swine, cattle, and chickens (51-54, 58, 87, 88).  Clostridium difficile is suspected to 
cause diarrhea in calves (95) and is a known cause of pseudomembranous colitis and 
enteritis in piglets (87, 96-99).  The finding of C. difficile in food animals has led 
scientists to speculate that they may be a source of CA-CDAD.  Studies evaluating the 
transmission of the bacterium between animals and humans have focused on the 
molecular similarity between strains (53, 54, 100-102), and one study found 100% 
similarity between swine and human strains (54).  Further findings of C. difficile in retail 
meat intended for human consumption has led to more research and continued studies in 
this area (48, 50, 103). 
 There have been limited studies investigating the significance of asymptomatic 
human carriers of C. difficile (104, 105).  The majority of investigations have been 
conducted in health care facilities and do not typically address the concerns of 
community-acquired cases.  Asymptomatic carriers may serve as an important source 
and route of transmission for CA-CDAD.  Conducting studies on CA-CDAD in the 
population-at-large is difficult and human wastewater samples may provide a valuable 
source to obtain information enteric bacteria arising from human populations outside 
health care facilities.  Clostridium difficile has been detected in biosolids from 
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wastewater facilities (106); however, the relevance of these findings to human 
populations is unknown. 
2.2 Community-acquired Clostridium difficile 
 Community-acquired C. difficile infections have recently gained attention, 
because of their occurrence in low-risk populations and an increase in the number of 
CDAD patients with no previous history of hospitalization (45).  Studies conducted since 
the 1990‟s have compared community-acquired CDAD to hospital-acquired infection 
(37, 44, 81, 107-109); however, until recently there have been few reported studies that 
have explored the risk factors associated with community-acquired infections.  The most 
common risk factor for CA-CDAD is previous antibiotic use (82-84); however, there are 
many cases of community-acquired CDAD with no history of antibiotic use.  Gastric 
acid suppressants are one of many other risk factors being explored for community-
acquired CDAD (86).   
2.2.1 Community- vs. hospital-acquired Clostridium difficile  
Community-acquired (CA) C. difficile was first mentioned in 1990 in a 
prospective case-control study examining the incidence of C. difficile in hospitalized 
children (81).  The researchers compared the prevalence of C. difficile in children with 
gastrointestinal symptoms or who had received antibiotics (the cases; n=337) to children 
without gastrointestinal symptoms or who had not received antibiotics (the controls; 
n=57).  The authors concluded that the majority of the C. difficile infections were, in 
fact, community-acquired, rather than hospital-acquired, since infection was typically 
detected within the first 48 hours of hospitalization.  The authors failed to mention 
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whether the patients‟ previous history of hospitalization was recorded.  They found that 
96% of the patients with either (or both) gastrointestinal symptoms or previous antibiotic 
treatment had culturable C. difficile in their stools.  On the other hand, 5% of the control 
patients (i.e., with no gastrointestinal symptoms or previous antibiotic treatment) had C. 
difficile in their stools.  When only comparing patients previously treated with antibiotics 
to patients without antibiotic treatment (patients with and without gastrointestinal 
symptoms were omitted), no difference in C. difficile infection rate was found.  One of 
the problems with this report is a lack of data about the age of the children in the study, 
which could confound the interpretation of results.  Clostridium difficile has been found 
to be a part of the gut flora of healthy infants.  All of the patients with no gastrointestinal 
symptoms or previous antibiotic use who had a positive stool sample for C. difficile were 
0 to 2 months in age (81).  The authors failed to provide the age distributions among the 
cases and controls to eliminate the possibility that there is an age-related confounding 
effect.  The authors themselves even suggest that there would be an increased risk of C. 
difficile infection in children 6 to 12 months in age, because this is when they begin to 
attend day care.  The conclusion that the C. difficile infections in this study were 
community-acquired appears to be premature given that no data on the history of 
previous hospitalization was provided and the data may need to be adjusted for age.  
This is one of the first articles to recognize and investigate community-acquired C. 
difficile among patients.  It is also interesting to note that there were cases of C. difficile 
with no history of antibiotic use; however, it is not known whether these cases were truly 
community or hospital-acquired. 
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In 2006, another study was conducted concerning the epidemiology of C. difficile 
in pediatric patients in California, once again identifying cases of community-acquired 
C. difficile (107).  This study collected data on pediatric patients in two different 
hospitals (one freestanding pediatric hospital and one hospital serving all ages) and 
tested stool samples for the presence of C. difficile.  Using the data collected from the 
patients, the authors identified several risk factors for C. difficile colonization in 
children, and tested the significance of these factors using univariate and multivariable 
logistic regression.  The authors concluded that the majority of their C. difficile isolates 
were community-acquired, because they had unique arbitrarily primed PCR fingerprints; 
however, there were some similar fingerprints, that may be evidence of nosocomial 
transmission.  The authors found that prior hospitalization, prior infection with C. 
difficile, use of 2 or more antibiotics, and underlying conditions (i.e., any medical 
condition requiring frequent and long-term medical intervention) were associated with 
risk of a positive stool sample.  We do not know if the isolates with unique fingerprints 
were from patients with these risk factors or not.  A positive stool sample in conjunction 
with any of these risk factors could be classified as a nosocomial infection, regardless of 
whether or not it had a unique PCR fingerprint.  A unique PCR fingerprint alone is not 
evidence that an isolate is community-acquired (especially since the organism is so 
prevalent in the environment).  Clostridium difficile spores can survive in the 
environment for long periods of time and patients may not become clinically ill with C. 
difficile until several weeks after they have been released from the hospital.  Also, as in 
the previously cited article, other pathogens including E. coli, Salmonella, and Shigella 
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were identified in the stool samples along with C. difficile.  Little is known about how C. 
difficile interacts with other bacteria in the gut, and it is possible that different strains of 
C. difficile are more commonly found in association with other bacteria.  It is difficult to 
conclude from the evidence presented in this article whether or not these truly were 
community-acquired cases of C. difficile. 
The epidemiology of CDAD was observed from 2000 to 2004 in a retrospective 
study published in 2007 (37).  A case of CDAD was considered community-acquired if 
diarrhea occurred in the patient within 72 hours of admission to the hospital or if the 
patient had not been hospitalized within the past month.  During the study, 2,257 patients 
had C. difficile fecal culture performed as directed by a physician, and, of these, 151 met 
the case definition of CDAD (diarrhea in a hospitalized patient with either (or, both) a 
positive stool cytotoxicity assay or else toxigenic culture for C. difficile).  The majority 
of the patients with CDAD were classified as hospital-acquired (81%); however, 19% of 
them were classified as community-acquired.  One of the interesting findings in this 
study is that only 10% of the cases that were considered hospital-acquired were infected 
with strains similar to those found in other patients hospitalized around the same time 
period.  The previously mentioned article by Rexach et. al. (107) classified cases as 
community- or hospital-acquired based purely on DNA fingerprints of the strain, but this 
study suggests that patients with characteristics of hospital-acquired infections did not 
necessarily have similar DNA fingerprints.  The authors of this study concluded that 
only 10% of the hospital-acquired infections were the result of other symptomatic 
patients and that the other 90% of hospital-acquired infections were a result of 
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asymptomatic carriers in the hospital.  They also found that the strains responsible for 
hospital-acquired infections were similar to the strains responsible for community-
acquired cases of CDAD.   
A retrospective case-control study investigating the role of binary toxin positive 
isolates in CDAD found an association between binary toxin isolates and community-
acquired cases (44).  Cases were defined as patients with antibiotic-associated diarrhea 
(AAD) due to a binary toxin positive C. difficile isolate.  Cases were matched to two 
controls on the basis of hospital ward and date of hospitalization.  Controls were 
sampled from patients with AAD caused by a binary toxin negative C. difficile isolate.  
Univariate analysis found that cases with binary toxin positive isolates were more often 
associated with community-acquired infections.  One of the problems with this study 
was that the authors did not define community-acquired infection, which makes it 
difficult to compare their results to other studies.  Another concern with this study is the 
small sample size.  There were 26 cases and 42 controls, and they were only able to 
match two controls to 16 of the cases; the remaining 10 cases were matched to a single 
control.  This shows that they had a limited number of binary toxin- negative C. difficile 
isolates.  It is difficult to explore an association between community-acquired infection 
and binary toxin negative C. difficile isolate status when other variables such as age, sex, 
and type of antibiotics are not also taken into account in the model.  Further research is 
needed to evaluate whether there is an association between binary toxin isolates and CA-
CDAD. 
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A study conducted in Hungary in 2004 also concluded that there was an 
association between binary toxin C. difficile isolates and CA-CDAD (109).  Researchers 
analyzed 112 C. difficile isolates from both inpatients and outpatients to report on the 
different toxin types found across the country.  The authors found that 79 of the isolates 
were positive for toxin A and toxin B, while the remaining 33 isolates were negative for 
toxin A and toxin B.  They did not report any isolates that were negative for toxin A and 
positive for toxin B.  Two of the isolates that were positive for both toxin A and B were 
also positive for the binary toxin.  Further data were collected from those patients 
harboring the binary toxin- positive strains.  It was found that both cases of CDAD were 
community-acquired.  Neither patient had any previous history of hospitalization; 
however, both patients had been treated with antibiotics at the onset of diarrhea.  The 
authors of this study concluded that binary toxin-, toxin A-, and toxin B-positive isolates 
may be responsible for cases of community-acquired C. difficile infection.  The authors 
do not supply any information regarding how many of the isolates were community-
acquired versus hospital-acquired.  These further data concerning history of 
hospitalization and antibiotic use were collected only from the two strains that were 
binary toxin-positive.  Because we do not know how many of the cases were 
community-acquired, it is difficult to determine associations between the binary toxin-
positive strains and community-acquired infection.  Since only two of the isolates were 
binary toxin-positive, most likely there was a higher prevalence of community-acquired 
cases that were binary toxin-negative.  Also, both of the binary toxin-positive cases were 
receiving antibiotics at the onset of diarrhea and this is most likely the primary reason 
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for infection.  The type of antibiotics the patients were taking may also have selected for 
a particular strain of C .difficile and this may be why these two cases had binary toxin-
positive isolates.  In order for the authors to form hypotheses about binary toxin positive 
strains and community-acquired infection, they needed to have collected further detailed 
information from all of the 121 cases. 
Clostridium difficile-associated disease is not a problem unique to the United 
States; there have also been large outbreaks reported in Canada and Europe.  A study 
was conducted in 2004 to observe the epidemiology of CDAD in a county in central 
Sweden (108).  That study comprised three different hospitals that served the 274,000 
inhabitants of the county.  A total of 372 cases of CDAD arising in 335 patients from 
February of 1999 to January of 2000 were further investigated.  CDAD was defined as 
diarrhea and presence of a toxin-positive C. difficile isolate or else presence of C. 
difficile toxin in the feces.  A community-acquired case was defined as a patient with 
CDAD and without recent hospitalization.  Ribotyping was performed on 330 of the 
isolates to compare strains and track nosocomial infections.  They found that 59 of the 
372 cases (22%) were community-acquired and 98% of the cases had a history of 
antibiotic use.  It was not reported as to whether the 2% of cases without antibiotic use 
were community- or hospital-acquired.  The 22% case fraction of community-acquired 
infections is similar to the 28% reported in a previous study in Sweden (110).   All of the 
ribotypes were equally represented among the community- and hospital-acquired cases, 
except for ribotype SE17, which was found in 93% of the hospital-acquired cases.  There 
are several factors that make it difficult to compare the prevalence of community-
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acquired cases reported in this study with other studies.  The first problem is that the 
definition of community-acquired cases is not explicit.  Recent hospitalization could 
refer to days, months, or years.  Also, it is difficult to compare studies from different 
countries, because of different health care systems; these may contribute to a varied 
demographic of patients that visit the health care facilities as well as the diagnostic tests 
conducted at each facility based on the patient‟s ability to pay.  The health care facilities 
in Sweden are financed by the county council and medical visits are less costly for 
patients than in the United States; this, in turn, may lead to an increase in testing for 
CDAD.  Studies from the United States reported a lower prevalence of community-
acquired cases and this may simply be due to less frequent testing for C. difficile in 
patients without a previous history of hospitalization (82, 111).  
None of the studies mentioned above were specifically designed to study CA-
CDAD.  Several of the studies surveyed C. difficile in health care facilities or outpatient 
clinics and from the data collected attempted to classify cases of CDAD as either 
community- or hospital-acquired.  The prevalence of CA-CDAD varies among these 
studies and comparing the data is difficult due to both the differing case definitions for 
CA-CDAD and the differences in the study populations.  It is difficult to estimate the 
true case fraction of community-acquired cases of C. difficile and this most likely will 
vary between jurisdictions with differing demographic profiles.  However, the 
identification of C. difficile in low-risk populations, such as those with no history of 
hospitalization or previous antibiotic use, is important and further studies need to be 
conducted to better identify the sources and risk factors of these community-acquired 
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infections.  One of the ways to identify potential sources is to identify risk factors 
commonly associated with these community-acquired cases. 
2.2.2 Risk factors associated with community-acquired C. difficile 
Results from several studies designed to examine risk factors associated with 
CA-CDAD have been published.  The risk factors investigated include: antibiotic use, 
sex, age, and the use of proton pump inhibitors.  Several of the risk factors, such as 
antibiotic use, previously known to be associated with hospital-acquired infection have 
also been found to be associated with community-acquired cases.  Other potential risk 
factors, such as gastric acid suppressants, exhibit conflicting evidence as to their 
association with CA-CDAD.   
 A retrospective cohort study published in 1994 observed the epidemiology of 
CA-CDAD and possible risk factors associated with infection such as antibiotic use, sex, 
and age (82).  Data were collected from the Harvard Community Health Plan, one of the 
largest health maintenance organizations (HMO) in New England.  Patients from the five 
hospitals in the HMO whose primary reason for hospitalization was not psychiatric or 
substance abuse were included in the study.  All hospitals maintained records on patients 
with C. difficile toxin assays run from April of 1988 to November of 1990.  CDAD was 
defined as a patient with both symptoms of diarrhea or colitis and a positive C. difficile 
toxin assay.  A CA-CDAD patient was further defined as CDAD with either: 1) onset of 
diarrhea at least 42 days after the most recent hospitalization, 2) onset within 48 hours of 
hospital admission, or 3) admission to a hospital exhibiting gastrointestinal symptoms 
and a positive C. difficile toxin assay result arising within 5 days.  There were 51 cases 
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of CA-CDAD and 54 cases of hospital-acquired CDAD identified out of the 619 C. 
difficile toxin assays administered.  The median age of the patients with CA-CDAD was 
37 and 63% of the cases were female.  There was a large percentage (43%) of patients 
with CA-CDAD harboring predisposing risk factors for C. difficile infection such as 
other illnesses.  Among community-acquired cases, 64.7% had a history of antibiotic use 
and increased age was also associated with a higher risk of CA-CDAD.  Sex of the 
patient, multiple antibiotic exposures (beyond a single episode), and HIV infection were 
not significantly associated with CA-CDAD.  This was one of the earliest studies of CA- 
CDAD and illustrates that CA-CDAD shares many of the same risk factors as hospital-
acquired CDAD.   
A two-phase survey was conducted in Australia to determine the prevalence of C. 
difficile in stool samples submitted to a private pathology laboratory by general 
practitioners and to study the importance of C. difficile in community-acquired diarrhea 
(83).  In Phase I, stool samples sent for microscopy and culture from patients greater 
than two years of age were cultured for C. difficile.  Prior to Phase II of the survey, all 
practitioners who used the pathology laboratory were sent information about CDAD, its 
causes, and when to test for the bacterium.  During Phase II, stool samples from patients 
greater than two years were cultured for C. difficile at the request of the general 
practitioner or if there was a history of antibiotic use in the previous four weeks.  A 
questionnaire was sent to all general practitioners whenever any of their patients tested 
positive for C. difficile.  There were 506 stool samples tested during Phase I and 580 
tested during Phase II.  The mean age, age range, and ratio of males to females were 
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similar for the two phases and none of the patients had been recently hospitalized or in a 
nursing home.  The prevalence of C. difficile increased from 2.6% (13 positive stool 
samples) in Phase I to 10.7% (62 positive stool samples) in Phase II.  The 75 positive 
stool samples were from 61 patients and questionnaires were sent to the general 
practitioners of these 61 patients.  Other enteric pathogens besides C. difficile were 
isolated during the study; however, there was no statistical difference between the 
proportions isolated in Phase I versus Phase II.  The majority of the questionnaires were 
returned (53 out of 61) and 85% of the patients had previously received antibiotics.  The 
authors concluded that antibiotic use was an important prerequisite for community-
acquired C. difficile; however, at the same time the patients must have come into contact 
with the bacterium.  Another important issue raised in this article is that many general 
practitioners believed that C. difficile was only a problem in hospitals and nursing homes 
and often did not request tests for C. difficile on patients in the community, even those 
exhibiting gastrointestinal symptoms.  This article was published in 1995 when there 
was little knowledge or data on community-acquired C. difficile.  The increase in 
screening for C. difficile from 9% in Phase I to 42% in Phase II shows that educating 
general practitioners about CDAD will lead to an increase in the number of sample 
submitted and cases detected.  There may have been misclassification of some of the 
cases in both phases, since other enteric pathogens were also detected alongside C. 
difficile in the stool samples, and the patients also may have been asymptomatic carriers 
of C. difficile.  This would lead to inflated prevalence estimates.  Also, the increase in 
prevalence in Phase II was most likely artificially inflated.  After receiving information 
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on C. difficile, general practitioners may have been overly concerned about patients with 
gastrointestinal symptoms and, therefore, sent in more samples for screening even if the 
symptoms did not exactly match those for CDAD.   
 A nested case-control study was carried out in both a semi-rural and an urban 
population in the United Kingdom to estimate the prevalence of CA-CDAD and 
determine the risk factors associated with infection (84).  Two cohorts of 1000 
individuals, each of whom had had fecal samples submitted for clinical reasons, were 
randomly selected from the two distinct geographic regions, both served by a single 
diagnostic laboratory.  Cases of CA-CDAD were defined as: 1) patients who visited their 
general practitioner while exhibiting symptoms of diarrhea, and 2) whose feces tested 
positive for C. difficile.  Controls were defined as: 1) patients with symptoms of diarrhea 
who visited their general practitioner, and 2) whose feces tested negative for C. difficile.  
Three controls were matched by age and sex to each case.  A questionnaire was sent to 
the general practitioner for each case and each control to obtain information on 
demographics, antibiotic use, hospitalization, and other risk factors for CDAD.  Among 
the 2000 individuals with fecal samples submitted to the diagnostic laboratory, there was 
a total of 42 cases of CA-CDAD; 21 from the semi-rural region and 21 from the urban 
region.  Cases were found to be significantly more likely than controls to have had 
antibiotic use and been hospitalized in the preceding 6 months; the most commonly 
prescribed antibiotic classes were aminopenicillins and cephalosporins.  About one third 
(35%) of the cases had no history of either hospitalization or antibiotic use.  Other risk 
factors that were significantly associated with CDAD were contact with infants two 
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years or younger in age, use of more than one antibiotic (when used), receipt of therapy 
for diarrheal symptoms, and an outcome of mortality.  Gastric-acid suppressant drugs, 
number of loose stools, and specific therapies for diarrheal symptoms were not found to 
be significantly associated with CDAD.  PCR ribotyping revealed that 60% of the 
isolates from the cases were PCR ribotype 1 and the isolates from the semi-rural and 
urban regions were different subtypes within PCR ribotype 1.  The authors describe their 
cases as community-associated rather than community-acquired, because some of the 
cases had been hospitalized within the past six months and may have acquired C. 
difficile in the hospital.  The finding that 35% of the cases had no previous history of 
hospitalization or antibiotic use and that the median age of the patients in the semi-rural 
population was 45 is good evidence that patients without the common risk factors for 
CDAD also need to be tested when they present with symptoms of diarrhea.  Another 
interesting finding was that the median age of cases in the semi-rural region (45 years of 
age) was significantly lower than the median age in the urban region (73 years of age).  
The difference in median ages raises questions about the underlying demographics and 
other differences in the regions that may account for the difference in median ages. One 
hypothesis could be that people in the semi-rural areas have more contact with those 
livestock species that have been shown to be carriers of C. difficile (53, 54, 58, 87).  One 
of the problems with this study was that univariate analysis was performed, because 
several of the questions did not generate enough response for multivariate analysis.  It is, 
therefore, difficult to know if confounding could play a role in any of the associations.  
Another problem with this study was that the definition used to describe a community-
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acquired case of CDAD is different than many of the other published reports.  The 
researchers assume that all patients who visited their general practitioner with symptoms 
of diarrhea and had a positive fecal culture for C. difficile had CA-CDAD.  The 
differences in definitions for community-acquired cases make it difficult to compare 
studies. 
A case report published in 2008 describes a patient with community-acquired C. 
difficile with no previous history of hospitalization or antibiotic use (85).  The young 
woman was referred to the hospital by her general practitioner after presenting with 
symptoms including abdominal pain, nausea, vomiting, and loose, bloody stools.  Her 
feces tested positive for C. difficile toxin A and she was treated with oral metronidazole.  
Extensive medical history records showed that the woman had no previous history of 
antibiotic use or hospitalization; however, she had spent a night at the hospital three 
months prior to admission with one of her ill children.  No previous C. difficile outbreaks 
had been recorded in the hospital and both her husband and children tested negative for 
C. difficile.  The researchers felt that the previous overnight hospital stay was not 
responsible for her C. difficile infection.  Clostridium difficile spores can survive in the 
environment for long periods of time and they are both heat and alcohol resistant; 
therefore, it is plausible that under extreme circumstances infection could occur several 
months after contact with bacterium.  The second case presented in the article was an 
elderly male who acquired C. difficile one week after being released from the hospital.  
The C. difficile isolated from the individual was ribotype 027 and at the time there was 
an outbreak of 027 in the hospital.  This was a case where the patient definitely was in 
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contact with C. difficile in the hospital, but did not become ill until he was at home.  This 
second case shows how hospital-acquired infections can later surface in out-patients and 
these are not necessarily community-acquired.  With the recent increase in C. difficile 
infections and large outbreaks it is easy to see how C. difficile can spread in hospitals 
and then appear to arise in the community.  This patient could have come in contact with 
and spread C. difficile to other healthy individuals in the community either as a clinically 
ill individual shedding the bacteria or as an asymptomatic infected carrier.  These case 
reports present the difference between a truly community-acquired case of CDAD and a 
case of hospital-acquired case of CDAD that merely surfaced in the community. 
One of the hypotheses being investigated as a risk factor for CA-CDAD is the 
use of gastric-acid suppressant drugs (86).  Gastric-acid suppressant drugs include both 
proton pump inhibitors (PPIs) and histamine receptor 2 antagonists (H2RAs).   Proton 
pump inhibitors block the hydrogen/potassium adenosine triphosphatase enzyme system, 
more commonly known as the gastric proton pump.  This system is the final stage in 
gastric acid suppression and is directly responsible for secreting H+ ions (47).  
Histamine receptor 2 antagonists inhibit histamine action at the H2 receptors of the 
parietal cells and decrease acid production stimulated by food intake (112).  It has been 
shown in laboratory studies that the decrease in H+ ions and subsequent increase in 
gastric pH favors the growth or gastric-passage survival of different bacterial species 
such as C. difficile (112).  In other words, it is possible that changes to the digestive tract 
brought about by these drugs may allow for colonization by C. difficile or may simply 
facilitate the survival of the spores (89).  Gastric-acid suppressant drugs have become 
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one of the most widely prescribed and utilized medications in both North America and 
the United Kingdom (86).  Not surprisingly, there have been studies published both 
supporting a hypothesized association between acid suppressant use and C. difficile in 
hospitalized patients (59, 90-92) and refuting it (93, 94).  There exists one reported study 
that supports the association between CA-CDAD and the use of gastric-acid 
suppressants (86).   
Dial et al. (2005) evaluated whether the use of gastric-acid suppressant drugs was 
associated with community-acquired C. difficile infections (86).  Their data were 
collected from the United Kingdom General Practice Research Database (GPRD) which 
contains data on demographics, diagnoses, hospitalization details, and mortality arising 
from over 400 general practitioners.  A case-control study was conducted comparing 
community-acquired cases (patients with a positive C. difficile toxin assay or clinical 
diagnosis, who had not been hospitalized the year prior to initial diagnosis) to ten 
controls matched on both the general practice they attended and their age.  The two types 
of gastric-acidsuppressant drugs evaluated were proton pump inhibitors and histamine 
receptor 2 antagonists (H2RAs).  After controlling for the number of patients, age, sex, 
prior gastrointestinal disorders, and other co-morbidities the authors found that proton 
pump inhibitors and H2RAs were associated with and increased risk of CA-CDAD.  The 
authors also reported an increase in the overall number of cases of CDAD as well as the 
number of community-acquired cases from 1994 to 2004.  This trend may perhaps be 
explained by an increased awareness of CDAD leading to more testing and therefore 
more diagnoses.  This study provided a large sample size and controlled for many factors 
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that could influence the association with C. difficile.  One of the disadvantages with this 
study was that the database did not provide details about the patients‟ symptoms.  It is, 
therefore, not known whether the cases were symptomatic or asymptomatic.  Since some 
of the cases were based on clinical diagnosis and not tested for C. difficile infection, one 
would assume that the patients exhibited symptoms consistent with CDAD; however, it 
is possible that some of the cases were misclassified.   
During the study mentioned above (86), the researchers also collected data on the 
association of community-acquired C. difficile with prescribed antimicrobials (113).   
The same matched cases and controls were used to evaluate tetracyclines, penicillins, 
sulfonamides and trimethoprim, macrolides, cephalosporins and other β-lactams, and 
fluoroquinolones.  The authors found an increased risk for CA- CDAD and antimicrobial 
use, especially for fluoroquinolones.  However, the authors speculated that the 
underlying reasons for prescribing the specific antimicrobials may have been responsible 
for the increased risk of C. difficile infection rather than the antimicrobials themselves.  
The use of antimicrobials, especially fluoroquinolones, has been shown to increase the 
risk of C. difficile infection in hospitalized patients (35, 114), so it is not difficult to 
believe that this was also the case for community-acquired cases.  The authors also noted 
that although there was a higher risk associated with CDAD and fluoroquinolone use, 
only 7% of the cases were prescribed fluoroquinolones and 37% were prescribed other 
classes of antibiotics.  The low percentages of antimicrobial use among the cases provide 
evidence that antimicrobial use may not have been the primary underlying cause of 
community-acquired cases in this population. 
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A study conducted by the Centers for Disease Control and Prevention (CDC) in 
2009 investigated the strains associated with community-acquired infection.  Data 
arising from a multi-state surveillance program for community-acquired C. difficile 
infection (CA-CDI) involving 19 clinical laboratories in 9 states were analyzed (115).  A 
CA-CDI case was classified as a C. difficile-positive stool specimen arising from an 
outpatient or a patient within 72 hours of admission, without a previous positive result in 
more than 8 weeks, or an overnight hospitalization in the last 3 months.   There were 175 
samples collected from patients with presumptive CA-CDI and 92 were subsequently 
confirmed as C. difficile.  The positive isolates were further characterized via the tcdC 
gene, binary toxin gene (cdtB), toxinotyping, PFGE, and antimicrobial susceptibility.  
These surveillance data gave rise to a very diverse set of strains, and these strains 
exhibited both similarities and differences to the currently reported hospital-acquired 
strains.  The most common strain was PFGE NAP1/ Toxinotype III, and this strain 
accounted for 14 of the isolates.  This strain is responsible for many of the recent 
outbreaks in hospitals in North America and Europe.  The authors noted that the 
prominence of this strain may be due to misclassification of cases as CA-CDI due to 
inaccurate records of hospital exposure.  The second most prominent strain was PFGE 
NAP7 / Toxinotype V.  This strain is most commonly found in food animals and the 
finding of this strain among CA-CDI, led the authors to suggest that C. difficile may be 
transmitted between animals and humans.  This was a rather bold statement for the 
authors to make given that they only found 7 isolates that were NAP7/Toxinotype V 
among the 92 confirmed positive.  With the large diversity among the 92 isolates we 
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would expect to see at least a few isolates from each of the North American pulsed field 
types (NAP) and toxinotypes.  There were 31 PFGE types identified and 32 of the 92 
isolates did not fall into one of the previously classified NAP types.  The large diversity 
of strains may be indicative of several sources of community-acquired infection, 
including the environment. 
2.3 Clostridium difficile in food animals 
 Recently, scientists have begun to explore the hypothesis that one of the risk 
factors for community-acquired C. difficile may be exposure to either food animals or 
food products.  There have been a number of studies focusing on the isolation of C. 
difficile from food animals, including swine, cattle, and chickens (51-54, 58, 87, 88).  
Clostridium difficile isolates have been identified from swine showing 100% similarity 
to human isolates (54).  Clostridium difficile is a suspected cause of diarrhea in calves 
(95) and is known to cause pseudomembranous colitis and enteritis in piglets (87, 96-
99).  The majority of the studies concerning food animals and food products have 
focused on the younger age classes where the bacterium is consistently known to occur 
and sometimes cause disease.  There have been limited studies investigating the presence 
of C. difficile in market and slaughter age animals; however, the finding of C. difficile in 
food animals raises concern about possible food-borne and occupational exposure. 
2.3.1 Clostridium difficile in swine 
There have been many studies published concerning C. difficile infection in 
piglets.  Clostridium difficile infection in pigs was first discovered in 1980 when 
gnotobiotic pigs were accidentally exposed to the bacterium (58, 116).  An outbreak of 
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C. difficile in piglets at a farm in Canada was described in 1998 (98).  Initially, only two-
week-old piglets were affected, but eventually the infection spread to also affect 
newborn piglets.  The primary post-mortem finding in the majority of the piglets was 
mesocolonic edema.  In addition, C. difficile was one of several bacteria cultured from 
the intestines of the symptomatic piglets.  Clostridium difficile was deemed to be 
responsible for the lesions in the colon of the piglets and also for the illness and 
mortality in the herd.   
 Clostridium difficile has since been found to be one of many primary agents 
responsible for diarrhea in piglets.  Clostridium difficile was found in 29% of the colons 
of piglets in a survey in Iowa that assessed the pathogens responsible for diarrhea (97).  
The retrospective survey consisted of data from 100 live piglets ranging in age from 1-
to-7 day- old submitted to the Iowa State University Veterinary Diagnostic Laboratory 
(ISU VDL) with symptoms of diarrhea.  Sections of the ileum, jejunum, and colon were 
cultured for E. coli, Salmonella, Enterococcus, and C. perfringens and the piglets were 
also examined during necropsy for porcine reproductive and respiratory syndrome virus 
(PRRSV).  Contents of the colon were tested by commercially available ELISAs for 
rotavirus and C. difficile toxins.  The most common pathogen identified was rotavirus 
followed by C. difficile toxins and PRRSV.  Clostridium difficile was identified in 29 of 
the 100 piglets and found in combination with other pathogens in 10 of those piglets.  
Mesocolonic edema was observed in all 29 of the piglets infected with C. difficile.  
When multiple piglets were submitted from the same herd with one piglet positive for C. 
difficile, 43.5% of the additional piglets were found to be positive.  Information on prior 
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antibiotic use was available for 14 of the 29 cases and 10 of these had received 
antibiotics.  The findings in this study are very much different than previous studies that 
had found E. coli, transmissible gastroenteritis (TGE) virus, and C. perfringens to be the 
most common causes of diarrhea in piglets.  The proportional morbidity estimates in this 
study were not population-based and, therefore, cannot be extrapolated to all 
populations; however, they do provide preliminary data about the epidemiology of 
piglets exhibiting diarrhea and should be further investigated.  It is also interesting that 
the majority of the piglets infected with C. difficile had prior exposure to antibiotics.  
Swine share many of the same monogastric anatomical and physiological characteristics 
as humans and, as a result, pigs may share some of the same risk factors for C. difficile 
infection as humans.   
Clostridium difficile has been found in both symptomatic piglets with diarrhea 
and asymptomatic piglets (117, 118), just as it has been found in humans.  A prospective 
case-control study was conducted to assess the association between C. difficile and 
evidence of diarrhea, mesocolonic edema, typhlitis, and colitis in piglets (117) using the 
same piglets as the previously mentioned study (97).  The cases consisted of 100 piglets 
1 to 7 days in age, submitted to the Iowa State University Veterinary Diagnostic 
Laboratory with symptoms of diarrhea.  The controls were 29 asymptomatic piglets 
purchased from litters with no history of diarrhea.   Contents of the jejunum, ileum, and 
colon were cultured for C. difficile during necropsy.  Piglets were given diarrhea scores 
based on fecal staining of the perineum, hydration, and consistency of the contents in the 
colon.  Including both cases and controls, C. difficile was isolated from the large 
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intestine in 51% of the piglets, from the small intestine in 47% of the piglets, and from 
the colon in 50% of the piglets.  Clostridium difficile was isolated from the colon in 23 
of the 29 control piglets and 42 of the 100 case piglets.  The reason for the high 
prevalence of C. difficile in the control piglets cannot be explained in the same manner 
as human infants.  Clostridium difficile is a normal component of the gut flora in infants; 
however, they lack the receptors for the toxin so it does not cause disease (119).  As the 
human infant gastrointestinal tract matures, C. difficile is replaced by other bacteria.  In 
piglets, C. difficile has been shown to cause disease and the receptors for toxin A have 
been identified (120).  However, the presence of C. difficile in the gastrointestinal tract 
of piglets does not necessarily result in clinical symptoms.  Therefore, while C. difficile 
is a necessary component cause (it is insufficient by itself), there must be other factors 
associated with disease.  Evidence from the previously mentioned study would indicate 
that antibiotic use is one of these risk factors (97). 
 Alarez-Perez et al. (118) also examined the presence of C. difficile in 
symptomatic and asymptomatic piglets as well as the prevalence in piglets of different 
ages. Thirteen different farms were sampled in three regions of Spain densely populated 
with swine.  Among the 13 farms, 10 had a previous history of neonatal swine diarrhea 
and served as the case farms, whereas the 3 remaining were clinically free of diarrhea 
and served as the control farms. Rectal swabs were taken from 541 piglets ranging in age 
from 1-to-7 days-old and 239 piglets ranging in age from 1-to-2 months-old.  Among the 
1-to-7 day-old piglets, 287 were asymptomatic and 254 were symptomatic (diarrhea).  
Among the 1-to-2 month-old piglets, 187 were asymptomatic and 52 were symptomatic. 
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C. difficile was isolated from 140 of the 541 (25.9%) rectal swabs from the 1-to-7 day-
old piglets and at least one asymptomatic piglet tested positive for C. difficile from each 
farm, including the clinically free farms.  Clostridium difficile was not isolated from any 
of the 1-to-2 month-old piglets.  Among the 1-to-7 day-old piglets, C. difficile was 
isolated from 82 (28.6%) of the asymptomatic piglets and 58 (22.8%) of the 
symptomatic piglets.  As in the previous study by Yaeger et al. (117), this study also 
provided evidence that C. difficile can be isolated from both symptomatic and 
asymptomatic piglets, and that C. difficile infection in piglets was similar in nature to 
infection in human infants.  C. difficile was not isolated from any of the 1-to-2 month- 
old piglets in this study, and as such it appears that C. difficile was replaced by other 
bacteria in the gut as the piglets matured (similar to humans).  
 The majority of the literature on C. difficile in swine has focused on the disease 
in piglets.  In 2005, an article was published describing an outbreak of C. difficile in 
postparturient sows in Croatia (121).  That outbreak took place in a large outdoor 
commercial swine operation consisting of 2,949 sows and occurred between January and 
March of 2003.  All of the sows had previously been vaccinated against parvovirus, 
erysipelas, leptospirosis, C. perfringens C, E. coli and pseudorabies.  Sows were 
routinely tested and treated for mastitis metritis agalactia (MMA) disease complex.  
Among 614 sows suffering from and treated for MMA, 122 (19.9%) showed signs of 
respiratory distress and 81 (13%) died.  In comparison, only 0.4% of the sows not 
suffering from or treated for MMA died.  Four sows, representative of all the mortalities, 
were sent for necropsy, bacteriological, and serological investigation.  A finding of 
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mesocolonic edema, lesions, C. difficile isolates, and C. difficile toxins led the 
researchers to conclude that all 4 mortalities were a result of C. difficile infection.  Other 
possibilities such as E. coli, Salmonella, PRRS, and classical swine fever were excluded 
as a result of the necropsy, bacteriological, and serological tests.  Postparturient death 
was 6.2% during the outbreak from January to March in comparison to 2.4% before 
January and 2.6% after March.  The sows with MMA had given birth to a similar 
number of litters to those without MMA; however, the sows treated for MMA were 
generally younger than the non-diseased herdmates.  This study demonstrates that older 
swine are at risk for C. difficile infection; however, other risk factors may be involved 
with the infection.   The risk factors involved with this outbreak include antibiotic use 
(treatment of MMA with enrofloxacin), environmental conditions, and a weakened 
immune system.  These sows were housed outdoors during the winter, which most likely 
put stress on the animals.  The sows also had weakened immune systems from recently 
having given birth.  It is also interesting to note that there was no increase in loss of 
piglets during the outbreak of C. difficile in the herds; this demonstrates further that the 
mere presence of the bacteria alone was not enough to cause disease.   
2.3.2 Transmission between species 
The finding of C. difficile in food animals has led researchers to explore the 
possibility of transmission between animals and humans.  Most studies providing 
evidence of transmission have focused on the similarities and differences among gene or 
toxin subtypes found in animals and humans (53, 54, 100-102).  There have been several 
studies exploring the subtypes of C. difficile in swine populations and some of these 
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studies have also compared swine isolates to human isolates (122, 123).  The most 
common ribotype and toxinotype found among swine isolates is ribotype 078, 
toxinotype V (101, 122).  This strain is characterized by a 39 base-pair deletion in the 
tcdC gene, which is the negative regulatory gene for toxin A and toxin B production, 
presence of the binary toxin gene, and presence of both the toxin A and toxin B genes.  
No studies have been published investigating the possibility of C. difficile transmission 
through exposure to food animals; however, one study has provided data supporting 
occupational exposure of health care workers to C. difficile in clinical settings (124). 
One of the first papers published comparing types of C. difficile found in humans 
and animals, to explore the possibility of transmission between species, compared 
ribotypes from clinical human cases to canine, equine, feline, and bovine isolates 
collected from previous studies (100).  A total of 133 isolates comprised of 92 canines, 
21 equine, 20 human, 1 feline, and 1 bovine isolate were analyzed using ribotyping and 
PCR to identify the toxin genes.  While there were 23 distinct ribotypes identified, there 
typically were 1 or 2 dominant ribotypes for each animal species.  The single bovine 
isolate was the same ribotype as a ribotype found among the equine isolates and the one 
feline isolate was a ribotype found among the canine isolates.  There were 7 different 
ribotypes identified among the human isolates and 2 of these ribotypes were also found 
among the canine and equine isolates.  There was a large diversity among the ribotypes 
for the equine isolates, whereas 77% of the canine isolates belonged to the same 
ribotype.  This dominant canine ribotype was found in 20% of the human isolates.  The 
toxin A and B genes were identified in all of the human and equine isolates and in 69% 
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of the canine isolates.  The remaining canine isolates were negative for both the toxin A 
and toxin B genes.  This study was the first to report that there were similar ribotypes 
found among humans and animals and that interspecies transmission was therefore a 
possibility.  The finding of similar ribotypes among dogs and horses is of concern, 
because these are companion animals and a large portion of the human population comes 
in contact with these animals on a daily basis.  In addition, dogs are often used for non-
medicinal therapy purposes in hospitals and nursing homes where patients tend to have 
additional known risk factors for C. difficile infection.  Several studies have been 
published exploring the presence of C. difficile in companion animals and in therapy 
dogs (125-128).   
 A study published in 2007 surveyed the relative proportion of ribotypes among 
swine, bovine, canine, equine, and human isolates from various geographic areas (101).  
A convenience sample (samples were selected based on ease of sampling) of swine 
isolates were collected from piglets in Iowa, Ohio, Montana, North Carolina, and Utah 
and bovine isolates were collected from calves less than 2 months of age in Arizona.  
Equine isolates were collected from Kansas, Arizona, and Canada and canine samples 
were also collected from Ontario, Canada.  Human isolates were from two hospitals in 
Colorado.  Information on signalment was not provided for the equine, canine, or human 
samples.  A total of 232 C. difficile isolates including 33 bovine, 12 canine, 20 equine, 
144 swine, and 23 human isolates were ribotyped and tested for the presence of toxin A 
and toxin B.  Nineteen different ribotypes were identified, with the largest diversity of 
ribotypes among the human, equine, and canine samples.  Ribotype 078 accounted for 
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94% (31/33) of the bovine isolates, 83% (119/144) of the swine isolates, 5% (1/20) of 
the equine isolates, 4.4% (1/23) of the human isolates, and none of the canine isolates.  
The majority of the canine isolates were type 010, the equine isolates were type 015, and 
the human isolates were type 020.  There were 4 different ribotypes found among the 
swine isolates and 12 different ribotypes found among the human isolates.  The lack of 
diversity in ribotypes among the swine isolates is interesting, because swine were the 
largest group sampled and had the most diverse geographic representation.  This study 
found that there was a larger diversity of ribotypes among human isolates than the swine 
isolates and there was no association between the strains found in swine and in humans. 
A second study comparing human and animal isolates found that the number of 
toxinotype V isolates had increased in recent decades and when analyzed by PFGE there 
was 100% similarity between the human and swine isolates (54).   Past isolates were 
analyzed from 1984 to 2001 in the Hine Veterans Affair (VA) Hospital database and 
compared to recent isolates from hospital outbreaks sent to the Center for Disease 
Control (CDC) from 2001 to 2007.  Clinical information was obtained for all the recent 
cases.  Cases were considered community-acquired if symptoms began less than 48 
hours after admission and it had been more than 12 weeks since they were discharged.  
Hospital-acquired cases were patients with symptoms beginning more than 48 hours 
after admission or less than 4 weeks after discharge.  Patients receiving antibiotics 
within 30 days of symptom onset were considered to be exposed to antibiotics.   Swine 
isolates were obtained from piglets from North Carolina, Iowa, Texas, Utah, Ohio, and 
Arizona from 1999 to 2005 and bovine isolates were obtained from 1-day to 6-week-old 
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calves in Arizona from 2003 to 2005.  Positive isolates were further analyzed by PCR 
for the tcdC gene deletion, binary toxin gene, toxin A gene, and toxin B gene.  
Toxinotyping and PFGE were also conducted to compare the isolates.   Seven toxinotype 
V isolates were identified among the more than 6,000 isolates of C. difficile from the 
Hine VA Hospital and 8 toxinotype V isolates were identified from the 620 recent cases 
sent to the CDC from hospital outbreaks.  They found a significant (P<0.001) difference 
between the 7 past and 8 recent toxinotype V isolates.  Among the recent cases, 38% 
were community-acquired and 88% were exposed to antibiotics.  Among the past cases 
with available data, 3 out of 5 cases (60%) were community-acquired and all 4 of the 
cases were exposed to antibiotics.  PFGE analysis revealed three different clusters, each 
containing at least one human and swine isolate with 100% similarity.  One of the major 
limitations of this study is that the past and recent populations are not comparable due to 
varied population sampling strategies.  The past isolates arose from a database of a VA 
hospital, whereas recent isolates were sent to the CDC from outbreaks.  It would be 
interesting to look at the number of toxinotype V isolates from the Hine VA  Hospital 
from 2001 to 2007 and compare this number to the seven cases from 1984 to 2001.  The 
researchers also tried to link the increase in toxinotype V in humans to the emergence of 
toxinotype V in animals.  There is no evidence that toxinotype V has only recently been 
found in animals, and the emergence of this strain in animals is most likely an artifact of 
increased testing in animals.  A major limitation in this study is the small number of 
toxinotype V isolates.  With only 15 total toxinotype V isolates there is little statistical 
power to compare toxinotype V with the risk of community-acquired infection.  The 
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human and swine isolates used in this study were also not from the same geographical 
regions or catchment areas and, therefore, it is difficult to suggest that transmission 
between host species is a reason for the similar toxinotypes. 
The discovery of C. difficile in food animals is not restricted to the United States.  
International studies have found both similar prevalence and types of C. difficile and 
some authors have suggested that any differences between nations may be related to 
demography and geography.  One study conducted in Slovenia reported survey data 
from swine and cattle farms tested for the presence of C. difficile and compared these 
isolates to those found on U.S. farms (53).  Samples were collected from 257 piglets 
from three different farms and 56 calves from two different farms.  All piglets and calves 
that were sampled exhibited symptoms of diarrhea.  Clostridium difficile was isolated 
from 133 (51.8%) of the piglets and 1 (1.8%) of the calves.  The single calf isolate was 
negative for both the toxin A and toxin B genes, but positive for the binary toxin and 
belonged to toxinotype XIa, ribotype 033.  The 102 piglet isolates from two of the farms 
were found to be toxinotype V, whereas the 31 piglet isolates from the third farm were 
toxinotype 0.  Isolates belonging to toxinotype 0 are positive for both toxin A and toxin 
B, but negative for the binary toxin.  Toxinotype 0 strains have been found in 150 
different ribotypes, but all of the isolates from this study belonged to the same ribotype 
that had not previously been identified.  Toxinotype V isolates have been classified as 
either ribotype 078 or 066.  All of the toxinotype V isolates in this study belong to 
ribotype 066.  The finding of ribotype 066 in piglets in Slovenia contrasts with data from 
the United States that have found the majority of isolates from piglets are ribotype 078.  
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Toxinotype V was found in piglets in the U.S. and Slovenia and it is possible that some 
of the studies from the U.S. that only compared toxinotypes and not ribotypes contained 
ribotypes other than 078.  The differences in ribotypes may also be explained by 
variations in the geographic distributions of different strains. 
Piglets were sampled from several farms in the Netherlands to describe the 
different C. difficile types in the population (122).  Forty-eight piglets between one to 
four days of age and suffering from diarrhea were sampled from two farms for the 
presence of C. difficile.  Another 272 asymptomatic piglets were sampled as controls 
from seven large farms that were members of the European Pig Producers Association.  
After nine months, the two case farms were still experiencing cases of diarrhea and 31 
more samples were taken from symptomatic piglets.  The number of positive isolates 
from each of the asymptomatic and symptomatic group of piglets was not provided.  All 
of the positive C. difficile isolates were found to be ribotype 078, toxinotype V.  These 
isolates were similar to those isolates characterized and arising from hospitalized 
patients in the Netherlands (129).  In order to test the relatedness of the isolates, 11 of 
the swine isolates and 21 of the human isolates were analyzed using multi-locus 
variable-number tandem-repeat analysis (MLVA) (122,129).  All of the isolates were 
found to be genetically related and in one of four clonal complexes.  One of the clonal 
complexes contained both human and swine isolates and two pairs of human and swine 
isolates were found to be 100% homologous.  It is interesting that both swine and human 
isolates in the Netherlands were found to be ribotype 078, toxinotype V; however, the 
swine and humans are not from the same population so it is difficult to make any 
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meaningful comparisons between the isolates.  The authors have merely pointed out that 
the swine and humans colonized with these isolates may have been exposed to a 
common point source.  Another concern with this article is that the number of positive 
isolates from each of the symptomatic and asymptomatic piglets is not given.  We do not 
know if the 11 isolates that were analyzed by MLVA were the only isolates recovered or 
if it was a sample.  We also do not know how many of the isolates came from each of the 
two case farms and the seven control farms.  A table showing the antimicrobial 
susceptibility testing from the case farms only provides data from 1 isolate from farm 
one and 4 isolates from farm 2.  In addition, no information is provided on the number of 
isolates typed and whether all the isolates were ribotype 078, toxinotype V or if this was 
simply the majority. 
 The human samples mentioned above were collected during a study in the 
Netherlands from January 2005 through January 2008 (130).  A total of 1,687 isolates 
from patients with CDAD were typed at the National Reference Laboratory at Leiden 
University Medical Center.  Questionnaires were sent to patients with CDAD to study 
the risk factors associated with each of the different ribotypes.  The most common 
ribotypes identified were type 027 (17%, 289 isolates), type 014 (10%, 173 isolates), 
type 078 (9%, 150 isolates), and type 001 (2%, 29 isolates).  During the study period, the 
proportion of ribotype 078 isolates increased from 3% to 13% and the proportion of 
ribotype 027 isolates decreased from 27% to 1%.  Approximately 40% of the 
questionnaires were returned from each of the groups of patients; type 027, type 078, 
and all other ribotypes.  Odds ratios were reported for comparisons between ribotype 
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078 to all other ribotypes (except 027), ribotype 078 to ribotype 027, and ribotype 027 to 
all other ribotypes (except 078).  When comparing patients with ribotype 078 to the 
other ribotypes (except 027), patients with 078 were more likely to have used 
fluoroquinolones (OR 2.17 (1.06, 4.44)), but were less likely to have other diseases (OR 
0.44 (0.20, 0.95)).  Comparing patients with type 078 and type 027, patients with 078 
were generally younger and cases were more often community-acquired (OR 2.98 (1.11, 
8.02)).  The risks of severe diarrhea and mortality were similar for type 078 and 027; 
however, patients with 078 generally had a less complicated course of treatment (OR 
0.20 (0.04, 0.91)).  Patients with type 027 generally were older (OR 1.94 (1.35, 2.79)) 
and cases were more frequently health care- associated when compared with ribotypes 
other than 078 (OR 3.85 (1.82, 8.15)).  Patients with 027 isolates also were more 
frequent users of cephalosporins (OR 1.66 (1.03, 2.67)) or fluoroquinolones (OR 1.69 
(1.00, 2.88)), exhibited symptoms of severe diarrhea (OR 1.65 (1.02, 2.67)), had a more 
complicated course of treatment (OR 1.53 (0.81, 2.88)), and resulted in mortality (OR 
1.57 (0.74, 3.35)) when compared to ribotypes other than 078.  A random selection of 51 
of the type 078 isolates revealed that all of the isolates were positive for: 1) toxin A, b) 
toxin B, c) the binary toxin, d) had a 39 base pair deletion in the tcdC gene, and e) were 
toxinotype V.  As mentioned, these human isolates had a high degree of relatedness to 
the swine isolates collected from two farms in the Netherlands.  The majority of the 
samples surveyed were from hospitals and regional laboratories that submit samples on a 
monthly basis.  The remaining samples were from facilities that only submit samples for 
patients with severe CDAD or when there is an outbreak of CDAD.  When the results 
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from these two groups were analyzed separately, similar results were found so this likely 
did not introduce bias into the study.  Although questionnaires were not returned for all 
the patients, an even proportion was returned for each ribotype group.  This study 
provides evidence that ribotype 078, toxinotype V is found among human cases of 
CDAD and the proportion of patients with this type appears to be increasing.  One of the 
previously mentioned studies conducted in the United States also found that the number 
of toxinotype V cases is increasing (54). The relationship between human cases of 
ribotype 078, toxinotype V and swine cases is not yet known, but they have a high 
degree of relatedness, which raises the specter of either transmission between the two 
species or else infection from a common source. 
 Ribotyping, toxinotyping, and PFGE are the most common techniques used to 
analyze and compare isolates; however, other techniques have also been used.  One of 
the other published techniques involved triple-locus sequence analysis of the toxin 
regulatory genes tcdC, tcdR, and cdtR and also analysis of deletions in the tcdC gene to 
compare human, swine, and equine isolates (102).  The tcdC gene is a negative 
regulatory gene for the production of toxin A and B, the tcdR gene is a positive 
regulatory gene for the production of toxin A and B, and the cdtR gene is a positive 
regulatory gene for the binary toxin.  The tcdC gene, cdtR gene, and a 473-base pair 
fragment of the tcdR gene were amplified for 53 isolates chosen based on the size of 
their tcdC gene deletion (102).  These isolates included 38 human, 4 swine, and 11 
equine samples.  There also were 4 control strains from human clinical cases included, 
each with known sequenced tcdC genes.  Deletions in the tcdC gene were identified in 
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43 (75.4%) of the 57 isolates and there were 4 different deletions identified including an 
18-, 36-, 39-, and 54-base pair deletion.  Ten different clusters were found using triple-
locus sequence analysis varying from 1 to 20 nucleotide differences in the isolates.  The 
majority of the sequences with the same tcdC gene base pair deletion clustered together; 
however, some of the isolates with an 18-base pair deletion also clustered with isolates 
with no deletion in the tcdC gene.  All of the isolates with a tcdC gene deletion also 
contained the binary toxin.  Three clusters of isolates had specific alleles in the tcdC, 
tcdR, and cdtR genes that were not found in any of the other isolates.  The three clusters 
were the toxin A- negative, toxin B-positive isolates belonging to toxinotype VIII, the 
isolates with a 39-base pair deletion in the tcdC gene belonging to toxinotype V, and the 
isolates with the 54-base pair deletion in the tcdC gene.  These three clusters each had a 
separate lineage and appeared to have evolved separately, whereas the strains with a 36-
base pair deletion, 18-base pair deletion, and the wild type with no deletion had 
overlapping lineages.  This is interesting, because it appears that the toxinotype V 
isolates did not evolve from one of the other strains of C. difficile, although it has only 
recently been recognized and may be increasing in prevalence.  Toxinotype V isolates 
are found in both humans and animals, but do not share a similar lineage with any of the 
other toxinotypes in this study identified from humans, swine, or equine.  The findings 
from this study provide evidence to support the hypothesis that toxinotype V isolates 
originated from a common source, such as the environment, rather than originating in 
either human or animal hosts. 
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 The prevalence of C. difficile in food animals was estimated in a study in Austria 
in 2008 (123).  Fecal samples were collected from 67 cattle, 61 swine, and 59 broiler 
chickens from 65 abattoirs from March to July.  Positive isolates were further 
characterized by ribotyping, as well as by PCR for the presence of the binary toxin, toxin 
A, and toxin B genes.  Clostridium difficile was isolated from 8 of the 187 fecal samples 
including 3 (4.5%) from cattle, 2 (3.3%) from swine, and 3 (5%) from broiler chickens.  
All eight of the positive samples were of a different ribotype and included: 126 and A-50 
in the swine; Al-225, 420, and 014/0 in the cattle; and Al-79, 001, and 446 in the 
chickens.  Based on previous work, the most common ribotype found among cattle and 
swine is type 078 (101).  Ribotype 126, as found in one of the swine samples in this 
study, is very closely related to ribotype 078.  It is important to note in this study that 
these samples were taken from asymptomatic animals at slaughter.  This is the most 
likely explanation for the lower prevalence of C. difficile than in previous studies (53, 
87).  Previous studies have focused on piglets and calves with diarrhea, whereas this 
study sampled older animals that were headed to slaughter.  The lower prevalence of C. 
difficile in animals headed to slaughter could be seen as evidence of a lowered risk of 
transmission of C. difficile from animals to humans through food. 
 Although no studies have investigated the possible transmission of C. difficile 
from food animals through occupational exposure, a study published in 2009 evaluated 
the occupational exposure of health care workers to patients with C. difficile infection 
(124).  Health care workers from 4 different internal medicine wards at an academic 
hospital were evaluated for skin and fecal carriage of C. difficile.  One of the 4 wards 
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had patients with confirmed C. difficile infection, whereas the remaining three wards did 
not contain any patients with diarrhea or confirmed cases of C. difficile.  Information on 
profession, antibiotic use, contact with symptomatic C. difficile infected patients, and 
bowel movements was collected from participating health care workers; as well as hand 
swabs, swabs from the lower abdominal region, and fecal cultures.  Clostridium difficile 
was not isolated from any of the hand or abdominal swabs.  A total of 30 fecal samples 
were collected (13 from the C. difficile ward and 17 from the control wards) and 3 (23%) 
from the C. difficile ward and 1 (6%) from the control wards tested positive for C. 
difficile.  Unfortunately, the researchers did not type the isolates found among the health 
care workers, so it is not known whether the health care workers and patients were 
infected with the same strains of C. difficile.  Although the data on the strains is lacking 
from this study, it suggests that occupational exposure to C. difficile may occur in the 
clinical setting. 
2.4 Clostridium difficile in retail meat samples 
 In contrast to the low prevalence of C. difficile found in slaughter age animals, C. 
difficile has been more readily, if inconsistently, identified in surveys of retail meats (48, 
50, 103).  The reported prevalence of C. difficile in retail meats has ranged from 12% to 
40%.  Many of these studies have covered small geographic areas and this may partially 
explain the wide distribution of prevalences.  The published studies have included both 
raw and ready-to-eat products from various sources including swine, cattle, and 
chickens.  The finding of C. difficile in retail meat raises the possibility of the bacteria to 
be classified as a foodborne pathogen.  Clostridium difficile spores can survive under 
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extreme heat and will readily survive when meat is cooked to the recommended 
temperatures (56)  
One of the first published studies evaluating the presence of C. difficile in retail 
meat samples was conducted in Canada (56).  Fifty-three ground beef and 7 ground veal 
samples were collected from 4 grocery stores in Ontario and 1 in Quebec.  The 57 
samples from the 4 stores in Ontario and the 3 samples from the store in Quebec were 
collected from January to October in 2005.  Clostridium difficile was isolated from 12 
(20.0%) of the 60 retail meat samples including 11 (20.8%) ground beef samples and 1 
(14.3%) ground veal sample.  Eight of the 12 isolates were of a ribotype that had not 
been previously identified in the authors‟ laboratory and were designated ribotype M13.  
Isolates belonging to this ribotype were positive for the binary toxin, toxin A, and toxin 
B genes, had an 18-base pair deletion in the tcdC gene, and were toxinotype III.  The 
molecular characteristics of ribotype M13 are the same as those for the virulent human 
strain ribotype 027, but the ribotype patterns were distinctly different.  PFGE analysis of 
these ribotype M13 strains resulted in a pattern 80% similar to strain NAP1, which is 
also the PFGE classification of the virulent strain.  The three remaining isolates 
belonged to ribotypes 077, 014, and M26.  Ribotypes 077 and 014 have been identified 
as human pathogenic strains.  Previous to this study, C. difficile had been incidentally 
identified in a commercial raw meat diet intended for dogs (131) and in a study on  
“blown package” spoilage of vacuum-packed meats (132), but had not been identified in 
retail meat intended for human consumption.  One of the major disadvantages of this 
study is that the samples were selected by convenience.  The samples originated from 5 
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different grocery stores; however, the majority of the samples originated from just 4 of 
the stores.  The 8 samples that were identified as ribotype M13 all originated from the 
same store, which suggests cross-contamination at the packaging or distribution level.  
The only other ribotype that was found in more than one sample was type 077 and this 
ribotype was found in two ground beef samples from the same store.  The prevalence of 
C. difficile in retail meat samples appears to be high based on previous incidental 
findings of C. difficile in raw meat (131, 132).   This higher prevalence may be explained 
by the isolation technique used in this study.  The isolation technique included a 2-week 
enrichment process prior to plating and this long enrichment process could have helped 
detect low levels of spores.   However, since this was the first study to evaluate the 
prevalence of C. difficile in retail meat intended for human consumption, it is difficult to 
know if this was an accurate representation or if the prevalence was high due to a 
potentially post-harvest (or during processing) contaminated batch in one of the stores. 
A study evaluating the presence of C. difficile both in raw and ready to eat retail 
meat samples conducted in 2007 reported a much higher prevalence (48).  Samples were 
collected from three retail stores in Tucson, Arizona on three different dates in one 
month intervals from January to April.  Samples included 26 ground beef, 7 ground 
pork, 9 ground turkey, 13 pork sausage, 10 pork chorizo, 7 beef summer sausage, and 16 
pork braunschweiger sausage.  Products with different sell-by dates were selected for 
each type of meat sample to observe associations with production date.  Both a heat-
shocked and non-heat-shocked culture technique was used to isolate C. difficile.  
Interpreting both culture techniques in parallel, Clostridium difficile was isolated from 
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37 (42.0%) of the 88 retail meat samples, including 13 (50%) ground beef, 1(14.3%) 
summer sausage, 3 (42.9%) ground pork, 10 (62.5%) braunschweiger sausage, 3 (30%) 
chorizo, 3 (23.2%) pork sausage, and 4 (44.4%) ground turkey.  Positive samples 
originated from both the heat-shocked and non-heat-shocked isolation techniques.  All 
samples that were classified as negative were negative for both culture techniques; 
whereas samples classified as positive were positive for at least one of the culture 
techniques.  None of the samples were positive for both culture techniques.  No 
associations were found with the meat processor, sell-by date, store, or month sampled.  
Twenty seven (73.0%) of the isolates were ribotype 078 and toxinotype V and the 
remaining 10 (27.0%) isolates were ribotype 027 and toxinotype III.  The C. difficile 
strains isolated from retail meat in this study are interesting, because ribotype 078 is the 
most common strain isolated from food animals including pigs and cattle, whereas 
ribotype 027 is the virulent strain associated with increased human outbreaks both in 
North America and Europe.  One of the key pieces of information missing in this article 
are the data on the number of samples collected from each retail store and retail store 
data for the positive isolates.  The authors state that there were no associations between 
positive isolates and the processor, sell-by-date, store, or month sampled; however, none 
of these data are provided.  The prevalence estimated in this study was much higher than 
that reported in Canada.  Reasons for this might include: different isolation techniques, 
different types of meats sampled, different processing methods, and geographical 
variation.  The isolation technique used in this study included a 3-day enrichment 
process prior to plating; whereas the study in Canada used a 2-week enrichment.  It 
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would seem that the two week enrichment used in the Canadian study would be a more 
sensitive method than the 3-day enrichment used in this study; however, the other 
difference in the isolation techniques involved the heat- or alcohol-shock treatments.  
This study used a heat-shock procedure, whereas the Canadian study used an alcohol-
shock procedure.  Another study evaluated different isolation techniques and reported 
that alcohol-shock was more effective than heat shock at isolating C. difficile (133).  
Based on the shorter enrichment time and use of heat-shock instead of alcohol-shock, it 
does not appear that the isolation techniques used in this study are responsible for the 
higher apparent prevalence.  This study sampled a variety of different meats, whereas the 
Canadian study only sampled ground beef and ground veal.  However, when we observe 
only the ground beef samples this study estimated prevalence at 50%, whereas the 
Canadian study yielded 20% prevalence. Even if this study only evaluated the ground 
beef samples, it would still have estimated a much higher prevalence of C. difficile.   
 There have been several studies conducted outside of North America evaluating 
the presence of C. difficile in retail meat samples.  An extension of report described 
earlier, one of these studies was conducted in Austria in 2008 (123).  Meat samples, 
including 51 beef, 27 pork, and 6 chickens, were collected from 11 retail outlets from 
February to April of 2008.  The beef and pork samples included trim samples as well as 
ground samples.  Clostridium difficile was not detected in any of the meat samples.  One 
of the problems with this report is that the geographic distribution of the source of the 
retail meat samples was not reported.  The samples were collected from 11 retail outlets, 
but it is not known if these samples were representative of all of Austria or only a 
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specific region.  The data on the distribution of samples from each retail outlet are also 
not provided.  The finding of C. difficile in retail meat may be a result of contamination 
at packaging or distribution and if all of the samples came from the same packaging or 
distribution plants then the samples are not representative of the broader population.  It 
has been suggested that the prevalence of C. difficile in retail meat is higher in North 
American than in Europe.  The prevalence and strains of C. difficile in food animals are 
similar in North America and Europe and if animals were the source of the 
contamination in retail meat a similar prevalence would be expected in North America 
and Europe.  The isolation techniques used in this report were comparable to those used 
in North America and do not appear to be responsible for poor sensitivity of C. difficile 
detection.  The samples were analyzed using a direct plating technique in conjunction 
with a technique that included a 2-week enrichment step prior to plating.  Studies 
published from the United States have included both a 1-week and 2-week enrichment 
step prior to plating (48, 56).  Seasonality may be another reason for the lack of 
detection of C. difficile in the samples in this study.  Samples in this study were only 
collected from February to April.  Other studies have suggested a possible season trend 
in detection from retail meat samples (50).   
 A low prevalence of C. difficile in retail meat was also found during a pilot study 
conducted in Sweden in 2008 (134).  Samples were collected from randomly selected 
retail shops in Uppsala, Sweden from April to September.  A total of 82 ground meat 
samples were collected and comprised 32 beef, 11 pork, 12 mixed beef and pork, 7 
sheep, 2 moose, 1 calf, 2 poultry, 5 beef hamburger meat, 1 mixed beef and pork 
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hamburger meat, 1 cooked hamburger meat, 2 cooked poultry sausage, and 6 cooked 
beef or pork sausage.  Several different isolation techniques were used including direct 
plating on selective agar, a 10-to 12-day enrichment process followed by plating to 
selective agar, and an alcohol-shock treatment followed by plating to selective agar.  
Clostridium difficile was isolated from only 2 (2.4%) of the 82 retail meat samples.  The 
2 positive samples originated from ground beef; however, they were purchased from 
separate stores in different months (one of the samples was purchased in May and the 
other in September).  Both of the samples were isolated using the 10- to 12-day 
enrichment process followed by plating onto selective agar.  The positive isolates were 
positive both for toxin A and toxin B.  The prevalence of C. difficile in retail meat was 
much lower in this report compared to studies reported from the United States and 
Canada (48, 56).  The low prevalence estimated in this report is more comparable to the 
Austrian investigation that failed to detect any C. difficile in retail meat (123).  The 
Swedish researchers used a culturing technique that included a 10- to 12-day enrichment 
process; this is comparable to the technique used by Rodriguez-Palacios et al. (56), 
therefore the isolation technique cannot be solely responsible for the lower prevalence.   
Initial studies on the prevalence of C. difficile in retail meat vary in estimates of 
prevalence from 0 to 40%.  It is not known whether differences in estimates are due to 
culturing techniques, the types of meat sampled, limited sampling distribution, or 
geographic distributions.  A study conducted in Canada in 2009 set out to move beyond 
these limitations by analyzing the prevalence of C. difficile in retail meat using a broad 
government sampling infrastructure, 3 different culture techniques, and evaluating 
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month to month variability (50).  Samples were collected as part of an active 
surveillance program for the Canadian Integrated Program for Antimicrobial Resistance 
Surveillance (CIPARS).  Ground beef and veal chops were purchased from two 
randomly selected census divisions per week from various retailers throughout Canada.  
A total of 214 retail meat samples, including 149 ground beef and 65 veal chops, 
collected from 210 different retailers from January to August 2006 were tested using the 
three different culture techniques.  All of the culture techniques included a 7-day 
enrichment, an alcohol-shock treatment, and plating onto solid agar.  The three 
techniques were a rinsate sample enriched in Clostridium difficile moxalactam 
norfloxacin broth supplemented with 0.1% sodium taurocholate (TCDMNB) and plated 
on Clostridium difficile moxalactam norfloxacin agar (CDMNA); a meat sample 
enriched in TCDMNB and plated on CDMNA; and a meat sample enriched in 
cycloserine cefoxitin fructose broth supplemented with 0.1% sodium taurocholate 
(TCCFB) and plated on blood agar.  Clostridium difficile was cultured from 13 (6.1%) of 
the 214 samples including 10 (6.7%) ground beef and 3 (4.6%) veal chops.  Analyzing 
the data by month, C. difficile was more commonly isolated in January and February 
(11.5%) than in March through August (4%).   When comparing the three different 
culture techniques, isolation rates varied from 1.4 to 2.3% and there was little or no 
agreement or reproducibility between the techniques.  The reported sensitivities of the 
culture techniques were low and varied from 23 to 39%.  The broad government 
sampling infrastructure used in this study represents a great improvement over the 
convenience samples used in the previous studies.  However, this study did not address 
  
54 
all of the limitations of past studies and also introduced some new limitations of its own.  
One of the limitations with this study was the way the prevalence data were presented.  
The authors presented an overall prevalence of 6.1%; however, this was interpreting the 
results of the three techniques in parallel, which would falsely inflate the sensitivity.  
There were no samples that were positive for more than one culture technique.  When 
presenting estimates of prevalence, the sensitivity and specificity of the culture 
techniques need to be taken into account.  In this study, it would be more accurate to 
present the prevalence of each technique separately.  This would reduce the prevalence 
estimates to 1.4, 1.9, and 2.3% for each of the three techniques, respectively.  Also, the 
sensitivity of the three techniques was calculated based on parallel interpretation of the 
culture techniques and an overall prevalence of 6.1%.  Sensitivity and specificity 
estimates of a culture technique need to be calculated using comparison to a gold 
standard technique or through prior estimates and Bayesian estimation.  In this article the 
authors used their own data to estimate sensitivity and no data was known about the 
number of true positives, false positives, true negatives, and false negative among the 
retail meat samples.  Another problem with the three different culture techniques is that 
the authors did not address the differences found when compared with previous studies.  
Some of the differences in other studies that needed to be addressed were differences in 
enrichment periods and also the difference between alcohol-shock treatment and heat-
shock treatment.  The culture techniques in this paper compared different enrichment 
broths and selective agars as well as looked at the difference between using the meat 
samples and a rinsate sample.  The advantage of using a rinsate sample is that the meat 
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samples are added to peptone water and then mixed in a stomacher to create a 
homogenous sample.  It would be interesting to determine whether rinsate samples tested 
in duplicate would yield replicated results.  Another limitation of this study was that the 
researchers set out to analyze the month-to-month variability of C. difficile in retail meat 
samples, but then only collected samples from January to August, with a 
disproportionate number of samples collected during a few months.  The number of 
samples collected each month ranged from a high of 73 samples collected in May to 0 
samples collected in July.  The authors believed that there was a possible seasonal 
difference in C. difficile prevalence in retail meat, but it is difficult to support this 
hypothesis when samples were not collected for the entire year and were 
disproportionately collected each month during the sample period.  In order to test if 
there is a significant difference in C. difficile in retail meat during the winter seasons it 
would also be helpful to have samples from more than one year.  It is possible to have a 
significant difference in season for one year; however, this may easily be caused by 
other confounding factors and may not hold up over several years. 
 Several studies have focused on C. difficile in retail chicken.  One study 
conducted in Canada evaluated the prevalence and types of C. difficile in chicken legs, 
thighs, and wings purchased from retail stores (135).  A total of 203 samples (111 thighs, 
72 wings, and 20 legs) were collected as part of the Canadian Integrated Program for 
Antimicrobial Resistance Surveillance (CIPARS) from November of 2008 to June of 
2009.  Samples were cultured using a direct plating method on selective agar as well as a 
method that involved a 48-hour enrichment process and an alcohol-shock treatment, 
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followed by direct plating to selective media.  Clostridium difficile was isolated from 26 
(12.8%) of the 203 samples including 10 thighs (9.0%), 13 wings (18%), and 3 (15%) 
legs.  The 26 positive isolates were all ribotype 078, positive for toxin A, positive for 
toxin B, and positive for the binary toxin.  The prevalence of C. difficile found in the 
chicken samples in this study was similar to the 20% found for retail beef and veal in a 
previous Canadian study (56).  The prevalence was higher than that found in retail meat 
in Austria and Sweden (123, 134) but lower than the prevalence found in a study in 
Arizona (48).  The studies conducted in Sweden and Austria included a handful of 
chicken samples and did not detect C. difficile in any of these (123, 134).  This Canadian 
report was the first to look at a larger sample size of retail chicken samples and the 
results were similar to other studies that found C. difficile in retail meat and also found 
strains commonly found in food animals (135).  However, ribotype 078 is not one of the 
strains commonly isolated from chicken fecal samples (51).  A study in Slovenia found 
that the majority of the isolates from chicken fecal samples were toxinotype 0 and none 
of the isolates were toxinotype V, the toxinotype associated with ribotype 078 (51).    
Another study in Austria found ribotypes AI-79, 001, and 446 among the chicken fecal 
samples (123).  The Austrian study used both an enrichment procedure and direct plating 
procedure for the isolation of C. difficile.  All of the positive samples were isolated using 
the enrichment procedure with a detection limit of less than 10 spores per gram of 
sample, which would suggest that the chicken samples were contaminated with a low 
level of C. difficile.  The  previously mentioned study conducted in Canada that found a 
similar prevalence of C. difficile in ground beef and veal used the same isolation 
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procedure (50).  The isolation procedure in these studies is different than those used in 
the other studies in Austria, Sweden, and the United States and may be a major reason 
for the differing prevalence.   
 The finding of C. difficile in calves has raised concern about C. difficile in retail 
beef products as well as in milk.  Another study conducted in Austria evaluated the 
presence of C. difficile in ground beef (and pork samples) as well as in raw milk samples 
(136).  One hundred ground meat samples were purchased from retail stores from July 
2007 to February 2008.  Raw milk samples were taken from bactofugates in two large 
dairies from February to June of 2008.   Bactofugation is a centrifugation process used at 
dairies to reduce the number of spores in the raw milk before heat treatment.  Prior to 
culturing the meat and milk samples the researchers tested four different isolation 
procedures using spiked retail meat and raw milk samples.  The only procedure that 
supported the growth of C. difficile was enrichment in CDMN broth followed by plating 
on the corresponding selective agar (CDMN).  The other isolation methods resulted in 
the isolation of other Clostridium species including bifermentans and glycolicum.  
Clostridium difficile was isolated from 3 (3.0%) of the 100 ground meat samples.  All 
three of the positive samples were mixed beef and pork meat and came from different 
retailers.  Two of the isolates were found to be ribotype AI-57 (Austrian Isolate-57), 
negative for the toxin A gene, and negative for the toxin B gene.  One of these isolates 
was purchased from a butcher shop and the other from a grocery store so it is unlikely 
that the isolates came from a similar source.  The third isolate was found to be ribotype 
053, positive for the toxin A gene, and positive for the toxin B gene.  Clostridium 
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difficile was not isolated from any of the bactofugate raw milk samples.  The spores 
recovered from the bactofugates were from aerobic spore formers and other clostridia 
species. Clostridium difficile has not previously been isolated from raw milk samples; 
however, other clostridia species have been found in raw milk (137).  The bactofugates 
were chosen to sample raw milk because these samples should contain an increased 
number of bacterial spores (should they be present) and this would aid isolation methods 
with low detection limits.  Clostridium difficile may not have been found in these 
samples, because concentration levels were lower than the detection limits of the 
isolation procedure or else the raw milk in the bactofugates may not have been a suitable 
environment for C. difficile spores.  This study found a much lower prevalence of C. 
difficile in retail meat than the studies performed in the United States and Canada (48, 
50, 56).  However, the 3.0% prevalence found in this study is higher than in a previous 
study conducted in Austria that did not detect C. difficile in any of the 84 retail meat 
samples tested (123).  The enrichment technique used in this report is similar to the one 
used by Rodriguez-Palacios et. al. (2007, 2009) and, therefore, could be expected to 
yield a similar prevalence.  It is also interesting that the authors did not detect C. difficile 
in any of the ground beef samples.  Previous studies have found a higher prevalence of 
C. difficile in ground beef than in other retail meats (48, 50, 56, 134).  The reason for the 
lower prevalence and differences in detection in ground beef may be due to geographic 
differences or in the ground meat batch sizes processed in North America versus Europe.  
One of the problems with this study is the procedure they used to select an isolation 
technique.  A known strain of C. difficile was inoculated into ground meat and raw milk 
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samples.   These samples had not been previously tested for C. difficile so it is not 
known if they already contained C. difficile.  The same sample of meat was used for all 4 
isolation techniques; however, C. difficile was not evenly distributed throughout the 
samples so one of the isolation techniques may have used a sample containing spores 
whereas another may not.  It is difficult to compare culture techniques and determine 
detection limits when there is no gold standard available to determine if a sample is truly 
negative for C. difficile. 
 The majority of the studies evaluating the presence of C. difficile in meat have 
been qualitative and focused on using enrichment methods to culture the bacteria from 
samples.  Enrichment methods can only test for the presence or absence of the bacteria 
and quantitative data on how many bacteria or spores are present in the sample cannot be 
calculated.   A study in Canada evaluated the prevalence of C. difficile in retail meat 
samples using both qualitative and quantitative methods in order to estimate the levels of 
contamination (103).  A total of 230 samples were collected from British Columbia, 
Saskatchewan, Ontario, and Quebec from August to November as part of the Canadian 
Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) in 2008.  One 
hundred fifteen ground beef and 115 ground pork samples were purchased from retail 
stores in 17 randomly selected census divisions in each province.  Qualitative methods 
involved a 48-hour enrichment process followed by an alcohol-shock treatment and then 
direct plating onto selective agar.  Quantitative methods involved setting up serial 10-
fold dilutions that were plated onto selective agar.  Clostridium difficile was isolated 
from 28 (12%) of the 230 retail meat samples including 14 (12%) ground beef and 14 
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(12%) ground pork samples.  Among the isolates from ground beef, 10 were positive 
only by the enrichment method, 2 were positive by both the enrichment method and 
direct plating, and 2 were positive only by direct plating.  The same distribution among 
culture methods was seen for the 14 isolates from ground pork.  The number of spores in 
the positive isolates from ground beef that were identified from direct plating was 
estimated at 20 spores per gram for two of the samples and 120 and 240 spores per gram 
for the other two samples.  For the isolates from ground pork, as a result of direct 
plating, three of the samples harbored 20 spores per gram and the other sample had 60 
spores per gram.  Analysis using the kappa statistic found a low level of agreement 
(0.22) between the two methods.  No geographic association was found between the 
prevalence of C. difficile and the different provinces.  The majority of the isolates were 
found to be ribotype 078, toxinotype V which is the strain commonly found in food 
animals.  This study is important, because it shows that the level of C. difficile 
contamination in retail meat is low and often is only detected using an enrichment 
process.  The enrichment process used in this study had a detection limit of less than 10 
spores per gram of sample.  Most of the positive samples that were identified using the 
direct plating method also had low levels of contamination.  Interestingly, two of the 
ground beef samples and two of the ground pork samples were identified only using the 
direct plating method and this may be explained by an uneven distribution of spores in 
the sample.   
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2.5 Asymptomatic carriers and Clostridium difficile in human wastewater  
 The majority of C. difficile studies in human populations have focused on clinical 
individuals in hospitals and nursing homes.  A limited amount of research has been 
conducted on the presence of C. difficile in asymptomatic individuals; and only one 
study has been conducted to evaluate the presence of C. difficile in human wastewater 
samples (106).  There have been several studies evaluating the role of asymptomatic 
carriers in the spread of C. difficile (105, 138, 139), and one study investigated the 
different strains found among asymptomatic individuals versus those with symptoms of 
diarrhea (104).  The majority of the studies have evaluated asymptomatic carriers in 
hospitals and although there is scarce data on the percentage among the general 
population, it has been estimated that 1-3% of healthy adults are asymptomatic carriers 
of C. difficile (2).  Typing of isolates arising from asymptomatic carriers may provide 
valuable information on the potential sources and routes of transmission for C. difficile 
in both hospital and community settings.  Designing studies to evaluate C. difficile in the 
community is difficult and using human wastewater samples may be a valuable tool to 
avoid difficulties in compliance and access while protecting anonymity.  The finding of 
C. difficile in biosolids provides support that human wastewater samples may be used to 
study the bacterium in human populations; however, more studies need to be conducted 
to assess whether wastewater samples provide reliable information about C. difficile in 
the human population. 
 A prospective study was performed in a long-term care facility to determine the 
prevalence of asymptomatic carriage of C. difficile in 2006 (105).  Stool samples and 
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rectal swabs were collected from 73 male patients in 2 adjacent wards along with 
information on demographics, illnesses, fecal incontinence, and antibiotic use.  Skin and 
environmental samples from the patients and their rooms were also cultured for C. 
difficile.  Patients without CDAD during the initial survey were monitored for the 
subsequent six months for development of CDAD, admission to an acute care facility, or 
death.  The patients who were initially classified as asymptomatic carriers and remained 
in the long-term care facility had stool samples collected 1 to 3 months after the initial 
sample to determine if carriage persisted.  During the initial survey, 5 (6.8%) of the 73 
patients had CDAD and 35 (47.9%) were asymptomatic carriers.  Twelve of the 35 
asymptomatic carriers had follow-up stool samples collected and 10 of these individuals 
had a positive fecal culture.  Asymptomatic carriers were found to be more likely than 
non-carriers to have had previous CDAD, exposure to antibiotics in the previous 3 
months, and previous exposure to fluoroquinolones.  Seven of the asymptomatic carriers 
developed CDAD during the 6 month follow-up period.  Asymptomatic carriers had 
significantly (p<0.05) higher rates of skin and environmental contamination than non-
carriers; however, asymptomatic carriers had significantly (p<0.05) lower rates of 
contamination than patients with CDAD.  This study provides evidence that 
asymptomatic carriers may contribute to transmission of C. difficile in health care 
facilities through contamination of environmental surfaces.  We do not know if any of 
the asymptomatic carriers were released from the long-term health care facility, but 
some of these individuals may have returned home and had the opportunity to spread C. 
difficile in the community.  The strains detected among the individuals with CDAD and 
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the asymptomatic carriers were not determined so no comparisons could be made about 
the potential spread from one population to the other or to the environment. 
Clostridium difficile strains isolated from asymptomatic infants, asymptomatic 
children, and adult patients with diarrhea were compared using PFGE to determine the 
significance of transmission from asymptomatic infants and children to adults (104).    A 
total of 446 fecal samples were collected from patients at Siriraj Hospital in Bangkok, 
Thailand from October 1998 to April 1999.  Samples originated from 235 asymptomatic 
infants (<12 months old), 76 asymptomatic children (1-11 yrs old), and 132 adult 
patients with symptoms of diarrhea.  Clostridium difficile was detected in 28 (11.9%) of 
the asymptomatic infants, 16 (21.1%) of the asymptomatic children, and 33 (25%) of the 
adult patients.  PFGE analysis demonstrated that the majority of the toxigenic isolates 
from symptomatic patients had the same pattern, whereas there was a much more diverse 
set of patterns found among the asymptomatic infants and children.   It is also interesting 
to note that C. difficile was detected in a larger percentage of asymptomatic children than 
infants.  Clostridium difficile is found in the gut flora of healthy infants, but rarely causes 
disease; and, as an infant matures, C. difficile is replaced by other bacteria (commensals) 
found in the normal gut flora of healthy adults (140).  There is evidence that the lack of 
toxin binding receptors and the immature nature of the gut flora in infants contribute to 
protection against CDAD (3).  However, asymptomatic infant carriers could also serve 
as an important route of transmission to adults.  This article provides evidence that the C. 
difficile strains found in asymptomatic infants and children are different than the strains 
causing disease in adults.  Asymptomatic infants and children may not be an important 
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source of C. difficile in the community.  However, there could also be different risk 
factors for clinical and community-acquired cases; and these risk factors select for 
certain strains of C. difficile. 
 The majority of studies on asymptomatic carriers of C. difficile has been 
conducted in health care facilities and does not address the concern of community-
acquired cases.  Human wastewater samples could serve as a valuable tool to investigate 
C. difficile in the community; however, there are limited data on the detection levels of 
the bacterium in these samples and their relevance to the human population that gave 
rise to the samples.  The level of human pathogens (including C. difficile) in biosolids 
from wastewater facilities were evaluated in a paper published in 2009 (106).  Biosolids 
are domestic sewer sludges that have been treated through mesophilic anaerobic 
digestion (MAD), temperature-phased anaerobic digestion (TPAD), or composting after 
anaerobic digestion (COM) to reduce pathogens; these are then used for agricultural 
field applications.  There has been concern that residents close to farms that apply 
biosolids to agricultural fields may be exposed to hazardous pathogens through the soil 
or air.  Biosolids are classified as class A (pathogen-free) or class B (contain pathogens), 
depending on the content of indicator organisms (bacterial and viral) or technologies 
used for treatment.  Samples were collected from 29 wastewater facilities where the 
biosolids were primarily used for agricultural application.  Real-time PCR was used to 
estimate the level of human adenovirus species, Legionella pneumnphila, 
Staphylococcus aureus, and Clostridium difficile.  Staphylococcus aureus and C. difficile 
were included in the study, because they are human pathogens found in the environment 
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that can survive under extreme circumstances.  Clostridium difficile was detected in 38% 
of the class A samples and 25% of the class B samples.  Although C. difficile was found 
more frequently in the class A samples, the concentrations in the class A samples were 
significantly (p<0.05) lower than in the class B samples.  This study is important, 
because it is the first and only to report the detection of C. difficile in biosolids from 
wastewater facilities.  However, it is important to note that biosolids have undergone 
treatment procedures to remove harmful pathogens; therefore, the types and quantities of 
pathogens found in these samples may have little relevance to the human population 
from which they originate.  In addition, the biosolids are a more concentrated biomass 
arising from wastewater, and likely have aged and changed considerably in their makeup 
since the fecal matter that originally was voided from the human host. 
2.6 Summary 
A number of studies have been conducted to estimate the incidence of CA-
CDAD and also the risk factors associated with these human cases.  Many of the risk 
factors for community-acquired cases are the same as for hospital acquired cases, such 
as antibiotic use and a compromised immune system.  However, there have been human 
cases that have no history of antibiotic use and do not have any other risk factors that are 
normally associated with CDAD.  Further research is being conducted to identify the 
possible sources of infection or other causes of these cases.  Currently, the most widely 
recognized and well-published risk factors being investigated are the use of gastric-acid 
suppressants, and exposure to food animals or consumption of retail meats.  The finding 
of C. difficile in food animals also raises concern about potential occupational exposures.  
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There are currently no published studies that evaluate the association between C. difficile 
infection and occupational exposure to food animals; however, occupational exposure to 
C. difficile has been documented in health care workers (124).  Our study evaluated C. 
difficile in a closed population with both human and swine hosts.  Within this closed 
population there existed a group cohort of individuals who worked with swine and a 
group cohort of individuals who did not work with swine.  These healthy asymptomatic 
individuals were housed separately from one another and, therefore, we were able to 
estimate the aggregate-level prevalence of C. difficile in human wastewater arising from 
the occupational group cohorts in the human population.  C. difficile has been detected in 
biosolids from wastewater facilities during a single study (106); however, biosolids have 
been treated to remove pathogens and may not serve as a good source to study C. 
difficile in  human populations.  Relatively freshly voided feces in human wastewater 
samples originating from manholes draining lavatories (and not yet subjected to 
treatment) therefore, may provide more accurate information concerning the bacterium 
in the human population.  The majority of studies in human populations have focused on 
clinical disease in health care facilities and there are limited studies on asymptomatic 
populations (104, 105).  Our human wastewater samples originated from asymptomatic 
populations in a community setting and may be more indicative of the prevalence of C. 
difficile among healthy adults than previously published studies. 
There have been numerous studies that have evaluated the prevalence of C. 
difficile in swine and compared those isolates to clinical human isolates.  One of the 
problems with previous swine studies is that these studies have focused on the 
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prevalence of C. difficile in piglets.  It is well documented that C. difficile is found in 
piglets and can cause disease in piglets.  However, for C. difficile to be evaluated as a 
potentially greater food safety risk, the bacterium needs to be studied in slaughter age 
swine.  In our study we observed the prevalence of C. difficile in different production 
groups of swine including pigs in the farrowing barn, nursery barn, breeding barn, and 
grower/finisher barn.   
Another problem with the studies that have compared swine isolates to human 
isolates is that these isolates have been from separate populations, often separated by 
vast geographic distances.  Many of these studies have shown similarities between the 
human and swine isolates, but this does not prove that transmission is occurring.  The 
strains in the two populations may have come from a common source.  In our study, the 
swine and human populations were part of the same closed population within the same 
geographical region.  We can therefore make more meaningful comparisons between the 
two populations. 
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3. MATERIALS AND METHODS 
 
3.1 Study population 
 Swine composite fecal samples and human composite wastewater samples were 
collected from a closed, vertically integrated population in the state of Texas.  The 
population consisted of 12 units in different geographical locations that contained both a 
human and swine population and an additional swine slaughter plant facility.  The 
human population contained occupational group cohorts of swine workers and non-
workers and all individuals had equal opportunity to consume the pork produced within 
the system.  The swine population flowed vertically from the farrowing barn to the 
grower/finisher slabs and all swine were slaughtered and consumed within the system. 
 3.1.1 Swine population  
There were 12 swine units in different geographical locations that housed a total 
of approximately 26,000 to 28,000 swine during a given month.  The units included five 
farrow-to-finish units, six grower-finisher units, and one purebred boar quarantine unit.  
The swine traveled vertically through the system from the farrowing barns to the hot 
nursery to the cold nursery and finally to the grower/finisher barn (or to the barns in 
other grower/finisher units).  Production groups were categorized as breeding boars and 
sows, farrowing barn pigs (lactating sows, suckling piglets), weaned nursery piglets, and 
grower and finisher pigs.  All of the swine were raised within the operation and 
remained in the system until slaughter.  Swine were sent to a central slaughter plant 
where pork products were processed for consumption by the human population.  There 
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were some purebred boars that were occasionally purchased and entered the system for 
breeding purposes.  These boars were housed in a single quarantine unit for 
approximately 4 weeks prior to entering the system.   
 3.1.2 Human population 
The targeted human population was comprised of approximately 39,000 male 
individuals who were housed in 13 units in different geographical locations.  Individuals 
in the population were categorized as either swine workers or non-swine workers based 
on their occupational exposure to the swine population.  There were 12 units with swine 
populations and 1 unit with a slaughter plant facility, where both workers and non-
workers were housed.  The swine workers and swine non-workers were housed 
separately.  All individuals had the opportunity to consume the pork products processed 
in the system. 
3.2 Sampling 
3.2.1 Swine fecal sampling 
Swine fecal samples were collected monthly at each of the 12 units from 
February 2004 to January 2007.  Composite fecal samples were each comprised of fecal 
pats from multiple pens containing feces from about ten asymptomatic, clinically healthy 
swine.  Several representative composite fecal samples were collected for each of the 
production groups mentioned above.  Pre-lagoon effluent samples were collected from 
specific locations that drained from the sampled pens.  The composite fecal and pre-
lagoon effluent samples were collected into sterile 50-ml conical tubes (BD, Franklin 
Lakes, NJ).  The samples were stored on ice and transported to the Food and Feed Safety 
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Research Unit (FFSRU) laboratory, USDA, ARS, College Station, TX.  Upon arrival, 
the samples were stirred to ensure uniform conformity and then 4 ml was placed into a 
5-ml tube containing 1 ml of sterile glycerol.  The samples were sealed and vortexed to 
distribute the glycerol evenly throughout the sample.  There were 3 replicates of 5-ml 
tubes produced for each original sample.  Samples were stored at -80°C until further 
microbiological analysis was performed.     
3.2.2 Human wastewater sampling 
Human wastewater samples were collected monthly at each of the 13 units from 
February 2004 to January 2007.  Typically, 3 swine-worker and 3 swine-non-worker 
samples were collected from each unit every month.  Samples were collected from 
representative manholes (i.e., directly draining lavatories of the two respective 
occupational cohorts) into 50-ml tubes.  Samples were stored on ice and shipped to the 
FFSRU laboratory.  Upon arrival, the wastewater samples were stirred to ensure 
uniformity and then 4 ml was placed into a 5-ml tube containing 1 ml of sterile glycerol 
and stored at -80°C.  There were 3 replicates of 5-ml tubes produced and stored for each 
original sample.   
3.3 Isolation of bacterium  
3.3.1 Isolation from swine 
Isolation of C. difficile was performed utilizing an enrichment procedure, 
alcohol-shock treatment, and restrictive media technique similar to the methods used by 
Rodriquez-Palacios et al. (95).  Samples containing 4 ml of sample and 1 ml of glycerol 
were allowed to thaw to room temperature on the laboratory bench and then transferred 
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into an anaerobic chamber.  The tubes were stirred to ensure a uniform composition and 
then 1 g was weighed out and added to a 15-ml tube containing 2 ml of 96% ethanol.  
The samples were agitated on a rotator for 50 minutes aerobically and then centrifuged 
aerobically at 3,800 x g for 10 minutes.  In an anaerobic chamber the supernatant was 
removed from the tubes and the sediment was suspended in 5 ml of cycloserine cefoxitin 
fructose broth (CCFB) (Table 1).  The enriched samples were incubated for seven days 
anaerobically at 37°C.  On the seventh day, 5 ml of 96% ethanol was added to the tubes 
in the anaerobic chamber.  The tubes were then centrifuged aerobically at 3,800 x g for 
10 minutes.  In the anaerobic chamber, the supernatant was removed, the sediment was 
suspended in 600 µl of sterile de-ionized water, and then 200 µl of the suspended 
sediment was spread onto a cycloserine cefoxitin fructose agar (CCFA) plate (Anaerobe 
Systems, Walnut, California.).  The plates were incubated anaerobically at 37°C and 
checked daily for 5 days for growth.   C. difficile were identified as yellow, broken glass 
appearing colonies on the plate.  A single suspect colony from each positive plate was 
streaked onto an anaerobic brucella plate (Anaerobe Systems) and incubated for 48 
hours anaerobically.  After 48 hours, the suspect isolate was confirmed as C. difficile 
using API (Rapid ID 32A, bio-Merieux, Durham, NC) per the manufacturer‟s 
instructions.   
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Table 1. Recipe and instructions for cycloserine cefoxitin fructose broth (CCFB). 
 
 
 
3.3.2 Isolation from wastewater 
Isolation of C. difficile from the wastewater samples was performed in a similar 
manner as for the swine samples except for one modification during the plating step.  On 
the seventh day of enrichment, 96% ethanol was added to the samples anaerobically and 
then the samples were centrifuged aerobically in the same manner as the swine samples.  
The difference for the wastewater samples as compared to the swine samples, was that 
after the supernatant was removed anaerobically, the sediment was suspended in 200 µl 
Add the following ingredients to 500 ml of de-ionized water.
Ingredient Amount (grams)
Proteose peptone                                                                
(Remel, Lenexa, KS)
20
Disodium hydrogen phosphate (Na2HPO4)                     
(Fisher Scientific, Fair Lawn, NJ)
2.5
Potassium dihydrogen phosphate (KH2PO4)                 
(Fisher Scientific, Fair Lawn, NJ)
0.5
Magnesium sulphate                                                          
(Fisher Scientific, Fair Lawn, NJ)
0.05
Sodium chloride                                                                   
(VWR International, West Chester, PA)
1
Fructose                                                                                 
(Fisher Scientific, Fair Lawn, NJ)
3
Stir ingredients together and then autoclave for 20 minutes.  
Allow autoclaved broth to cool to room temperature before adding selective supplement.  
Clostridium difficile  Selective Supplement SR0096E (Oxoid Ltd., Basingstoke, Hampshire, UK)
Antibiotic Amount (milligrams)
D-cycloserine 125
Cefoxitin 4
Aseptically add 2 ml of sterile water to the selective supplement and mix well.  
Add the selective supplement to the cooled broth and mix well.
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(instead of the 600 μl used for the swine samples) of sterile de-ionized water, and then 
200 µl of the suspended sediment was spread onto a CCFA plate (Anaerobe Systems).  
The plates were incubated anaerobically at 37°C and checked daily for 5 days for 
growth.   Clostridium difficile were identified as yellow, broken glass appearing colonies 
on the plate.  A single suspect colony from each positive plate was streaked onto an 
anaerobic brucella plate (Anaerobe Systems) and incubated anaerobically for 48 hours.  
After 48 hours, the suspect isolate was confirmed to be C. difficile using API (Rapid ID 
32A) per the manufacturer‟s instructions.   
3.4 Molecular analysis 
3.4.1 DNA preparation 
Isolates confirmed to be C. difficile by API were inoculated in Viande-Levure 
broth (VL) (Table 2) and incubated anaerobically for 24 hours at 37°C.  The positive 
cultures were kept at 4°C until DNA extraction was performed.  DNA extraction was 
performed using a QIAamp DNA Mini Kit (QIAGEN Sciences, Valencia, CA).  
Procedures followed the manufacturer‟s instructions for isolation of genomic DNA from 
Gram-positive bacteria.  A bacterial pellet was obtained by centrifugation of the VL 
culture broth for 10 minutes at 3,800 x g.  The bacterial pellet was suspended in 180 μl 
of lysozyme (20 mg/ml) (Amresco, Solon, OH) and incubated for 30 min at 37°C.  After 
30 minutes, 20 μl of proteinase K and 200 μl of Buffer AL (both provided in the kit) 
were added to the suspension and vortexed.  The samples were incubated at 56°C for 30 
minutes and then for an additional 15 minutes at 95°C.  The samples were then briefly 
centrifuged to remove liquid from the sides of the tubes and 200 μl of Buffer AL was 
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added.  The samples were vortexed for 15 seconds and incubated at 70°C for 10 minutes.  
After the incubation period, the samples were briefly centrifuged and 200 μl of 96% 
ethanol was added.  The samples were vortexed for 15 seconds and then briefly 
centrifuged.  The samples were then pipetted into the QIAamp Mini spin column and 
centrifuged at 6,000 x g for 1 minute.  The QIAamp Mini spin column was then placed 
in a clean 2-ml collection tube and the old collection tube containing the filtrate was 
discarded.  To the spin column, 500 μl of Buffer AW1 (provided) was added and the 
samples were centrifuged at 6,000 x g for 1 minute.  Once again, the spin column was 
placed in a clean 2-ml collection tube and the old tube containing the filtrate was 
discarded.  To the spin column, 500 μl of Buffer AW2 (provided) was added and the 
samples were centrifuged at 20,000 x g for 3 minutes.  The spin columns were placed in 
a clean 2-ml collection tube and the old tube containing the filtrate was discarded.  The 
samples were centrifuged at 20,000 x g for an additional minute.  The spin columns were 
placed in a clean 1.5-ml microcentrifuge tube and the collection tube containing the 
filtrate was discarded.  To the spin column, 200 μl of Buffer AE (provided) was added.  
The samples were incubated at room temperature for 1 minute and then centrifuged at 
6,000 x g for 1 minute.  The spin columns were discarded and the 1.5-ml 
microcentrifuge tubes containing the isolated DNA were stored at 4°C for further 
analysis. The concentration of the isolated DNA was measured using a 
spectrophotometer and all samples were diluted to 25 ng/µl using sterile Tris-EDTA 
(TE) buffer (10 ml of 1M Tris (GBiosciences, St. Louis, Mo) and 2 ml of 0.5M EDTA 
(Amresco, Solon, OH)).   
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Table 2. Recipe and ingredients for Viande-Levure broth. 
Add the following ingredients to 500 ml of de-ionized water. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Stir ingredients together and dispense 9 ml into glass tubes.  Place tubes in the  
anaerobic chamber overnight to reduce.  Place stoppers and screwcaps on tubes  
and autoclave for 30 minutes. 
 
 
3.4.2 Polymerase chain reactions  
Polymerase chain reactions (PCR) were used to test for the presence of the toxin 
A and toxin B genes, the tcdC gene deletion, and the binary toxin gene.  Three different 
PCR reactions were conducted using a thermocycler (Px2 Thermal Cycler, Thermo 
Electron Corporation, Waltham, MA) and the PCR primers used for amplification of the 
4 target genes are in Table 3.   Later, genomic characteristics of the isolates were 
compared using PCR toxinotyping and the PCR procedures followed slightly modified 
protocols as those utilized by the Centers for Disease Control and Prevention (CDC), 
Atlanta, GA (29, 141, 142). 
Ingredient Amount (grams)
Tryptose                                                                
(Becton, Dickinson, and Company, Sparks, MD)
5
Yeast Extract                                                         
(Becton, Dickinson, and Company, Sparks, MD)
2.5
Sodium Chloride (NaCl)                                         
(VWR International, West Chester, PA)
2.5
Beef Extract                                                           
(Becton, Dickinson, and Company, Sparks, MD)
1.2
Cysteine- HCl                                                     
(Thermo Scientific, Rockford, IL)
0.3
Dextrose                                                           
(Becton, Dickinson, and Company, Sparks, MD)
1.25
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Table 3. PCR primers used for amplification of tcdC gene, binary toxin gene, toxin A 
gene, and toxin B gene. 
 
 
 
3.4.2.1 Polymerase chain reaction for detection of the tcdC gene 
 The master mix for the PCR reaction for the tcdC gene consisted of 12.5 µl 
Jumpstart RedTaq ReadyMix (Sigma Chemical Company, St. Louis, MO), 1.0 µl Bovine 
Serum Albumin (10X) (BSA) (New England BioLabs, Ipswich, MA), 4.5 µl DNA-free 
water (Mo BIO Laboratories, Inc., Carlsbad, CA), 2.0 µl of Tim2 primer (50 μM) 
(Integrated DNA Technologies, Inc.(IDT), Coralville, IA), and 2.0 µl Struppi2 primer 
(50 μM) (IDT) for each sample.  The 22 µl of master mix was added to 3.0 µl of C. 
difficile DNA template.  The samples were kept on ice during the procedure and once 
master mix was added to the template of all the samples, the samples were gently 
centrifuged for a few seconds and then placed in the thermocycler.  The thermocycler 
protocol began with a 5-minute denaturation cycle at 95ºC.  The next 40 cycles consisted 
Target gene Primer name Primer sequence (5'-3')
tcdC  gene Tim2 GCA CCT CAT CAC CAT CTT CAA 
1
Struppi2 TGA AGA CCA TGA GGA GGT CAT 
1
Binary toxin gene Cdtpos CTT AAT GCA AGT AAA TAC TGA G 
2
Cdtrev AAC GGA TCT CTT GCT TCA GTC 
2
Toxin A gene A3C TAT TGA TAG CAC CTG ATT TAT ATA CAA G 
1
A4N TTA TCA AAC ATA TAT TTT AGC CAT ATA TC 
1
Toxin B gene B1C AGA AAA TTT TAT GAG TTT AGT TAA TAG AAA 
1
B2N CAG ATA ATG TAG GAA GTA AGT CTATAG 
1
1
 Spigaglia P, Mastrantonia P. Molecular analysis of the pathogenicity locus and polymorphism
in the putative negative regulator of toxin production (tcdC) among Clostridium difficile clinical
isolates. J Clin Microbiol. 2002;40(9):3470-5.
2
 Goncalves C, Decre D, Barbut F, Burghoffer B, Petit JC. Prevalence and characterization of a 
binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol. 2004; 
42(5):1933-9.
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of a 1-minute denaturation step at 95ºC, followed by 1-minute annealing step at 52ºC, 
and finally a 1-minute extension step at 72ºC.  Once the amplification process was 
complete the samples were held at 4ºC in the thermocycler until they could be 
transferred to the freezer.  Amplification products were run on a 2% agarose gel with 
three different controls.  The agarose gel was made by mixing 2 grams of agarose 
powder (Molecular Biology Grade, Fisher Scientific) with 100 ml of 0.5 M solution of 
Tris-Borate-EDTA (pH 8) (TBE) (Fisher Scientific) buffer in a small glass flask.  The 
agarose mixture was heated in the microwave until the agarose was completely in 
solution.  The agarose was allowed to cool on the laboratory bench until it was cool 
enough to handle (about 5 minutes) and then 2 µl of ethidium bromide (1% solution) 
(Fisher Scientific) was added to the agarose.  The agarose was slowly poured into the gel 
mold containing two, 20-well gel combs and allowed to cool for 20 to 30 minutes.  The 
gel combs and sides of the mold were removed and enough 0.5 M TBE solution was 
poured into the gel apparatus until the gel was completely submerged by at least 1mm.  
A 100-bp ladder (10X) (Lonza, Rockland, ME) was added to the first well of each gel, 
followed by four controls.  Samples were loaded into the remaining wells by adding 5 µl 
of loading dye (6X) (Lonza) to each 25 μl sample, mixing the sample well with the 
pipette, and then loading 5 µl of the sample/loading dye into a well.  The four controls 
included a negative control that did not contain C. difficile DNA template, a wild type 
strain that did not contain a deletion in the tcd gene, a sample with an 18-bp deletion in 
the tcd gene, and a sample with a 39-bp deletion in the tcd gene.  The gel was run at 140 
volts for 60 minutes and then imaged. 
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  3.4.2.2 Polymerase chain reaction for the binary toxin gene 
 The master mix for the binary toxin gene PCR was prepared by combining 12.5 
µl Jumpstart RedTaq ReadyMix, 1.0 µl BSA (10X), 3.5 µl DNA-free water, 2.5 µl 
cdtpos primer (50 μM) (IDT), and 2.5 µl cdtrev primer (50 μM) (IDT).  The 22 µl of 
master mix was added to 3 µl of C. difficile DNA template.  The samples were kept on 
ice during the procedure and once master mix was added to the template for all of the 
samples, the samples were gently centrifuged for a few seconds and then placed in the 
thermocycler.  The thermocycler protocol began with a 5-minute denaturation cycle at 
95ºC.  The next 35 cycles consisted of a 45-second denaturation step at 95ºC, followed 
by a 1-minute annealing step at 49ºC, and finally a 1-minute and 20-second extension 
step at 72ºC.  The samples were held at 4ºC in the thermocycler until they could be 
transferred to the freezer.  Amplification products were run on a 1.5% agarose gel at 140 
volts for 60 minutes and then imaged.  The agarose gel was prepared using the same 
steps mentioned above using 1.5 grams of agarose and 100 ml of 0.5 M TBE solution.  
The samples were run with a negative control that did not contain C. difficile DNA 
template and also a positive control that was known to contain the binary toxin gene. 
 
3.4.2.3 Polymerase chain reaction for detection of the toxin A and  
toxin B genes 
 The PCR for the toxin A and toxin B genes were run using the same master mix 
components and thermocycler protocol, except for the unique primers for each gene.  
The master mix for the toxin A PCR reaction consisted of 2.5 µl Accuprime Buffer II 
(10X) (Invitrogen), 0.5 µl Accuprime Taq (Invitrogen), 14.5 µl DNA-free water, 2.5 µl 
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A3C primer (5µM) (IDT), and 2.5 µl A4N primer (5µM) (IDT).  The master mix for the 
toxin B PCR reaction used the same amounts of Accuprime Buffer II, Accuprime Taq, 
and DNA-free water with 2.5 µl B1C primer (5µM) (IDT) and 2.5 µl B2N primer (5µM) 
(IDT).  The 22.5 µl of master mix for the toxin A gene was added to 2.5 µl of C. difficile 
DNA template and 22.5 µl of master mix for the toxin B gene was added to a separate 
tube with 2.5 µl of C. difficle DNA template.  The samples were kept on ice during the 
procedure and once master mix was added to the template for all of the samples, the 
samples were gently centrifuged for a few seconds and then placed in the thermocycler.  
The toxin A and B tubes were run together in the thermocycler with an initial 
denaturation cycle for 5-minutes at 95ºC.  The next 35 cycles included a 30-second 
denaturation step at 95ºC, followed by 30-second annealing step at 47ºC, and finally a 3- 
minute extension step at 68ºC.  Samples were held in the thermocycler at 4ºC until they 
could be transferred to the freezer.  Amplification products were run on a 1.5% agarose 
gel at 140 volts for 60 minutes and then imaged.  The agarose gel was prepared using the 
same instructions mentioned above.  The samples were run with a negative control that 
did not contain C. difficile DNA template and also a positive control that was known to 
contain the toxin A and toxin B genes. 
  3.4.2.4 Polymerase chain reaction for toxinotyping 
 The toxinotyping PCR consisted of three different reactions, run in three separate 
tubes, that were run in the thermocycler at the same time.  The three reactions used 
different restriction enzymes; EcoRI, HincII, and AccI.  The DNA templates for the 
reactions were the amplification products from the toxin A and toxin B gene PCR.  The 
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first reaction included 11.75 µl DNA-free water, 2.0 µl Buffer 3 (10X) (New England 
BioLabs), and 0.25 µl EcoRI enzyme (5U) (New England BioLabs) added to 6.0 µl of 
the toxin A amplification product.  The second reaction included 9.5 µl DNA-free water, 
2.0 µl Buffer 3 (10X), 2.0 µl BSA (10X), and 0.5 µl HincII enzyme (5U) (New England 
BioLabs) added to 6.0 µl of the toxin B amplification product.  The third reaction 
included 11.5 µl DNA-free water, 2.0 µl Buffer 4 (10X) (New England BioLabs), and 
0.5 µl AccI enzyme (5U) (New England BioLabs) added to 6.0 µl of the toxin B 
amplification product.  The tubes were kept on ice during the process and then all the 
tubes were gently centrifuged for a few seconds and placed in the thermocycler.  The 
samples were held at 37ºC in the thermocycler overnight and then transferred to the 
freezer.  The reaction products were run on a 1.5% agarose gel at 140 volts for 60 
minutes.  The agarose gel was prepared as previously described.   
 3.4.3 Sequencing of the tcdC gene deletion 
 A representative sample of tcdC genes from the different toxinotypes found 
among the C. difficile isolates and three control samples was sent to the DNA 
Technologies Core Laboratory at the College of Veterinary Medicine and Biomedical 
Sciences, Texas A&M University, College Station, TX.  The genes were sequenced to 
determine the presence and size of the deletions in the tcdC gene.   The three controls 
submitted included a wild strain with no deletion, a toxinotype III strain with an 18-bp 
deletion, and a toxinotype V strain with a 39-bp deletion. We provided the amplification 
products from the PCR for the tcdC gene as well as the Tim2 primer.  Sequence products 
were separated and detected on an ABI 3130xl Genetic Analyzer by the DNA 
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Technologies Core Laboratory.  Once the results were provided by the DNA 
Technologies Core Laboratory; the Basic Local Alignment Search Tool (BLAST) was 
used to confirm that the products were C. difficile and to compare with other strains of 
C. difficile in the database.  Nucleotide sequences of the representative samples were 
visually compared to the three controls to determine the size of the deletion. 
3.4.4 Pulsed-field gel electrophoresis 
Clostridium difficile isolates were further compared using pulsed-field gel 
electrophoresis (PFGE).  The PFGE procedure followed modified techniques according 
to a 7-day protocol utilized by the CDC (Angela Thompson, CDD, personal 
communication).  On the first day, an isolate was inoculated onto an anaerobic brucella 
agar plate (Anaerobe Systems) and incubated anaerobically for 48 hours at 37°C.  On 
day two, 2 ml of protein yeast glucose (PYG) broth (PathCon, Norcross, GA) in a 15-ml 
falcon tube for each sample was placed in the anaerobic chamber with a loosened cap 
and left overnight to reduce.  The following day, the PYG broth was inoculated with a 
single large C. difficile colony and after the culture incubated for 7 hours, it was used to 
make PFGE agarose plugs.  Agarose plugs were made by combining a bacterial pellet 
from 750 µl of the PYG broth culture, 300 µl Gram-Positive Lysis Buffer, and 350 µl of 
agar (0.36 g SeaKem Gold agarose (Lonza) in 20 ml Tris-EDTA (TE) buffer (10 ml of 
1M Tris (GBiosciences, St. Louis, MO) and 2 ml of 0.5M EDTA (Amresco); dilute to 
1000 ml with RO (reverse osmosis) water)).  The Gram-positive lysis buffer was 
prepared ahead of time by mixing 10.8 ml Tris-HCl (1 M, pH 8.0) (Gibco, Carlsbad, 
CA), 360 ml NaCl (5 M) (Amresco), 360 ml EDTA (0.5 M, pH 8.0) (Amresco), 9 g Brij-
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58 (Polyoxyethylene 20 Cetyl Ether) (Sigma), 3.6 g sodium deoxycholate (Sigma), and 9 
g sodium lauryl sarcosine (Sigma) in a beaker.  The solution was thoroughly mixed with 
a stir bar, poured into a 2000-ml cylinder, and allowed to settle overnight.  The next day, 
enough RO water was added to bring the volume of the buffer up to 1800 ml.  The buffer 
was filter-sterilized using a 0.22-µm disposable filter and kept at room temperature until 
ready to use.  The plugs were left in lysis buffer (for each plug; 3 ml Gram-Positive 
Lysis Buffer; 60 µl RNase (20 mg/ml) (Amresco); 15 mg lysozyme (Amresco)) 
overnight.  The fourth day involved pouring out the lysis buffer and adding proteinase K 
and Sodium lauryl sulfate (for each plug; 3 ml EDTA (0.5M, pH 8.0) (Sigma); 30 mg 
Sodium lauryl sulfate (Fisher Scientific); 3 mg proteinase K (20 mg/ml) (Amresco)) to 
the plugs to dissolve cell membranes and inactivate the proteins.  The proteinase K was 
used to protect the DNA from degradation during the purification.  The plugs were 
washed 4 times on day 5 with TE buffer for 30 minutes to remove the SDS and 
proteinase K on day 5.  On the sixth day, the plugs were restricted with 3 µl SmaI (New 
England Biolabs Inc.) in 150 µl Buffer 4 (10X) (New England BioLabs) and 2 µl BSA 
(10X) and incubated at room temperature for at least 4 hours.  Enough Salmonella 
Braenderup reference plugs were restricted to place one in every five lanes.  The 
Salmonella plugs were prepared according the instructions available on the CDC website 
for PulseNet (http://www.cdc.gov/pulsenet/protocols.htm).  The Salmonella plugs were 
restricted with 5 µl XbaI (50 units) (New England Biolabs, Inc.) in 175 µl RO water and 
20 µl of Buffer 2 (New England Biolabs, Inc.) and incubated in a 37ºC water bath for at 
least 4 hours.  A 2000-ml TBE buffer solution with thiourea (200 μM) (Sigma) was used 
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to make the gel and the remaining buffer was added to the gel chamber.  The plugs were 
loaded into a gel prepared by combining 1.5 g SeaKem Gold Agarose and 150 ml of 
TBE.  The gel was run on a Bio-Rad CHEF Mapper system (Bio-Rad, Hercules, CA) 
with the following settings: two state, gradient of 6, run time of 18 hours, included angle 
of 120, initial switch time of 5 seconds; final switch time of 40 seconds; ramping factor 
of linear.  The gel was stained with 25 µl of ethidium bromide (1% solution) in 500 ml 
of RO water for 15 minutes on a rotator, de-stained in 1000-ml RO water for 60 minutes, 
and imaged.  Images were analyzed using BioNumerics software (Applied Maths, 
Austin, TX).   
Once all PFGE patterns were determined, a final master gel was run containing 
one representative isolate for each unique pattern.  The image from this master gel was 
imported into BioNumerics software for dendrogram analysis.  Banding patterns were 
standardized using the Salmonella Braenderup placed every 6 lanes on the gel.  In the 
comparison window we performed a cluster analysis on the master gel.  The cluster 
analysis was based on a matrix of similarities between the isolate patterns and a 
subsequent algorithm for calculating the dendrogram that represented the clusters among 
the isolates (BioNumerics manual, version 5.1).  The resulting dendrogram showed the 
average percentage similarity between the individual isolate patterns.  Along with the 
dendrogram, a similarity matrix was produced.  The similarity matrix contains the 
detailed comparison data for of all the isolates; and the comparison data between any 
two isolate patterns can be easily viewed.  We chose not to include a cluster cutoff value 
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at a given similarity value to differentiate between relevant and non-relevant clusters; 
instead we chose to classify all of our isolate patterns as relevant. 
3.5 Antibiotic sensitivity testing 
 Antibiotic sensitivity testing was performed using Etest® (AB Biodisk™ North 
America, Inc., Piscatway, NJ).  Eleven different antibiotics were tested including, 
ampicillin, chloramphenicol, tetracycline, amoxicillin/clavulanic acid, imipenem, 
cefoxitin, metronidazole, ciprofloxacin, clindamycin, piperacillin/tazobactam, and 
vancomycin.  Clostridium difficile isolates were grown anaerobically for 48 hours on 
anaerobic brucella plates (Anaerobe Systems) at 37ºC.  Enough culture from the brucella 
plate was added to 1 ml of VL broth to bring the broth to a McFarland standard of 0.5.  
Six brucella agar plates were streaked in three different directions with the VL broth 
culture using a sterile cotton swab per the instructions of the manufacturer (AB 
Biodisk™ North America, Inc.).  Two different antibiotic strips were placed on the plate 
in opposite directions and spaced about 2cm apart.  Plates were incubated anaerobically 
at 37°C and read as per the manufacturer‟s instructions at 24 hours and then again at 48 
hours.  Results were reported at 48 hours and interpreted according to the breakpoints 
provided by the Clinical and Laboratory Standards Institute (CLSI) (USA, 2009) (Table 
4).  Anaerobic breakpoints for Etests were not provided for vancomycin or 
ciprofloxacin.  Vancomycin results were interpreted based on the CLSI breakpoints 
reported for Gram-positive aerobes and ciprofloxacin results were interpreted based on 
trovafloxacin CLSI breakpoints reported for Gram-positive anaerobes (Table 4).  Quality 
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control strains Bacterioides fragilis (ATCC # 25285) and B. thetaiotaomicron (ATCC # 
29741) were tested and interpreted using the recommended CLSI breakpoints. 
 
Table 4.  Interpretive MIC breakpoints for antimicrobial susceptibility 
data for Clostridium difficile. 
 
 
 
 
 
 
 
 
 
 
 
3.6 Statistical analysis 
3.6.1 Descriptive statistics 
Descriptive statistics on the prevalence of C. difficile in the swine and human 
populations were generated for the phenotypic characteristics using cross tabulation by 
year, month, season, location, and production group/group cohort.  Months were 
collapsed into seasons as follows; winter (December, January, February), spring (March, 
April, May), summer (June, July, August), and fall (September, October, November).  In 
the swine population, the production groups explored were farrowing, grower/finisher, 
Antimicrobial MIC S 
1
R
Amoxicillin-clavulanic acid ≤ 4 ≥ 16
Ampicillin ≤ 0.5 ≥ 2
Cefoxitin ≤ 16 ≥ 64
Chloramphenicol ≤ 8 ≥ 32
Clindamycin ≤ 2 ≥ 8
Imipenem ≤ 4 ≥ 16
Metronidazole ≤ 8 ≥ 32
Piperacillin-tazobactam ≤ 32 ≥ 128
Tetracycline ≤ 4 ≥ 16
Ciprofloxacin 
2
≤ 2 ≥ 8
Vancomycin 
3
≤ 4 ≥ 32
1
 Sensitive and Resistant MIC values from CLSI
2
 interpretation based on MIC for trovafloxacin
3
 interpretation based on MIC for Gram-positive aerobes
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nursery, and breeding.  In the human population, the group cohorts were swine-workers 
and the swine-non-workers.  Genotypic characteristics were also explored using 
descriptive statistics both within and between the host species.  The genotypic 
characteristics included the size of the tcdC gene deletion, presence or absence of the 
binary toxin gene, toxin A, and toxin B genes, toxinotype, and PFGE pattern.  Fisher‟s 
exact test was used to examine unconditional associations both within and between host 
species (p<0.05) and exact confidence intervals were calculated (in Stata SE Release 
10.1, Stata Corp., College Station, TX).     
3.6.2 Multi-variable logistic regression of phenotypes 
Mixed model logistic regression (xtlogit-(RE) in Stata SE Release 10.1), taking 
into account both fixed and random factors, was used to examine the association 
between risk factors and C. difficile presence within the host species.  The random effect 
in the model was the geographical swine unit to account for the dependency of responses 
by location.  The fixed factors included season, swine production group/ human 
occupational group cohort, as well as the interaction between season and production 
type/group cohort.   
3.6.3 Multi-level mixed effects logistic regression of phenotypes  
Multi-level mixed effects logistic regression (xtmelogit in Stata SE Release 10.1) 
was used to explore the association between phenotypic characteristics, both within and 
between host species and prevalence of C. difficile.  The random factors in the model 
were unit and year to account for the dependency of responses by location and time.  The 
fixed factors (phenotypic characteristics) included season, month, and swine production 
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group/ human occupational group cohort.  Season, month, and production group (for the 
swine population), were nominal variables whereas occupational group cohort (for the 
human population) was a binary variable.  The interactions of the significant fixed 
factors were also explored. 
3.6.4 Analysis of antimicrobial susceptibility data 
The antimicrobial susceptibility profiles for the host species were explored using 
Fisher‟s exact test and non-parametric survival analysis.  The susceptibility, coded as 
binary, to each antibiotic was explored between and within host species using Fisher‟s 
exact test (p<0.05) (-tabulate- in Stata SE Release 10.1).  Antimicrobial data was 
collapsed into binary categories by collapsing the susceptible and intermediate 
breakpoings into one category and then the second category included the resistant 
isolates. Non-parametric survival analysis was used to assess differences in the 
distribution of MIC values both within and between the host species (-stset- and –stsum- 
in Stata SE Release 10.1).  Log-rank, Cox, Wilcoxon, and Tarone-Ware tests were used 
to test the equality of the MIC distributions both within and between host species (-sts- 
test in Stata SE Release 10.1).  Kaplan-Meier survival curves were produced to visually 
compare the MIC distributions (-sts- graph in Stata SE Release 10.1).  Etest MIC values 
of greater than 32 (for ciprofloxacin and imipenem) or greater than 256 (for 
amoxicillin/clavulanic acid, ampicillin, cefoxitin, chloramphenical, clindamycin, 
metronidazole, piperacillin/tazobactam, tetracycline, and vancomycin) were treated as 
right-censored observations.
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4.  RESULTS 
 
4.1 Descriptive statistics 
4.1.1 Swine descriptive statistics 
A total of 2,936 swine samples were tested and 252 of the samples (8.6%) were 
culture positive for C. difficile.  The prevalence of C. difficile varied across the three 
years from a high of 13.6% in 2006 to a low of 3.9% in 2005 (Table 5).  The prevalence 
was significantly (p<0.05) different among the production groups with the highest 
prevalence (24.9%) found in the farrowing barn and the lowest prevalence (2.7%) found 
in the grower/finisher swine (Table 6).  The prevalence did not differ significantly 
(p=0.96) among the seasons (Table 7).  The average monthly prevalence was 8.5% and 
varied from a low of 5.0% in July to a high of 12.1% in September (Table 8).  Across the 
12 swine production units the prevalence varied from 14.6% to 0.9% (Table 9).  Units 
one, five, six, and seven, had the highest prevalence and all four of these units were 
farrow-to-finish units.  Unit three was also a farrow-to-finish unit, and this unit had a 
much lower prevalence than the other farrow-to-finish units.       
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Table 5.  Prevalence of Clostridium difficile in the swine fecal samples  
from 2004 to 2006. 
 
 
 
 
 
Table 6.  Prevalence of Clostridium difficile across the swine production groups. 
 
 
 
 
 
 
Table 7.  Seasonal prevalence of Clostridium difficile among swine composite fecal  
samples. 
 
 
 
 
 
 
 
 
 
 
Season Prevalence 95% Confidence Interval
Fall 9.0% (63/701) (6.7, 11.1)
Winter 8.7% (61/702) (6.6, 10.8)
Spring 8.5% (69/814) (6.6, 10.4)
Summer 8.2% (59/719) (6.2, 10.2)
Year Prevalence 95% Confidence Interval
2004 8.6% (86/999) (6.9, 10.3)
2005 3.9% (39/1002) (2.7, 5.1) 
2006 13.6% (127/935) (11.4, 15.8) 
Overall 8.6% (252/2936) (7.6, 9.6)
Production group Prevalence 95% Confidence Interval
Farrowing 24.9% (175/703) (21.7, 28.1) 
Nursery 5.1% (14/276) (2.5, 7.7)
Breeding 4.3% (26/604) (2.7, 5.9) 
Grower/finisher 2.7% (37/1353) (1.9, 3.6) 
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Table 8.  Monthly prevalence of Clostridium difficile among swine composite fecal 
samples. 
 
 
 
 
Table 9.  Prevalence of Clostridium difficile in swine fecal samples from the 12 swine 
production units (ranked from highest to lowest prevalence). 
 
 
 
 
 
Month Prevalence 95% Confidence Interval
January 8.9% (46/459) (5.5, 12.4)
February 9.3% (32/432) (5.7, 12.9)
March 8.4% (50/445) (4.9, 11.8)
April 8.7% (44/452) (5.4, 12.1)
May 8.3% (67/482) (5.1, 11.5)
June 10.7% (41/468) (7.0, 14.3)
July 5.0% (35/399) (2.1, 7.9)
August 8.4% (43/409) (4.8, 12.0)
September 12.1% (49/439) (7.9, 16.3)
October 7.6% (38/423) (4.1, 11.0)
November 7.3% (34/438) (4.1, 10.6)
December 7.6% (44/382) (3.9, 11.3)
Unit Prevalence 95% Confidence Interval Unit type
1 14.6% (59/404) (11.3, 18.4) farrow-to-finish
6 14.5% (57/392) (11.2, 18.4) farrow-to-finish
7 11.6% (47/406) (8.6, 15.1) farrow-to-finish
5 10.9% (49/449) (8.2, 14.2) farrow-to-finish
2 6.5% (8/124) (2.8, 12.3) grower-finisher
8 4.6% (6/130) (1.7, 9.8) grower-finisher
12 4.1%(8/193) (1.8, 8.0) grower-finisher
11 4.1%(5/122) (1.3, 9.3) grower-finisher
4 2.5% (3/118) (0.5, 7.3) grower-finisher
3 1.9% (7/360) (0.8, 4.0) farrow-to-finish
9 1.6% (2/124) (0.2, 5.7) grower-finisher
10 0.9%(1/114) (0.02, 4.8) grower-finisher
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4.1.2 Human descriptive statistics 
There were 2,292 human wastewater samples tested and 271 of the samples 
(11.8%) were culture positive for C. difficile.  The prevalence of C. difficile varied 
across the three years from a low of 5.8% in 2006 to a high of 18.6% in 2005 (Table 10).  
There was no significant difference (p=0.42) in the prevalence of C. difficile between the 
swine worker and swine non-worker occupational group cohorts (Table 11).  The 
prevalence of C. difficile differed significantly (p<0.05) between the seasons, with a 
higher prevalence found during the spring; this included the months of March, April, and 
May (Table 12).  The average monthly prevalence was 11.6% and varied from an 
average low of 4.9% in February to a high of 22.2% in May (Table 13).  Across the 
units, the prevalence varied from a low of 7.6% in Unit 12 to a high of 17.2% in Unit 7 
(Table 14).  Units 7 and 3 had the highest prevalence of C. difficile in the human 
wastewater samples and both of these units were farrow-to-finish units.  However, when 
we further compared the prevalence of C. difficile in the swine samples and human 
wastewater samples across the units we found that units with a high prevalence in the 
swine samples did not necessarily have a high prevalence in the human wastewater 
samples (Table 15).  Unit 3 had the lowest prevalence in the swine samples among the 
farrow-to-finish units; however, it had the second highest prevalence among the human 
samples.  Unit 13 is the slaughter plant facility and it did not have a corresponding swine 
population. 
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Table 10.  Prevalence of Clostridium difficile among the human wastewater  
samples from 2004 to 2006. 
 
 
 
Table 11.  Prevalence of Clostridium difficile among the human occupational group 
cohort wastewater samples. 
 
 
 
 
 
 
Table 12.  Seasonal prevalence of Clostridum difficile among the human wastewater  
samples. 
 
 
 
Table 13.  Monthly prevalence of Clostridium difficile among the human wastewater 
samples. 
 
 
Cohort Prevalence 95% Confidence Interval
Swine worker 12.0% (131/1090) (10.1, 14.0)
Swine non-worker 11.6% (140/1202) (9.8, 13.5)
Month Prevalence 95% Confidence Interval
January 11.4% (23/202) (7.0, 15.8)
February 4.9% (9/185) (1.8, 8.0)
March 14.9% (29/194) (9.9, 20.0)
April 11.3% (20/177) (6.6, 16.0)
May 22.2% (43/194) (16.3, 28.0)
June 6.1% (12/196) (2.8, 9.5)
July 13.5% (24/178) (8.4, 18.5)
August 13.1% (24/183) (8.2, 18.0)
September 10.1% (21/208) (6.0, 14.2)
October 10.6% (21/198) (6.3, 14.9)
November 8.3% (16/193) (4.4, 12.2)
December 15.8% (29/184) (10.5, 21.0)
Year Prevalence 95% Confidence Interval
2004 10% (82/818) (8.0, 12.1)
2005 18.6% (150/805) (15.9, 21.3) 
2006 5.8% (39/669) (4.1, 7.6) 
Overall 11.8% (271/2292) (10.5, 13.1)
Season Prevalence 95% Confidence Interval
Spring 16.3% (92/565) (13.2, 19.3) 
Summer 10.8% (60/557) (8.2, 13.4)
Winter 10.7% (61/571) (8.1, 13.2)
Fall 9.7% (58/599) (7.3, 12.1)
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Table 14.  Prevalence of Clostridium difficile among the human wastewater samples in 
the 13 units. 
 
 
 
 
Table 15.  Comparison of the prevalence of Clostridium difficile among the human  
wastewater and swine fecal samples, stratified by the 13 units. 
 
 
 
Unit Prevalence 95% Confidence Interval Unit type
7 17.2% (28/163) (11.7, 23.9) farrow-to-finish
3 15.7% (26/166) (10.5, 22.1) farrow-to-finish
12 7.6% (13/171) (4.1, 12.6) grower-finisher
10 10.1% (20/198) (6.3, 15.2) grower-finisher
2 13.0% (21/162) (8.2, 19.1) grower-finisher
5 12.8% (20/156) (8.0, 19.1) farrow-to-finish
4 10.8% (23/213) (7.0, 15.8) grower-finisher
9 13.7% (19/139) (8.4, 20.5) grower-finisher
1 10.6% (17/161) (6.3, 16.4) farrow-to-finish
11 14.1% (29/206) (9.6, 19.6) grower-finisher
8 9.9% (21/212) (6.2, 14.7) grower-finisher
6 9.1% (17/187) (5.4, 14.2) farrow-to-finish
13 10.8% (17/158) (6.4, 16.7) grower-finisher
Unit Swine Prevalence (95% C.I.) Human Prevalence (95% C.I.)
1 14.6% (11.3, 18.4) 10.6% (6.3, 16.4)
2 6.5% (2.8, 12.3) 13.0% (8.2, 19.1)
3 1.9% (0.8, 4.0) 15.7% (10.5, 22.1)
4 2.5% (0.5, 7.3) 10.8% (7.0, 15.8)
5 10.9% (8.2, 14.2) 12.8% (8.0, 19.1)
6 14.5% (11.2, 18.4) 9.1% (5.4, 14.2)
7 11.6% (8.6, 15.1) 17.2% (11.7, 23.9)
8 4.6% (1.7, 9.8) 9.9% (6.2, 14.7)
9 1.6% (0.2, 5.7) 13.7% (8.4, 20.5)
10 0.9% (0.02, 4.8) 10.1% (6.3, 15.2)
11 4.1% (1.3, 9.3) 14.1% (9.6, 19.6)
12 4.1% (1.8, 8.0) 7.6% (4.1, 12.6)
13 ND
1
10.8% (6.4, 16.7)
1
ND = not determined
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4.2 Molecular biology results 
 
4.2.1. Swine PCR results 
  
 All of the 252 C. difficile isolates arising from the swine population were further 
characterized using PCR for detecting the presence of the tcdC gene, presence of the 
binary toxin gene, presence of the toxin A and toxin B genes, and for toxinotyping.  The 
PCR for the tcdC gene is generally thought to be specific for C. difficile and, therefore, 
this test served to eliminate any false positive isolates not ruled out by the API 
biochemical panel strips.  The tcdC gene was present in all 252 of our isolates.  All 
isolates belonging to the same toxinotype will have the same tcdC gene deletion size; 
therefore, we sent a representative sample of different toxinotypes for gene sequencing.  
We found that 250 of our isolates contained the 39-bp deletion and 2 isolates did not 
contain a deletion in the tcdC gene (Table 16).  Figure 1 depicts an image of a gel 
portraying amplified products from the tcdC gene PCR.  The first five lanes in the gel 
contain a 100-bp ladder, a wild type strain with no deletion, a toxinotype III strain with 
an 18-bp deletion, a toxinotype V strain with a 39-bp deletion, and a negative control 
(not seen), respectively.  From the image it can be seen that it is difficult to visually 
differentiate between the strains with an 18-bp deletion and a 39-bp deletion; this is why 
gene sequencing of a representative sample of tcdC genes from different toxinotypes 
was necessary.  Isolates of the same toxinotype are documented to have some identical 
characteristics such as size of the tcdC gene deletion, presence or absence of the binary 
toxin gene, or presence or absence of the toxin A and toxin B genes (27) (Table 17).   
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tcdC  deletion size # of isolates
no deletion 2 (0.8%)
18 base pair 0 (0.0%)
39 base pair 250 (99.2%)
Total 252
Table 16.  Deletion sizes of the tcdC gene among Clostridium 
difficile isolated from the swine fecal samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Image of the PCR products for the tcdC gene with 
three controls run on a 2% agarose gel.  Lane 1 contains a 
100-bp ladder, Lane 2 contains a wild strain with no deletion, 
Lane 3 contains a toxinotype III with an 18-bp deletion, 
Lane 4 contains a toxinotype V with a 39-bp deletion, 
and Lane 5 contains a negative control. 
 
 
 
 
Table 17.  Toxinotype results among Clostridium difficile isolated from the swine fecal 
samples. 
 
Toxinotype Toxin A Toxin B Binary toxin tcdC deletion size # isolates
V + + + 39 bp 236
V-like - + + 39 bp 7
XI - - + 39 bp 7
Unknown 1 + + + no deletion 2
Total 252
  
96 
All 252 isolates from the swine population were positive for the binary toxin 
gene (Figure 2).  For the toxin A and toxin B genes, 238 (94.4%) of our isolates were 
positive for both the toxin A and toxin B genes (A+/B+), 7 (2.8%) were negative for the 
toxin A gene and positive for the toxin B gene (A-/B+), and 7 (2.8%) were negative for 
both the toxin A and toxin B genes (A-/B-) (Table 18).  Clostridium difficile isolates 
positive for the toxin A gene and negative for the toxin B gene have not been reported 
(143).   
 
 
Figure 2.  Image of the PCR products for the binary toxin gene run on a 1.5% agarose 
gel.  Lane 1 contains a 100-bp ladder, Lane 2 contains a toxinotype V strain that is 
known to contain the binary toxin gene, and Lane 3 contains a negative control. 
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Table 18.  Toxin A and toxin B results among Clostridium 
 difficile isolated from the swine fecal samples. 
 
 
 
 
 
 
* This combination has never been reported in the C. difficile  
literature (143). 
 
 
Figure 3 is a gel image of the amplification products from each of a toxin A and 
toxin B gene PCR.  Lane 1 contains a 100-bp ladder, Lane 2 contains a control strain 
known to contain toxin A, and Lane 3 contains a control known to contain toxin B.  
Lanes 4 and 5 as well as 6 and 7 are from isolates that were positive for both the toxin A 
and toxin B genes (A+/B+).  Lanes 8 and 9 are from an isolate that was negative for the 
toxin A gene and positive for the toxin B gene (A-/B+).  Lanes 10 and 11 are from an 
isolate that was negative for both the toxin A and toxin B genes (A-/B-).   
 
 
 
 
 
 
 
 
 
Figure 3.  Image of the PCR products for the toxin A and toxin B genes run on a  
1.5% agarose gel.  Lane 1 contains the 100-bp ladder; Lane 2 and Lane 3 are a 
toxinotype V strain that is known to be toxin A+/B+; Lanes 8 and 9 are a toxin  
A-/B+ stain; Lanes 10 and 11 are a toxin A-/B- strain. 
 
Toxin A / B # isolates
A+ / B+ 238
A- / B+ 7
A- / B- 7
A+ / B- * 0
Total 252
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The majority of the swine isolates (n=236; 93.7%) were of toxinotype V (Table 
17).  The other toxinotypes found among the swine isolates included 7 (2.8%) toxinotype 
V-like, 7 (2.8%) toxinotype XI, and 2 (0.8%) that were of the same unknown toxinotype 
(Table 17).  Toxinotype V isolates are characterized by a 39-bp deletion in the tcdC 
gene, presence of the binary toxin gene, and presence of both toxin A and B genes.  
Toxinotype V-like isolates have an identical restriction pattern for the toxin B gene as 
toxinotype V isolates, are positive for the binary toxin gene, and positive for B gene; 
however, they are negative for the toxin A gene.  Figure 4 depicts a toxinotype V 
alongside a toxinotype V-like isolate for comparison purposes.  Lane 1 contains a 100- 
bp ladder.  Lanes 2 through 4 are the EcoRI, HincII, and AccI restriction products for a 
toxinotype V isolates, respectively.  Lanes 5 through 7 are the EcoRI, HincII, and AccI 
restriction products for a toxinotype V-like isolate, respectively.   Toxinotype XI isolates 
are characterized by a 39-bp deletion in the tcdC gene, the presence of the binary toxin 
gene, and absence of both the toxin A and toxin B genes (Table 17).  The two isolates of 
an unknown toxinotype had no deletion in the tcdC gene and were positive for the binary 
toxin gene, toxin A, and toxin B genes. 
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Figure 4.  Image of a toxinotype V and toxinotype V-like isolate 
run on a 1.5% agarose gel.  Lane 1 contains a 100-bp ladder.   
Lanes 2 through 4 contain the restriction products of a toxinotype  
V isolate of the EcoRI, HincII, and AccI reactions respectively.   
Lanes 5 through 7 contain the restriction products of a toxinotype  
V-like isolate of the EcoRI, HincII, and AccI reactions respectively. 
 
 
 
There was no significant difference in toxinotypes between units (p=0.18) or 
season (p=0.07); however, there was a significant difference (p<0.05) in toxinotypes 
between production groups (Figure 5).  Toxinotype V was found in all four of the 
production group categories whereas toxinotype V-like was only found in the farrowing, 
grower/finisher, and breeding production groups.  Toxinotype XI was found in the 
farrowing and breeding and the unknown toxinotype was found in the farrowing and 
grower/finisher production groups.  All isolates in the nursery production group were 
toxinotype V
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 Figure 5.  Toxinotypes among swine production groups for the Clostridium difficile isolates. 
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All 252 isolates from the swine population were also characterized using PFGE.  
We found that 66 (26.2%) of the isolates were PFGE type NAP7 (North American 
Pulsed-field type 7) (Table 19).  The most commonly found PFGE pattern (173 isolates, 
68.7%) was a “NAP7-variant” pattern that differed only slightly from the standard NAP7 
PFGE pattern by one band.  Dendrogram analysis indicated that these patterns were 
90.5% similar (Figure 6).  There were another 13 isolates that belonged to 4 different 
unknown PFGE patterns (Table 19).  Figure 7 shows a dendrogram of the 6 different 
PFGE patterns found among the swine isolates.  The NAP7 and NAP7-variant patterns 
are the most similar (90.5%) and Unknown 2 is 86.8% similar to them.  Unknown 4, 
Unknown 1, and Unknown 3 are 82.5%, 70.0%, and 63.0% similar to the NAP7 and 
variant patterns, respectively.  This dendrogram shows that there is a high degree of 
similarity among the PFGE patterns found in the swine isolates.   
 
Table 19.  Pulsed-field gel electrophoresis patterns for positive  
Clostridium difficile isolates from the swine fecal samples. 
 
 
PFGE # isolates
NAP7 66
NAP7 variant 173
unknown 1 1
unknown 2 3
unknown 3 8
unknown 4 1
Total 252
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Figure 6.  Dendrogram comparing the NAP7 and NAP7-variant PFGE patterns. 
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Figure 7.  Dendrogram comparing the 6 different PFGE patterns found among the isolates from the swine population.
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Figure 8 shows an image of a typical PFGE gel containing restriction enzyme 
products from swine isolates.  Starting in Lane 1, every sixth lane on the gel contains a 
Salmonella Braenderup standard.  Lane 2 is a NAP7-variant PFGE pattern, Lane 3 is a 
NAP7 PFGE pattern, and Lane 21 is Unknown 4 PFGE pattern.  Each PFGE pattern can 
contain several different toxinotypes.  A total of 11 unique combinations of PFGE 
patterns and PCR toxinotypes were found among the 252 swine isolates (Table 20).  The 
majority of the isolates (64.7%) were a combination of the variant PFGE pattern and 
toxinotype V, followed next by the NAP7 PFGE pattern and toxinotype V combination 
(25.4%).  The remaining 9 combinations were found in a total of less than 5% of the 
swine fecal isolates.  We found that the PFGE pattern did not differ significantly across 
season (p=0.25); however, we did find that PFGE pattern differed significantly (p<0.05) 
across units and production groups when the 4 unknown patterns were collapsed into one 
category (Figures 9 and 10). 
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Figure 8.  Image of a typical PFGE gel for the isolates from the swine population; Lanes 1, 7, 13, and 25 contain  
a Salmonella Braenderup reference; Lanes 2, 6, 8, 9, 10, 12, 17, 18, 22, 23, and 27 contain the variant pattern;  
Lanes 3, 4, 5, 11, 14, 15, 16, 24, 26, 28 and 30 contain the NAP7 pattern; Lane 21 contains an unknown pattern. 
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Table 20.  Molecular summary results for positive Clostridium difficile isolates from the 
swine fecal samples. 
 
PFGE Toxinotype Toxin A Toxin B Binary Toxin tcdC  deletion # isolates
NAP7 V + + + 39 bp 64
NAP7 XI - - + 39 bp 1
NAP7 Unknown 1 + + + No deletion 1
Variant V + + + 39 bp 163
Variant V-like - + + 39 bp 7
Variant XI - - + 39 bp 3
Unknown 1 XI - - + 39 bp 1
Unknown 2 XI - - + 39 bp 2
Unknown 2 V + + + 39 bp 1
Unknown 3 V + + + 39 bp 8
Unknown 4 Unknown 1 + + + No deletion 1
Total 252
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Figure 9. PFGE patterns among swine production groups for Clostridium difficile isolates. 
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Figure 10.  PFGE patterns among the 12 swine units for Clostridium difficile isolates. 
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4.2.2 Human molecular biology results 
 
The 271 C. difficile isolates from the human population were further 
characterized using PCR for the tcdC gene, binary toxin gene, toxin A and toxin B 
genes, and toxinotyping.  We found that 244 (90.0%) of our human isolates contained a 
39-bp deletion, 26 (9.6%) contained no deletion, and 1 (0.4%) contained an 18-bp 
deletion in the tcdC gene (Table 21).  We also found that 244 (90.0%) of our isolates 
were positive for the binary toxin gene (Table 22).  Results from the toxin A and toxin B 
gene PCR indicated that 259 (95.6%) of the isolates were positive for both the toxin A 
and toxin B genes (A+/B+), 7 (2.6%) were negative for the toxin A gene and positive for 
the toxin B gene (A-/B+), and 5 (1.8%) were negative for both the toxin A and toxin B 
genes (A-/B-) (Table 23).   
 
 
 
Table 21.  Deletion sizes of the tcdC gene for Clostridium difficile  
isolates from culture-positive human wastewater samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tcdC  deletion size # of isolates
no deletion 26
18 base pair 1
39 base pair 244
Total 271
110 
 
 
 
1
1
0
 
Table 22.  Binary toxin results for Clostridium difficile isolates  
arising from the human wastewater samples. 
 
 
 
 
 
 
 
 
 
 
Table 23.  Toxin A and toxin B results for Clostridium difficile  
isolates arising from the human wastewater samples. 
 
 
 
 
 
 
 
* This combination has not been previously reported in the C. difficile literature (143). 
 
Binary Toxin # of isolates
positive 244
negative 27
Total 271
Toxin A / B # isolates
A+ / B+ 259
A- / B+ 7
A- / B- 5
A+ / B- * 0
Total 271
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PCR toxinotyping indicated that 229 (84.5%) of our isolates were toxinotype V, 
7 (2.6%) were toxinotype V-like, 5 (1.8%) were toxinotype XI, 1 was toxinotype III, 6 
(2.2%) were of a single unknown toxinotype (Unknown 2), 3 (1.1%) were of another 
unknown toxinotype (Unknown 3), and 20 (7.4%) were a third unknown toxinotype 
(Unknown 4) (Table 24).  Toxinotype III isolates are characterized by an 18-bp deletion 
in the tcdC gene, presence of the binary toxin gene, and presence of the toxin A and 
toxin B genes.  Unknown toxinotype 2 isolates had no tcdC gene deletion, were negative 
for the binary toxin gene, and were positive for the toxin A and toxin B genes.  
Unknown toxinotype 3 isolates had a 39-bp deletion in the tcdC gene, were positive for 
the binary toxin, toxin A, and toxin B genes, but had a different restriction pattern than 
the toxinotype V isolates.  Unknown toxinotype 4 isolates had no tcdC gene deletion, 
were negative for the binary toxin, were positive for the toxin A and toxin B genes, and 
had a different restriction pattern than unknown 2 (Table 24).  There was no significant 
difference in toxinotypes across season (p=0.12), unit (p=0.21), or occupational group 
cohort (p=0.48). 
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Table 24.  Toxinotype results for Clostridium difficile isolates arising from the human 
wastewater samples. 
 
 
Among the isolates from the human population, seventeen different PFGE 
patterns were identified.  The two most common PFGE patterns were NAP7 (23.6%) and 
a variant pattern (66.8%) that was 90.5% similar to the NAP7 pattern (Table 25).  The 
remaining 26 isolates belonged to 15 different unknown patterns (Table 25).  There was 
only one isolate for each of nine of the 15 patterns.  A dendrogram of the 17 different 
patterns showed that many of the unknown PFGE patterns in the human isolates were 
very similar (Figure 11).  Unknown 12 and Unknown 17 are the most similar (96.3%) 
and Unknown 14 and Unknown 9 are 94.4% and 93.0% similar, respectively, to 
unknown 12 and unknown 17.  There were two major clusters among the human isolates 
and the isolates in each cluster were more than 80% similar.  Unknown 3 was an outlier 
from the two clusters and showed the least similarity with the other isolates (75.5%).   
There was no significant difference in PFGE patterns among seasons (p=0.06), units 
(p=0.39), or occupational group cohorts (p=0.77).   
 
 
 
Toxinotype Toxin A Toxin B Binary toxin tcdC  deletion size # isolates
V + + + 39bp 229
V-like - + + 39bp 7
XI - - - 39bp 5
III + + + 18bp 1
Unknown 2 + + - no deletion 6
Unknown 3 + + + 39 bp 3
Unknown 4 + + - no deletion 20
Total 271
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Table 25.  Pulsed-field gel electrophoresis results for Clostridium  
difficile isolates arising from the human wastewater samples.   
See Figure 12 for images of a selection of unknown patterns. 
 
 
 
 
 
PFGE # isolates
NAP7 64
Variant 181
Unknown 3 6
Unknown 4 2
Unknown 5 2
Unknown 6 1
Unknown 7 2
Unknown 8 2
Unknown 9 3
Unknown 10 1
Unknown 11 1
Unknown 12 1
Unknown 13 1
Unknown 14 1
Unknown 15 1
Unknown 16 1
Unknown 17 1
Total 271
  
 
1
1
4
 
Pearson correlation [0.0%-100.0%]
PFGE
1
0
0
9
0
8
0
7
0
PFGE
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Unk 6
Unk 10
NAP7
Variant
Unk 5
Unk 4
Unk 11
Unk 12
Unk 17
Unk 14
Unk 9
Unk 13
Unk 7
Unk 16
Unk 15
Unk 8
Unk 3
 
Figure 11.  Dendrogram comparing the 17 different PFGE patterns found in the Clostridiium difficile isolates from the human 
population. 
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Figure 12 shows a typical image from a PFGE gel arising from the human 
isolates.  Starting with the first lane, every sixth lane contains a Salmonella Braenderup 
reference.  Lane 2 is a variant pattern, Lane 20 is an NAP7 isolate, and Lanes 6, 8, 9, 16, 
17, 18, and 27 show some of the unknown PFGE patterns.  The human population 
isolates represented a greater diversity of toxinotypes and PFGE patterns than swine; 
among the human isolates there were 29 unique combinations of PFGE patterns and 
toxinotypes (Table 26).  The majority of the isolates (61.6%) were of the variant (NAP7) 
PFGE pattern and toxinotype V followed by the NAP7 PFGE pattern and toxinotype V 
combination (22.1%).  The remaining 27 combinations were found in less than 2% of the 
isolates arising from the human population. 
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Figure 12.  PFGE gel image of restriction enzyme fragments of Clostridium difficile isolates arising from the  
human population.  Lanes 1, 7, 13, 19, 25, and 30 contain the Salmonella Braenderup reference.  Lanes 2, 3, 4, 5,  
10, 11, 12, 14, 15, 22, 23, 24, 26, 28, and 29 contain the variant pattern; Lanes 20 and 21 contain the NAP7 pattern;  
Lane 6 contains Unknown 14; Lane 8 contains Unknown 9; Lanes 9 and 27 contain Unknown 16.  Lanes 17 and  
18 contain Unknown 5. 
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Table 26.  Molecular summary results for Clostridium difficile isolates arising from the human wastewater 
 samples 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PFGE Toxinotype Toxin A Toxin B Binary Toxin tcdC  deletion # isolates
NAP7 V + + + 39-bp 60
NAP7 V-like - + + 39-bp 3
NAP7 Unknown 3 + + + 39-bp 1
Variant V + + + 39-bp 167
Variant V-like - + + 39-bp 4
Variant XI - - + 39-bp 5
Variant III + + + 18-bp 1
Variant Unknown 2 + + - no deletion 2
Variant Unknown 3 + + + 39-bp 1
Variant Unknown 4 + + - no deletion 1
Unknown 3 Unknown 2 + + - no deletion 1
Unknown 3 Unknown 4 + + - no deletion 5
Unknown 4 Unknown 2 + + - no deletion 1
Unknown 4 Unknown 4 + + - no deletion 1
Unknown 5 V + + + 39-bp 2
Unknown 6 Unknown 4 + + - no deletion 1
Unknown 7 Unknown 2 + + - no deletion 1
Unknown 7 Unknown 4 + + - no deletion 1
Unknown 8 Unknown 2 + + - no deletion 1
Unknown 8 Unknown 4 + + - no deletion 1
Unknown 9 Unknown 4 + + - no deletion 3
Unknown 10 Unknown 4 + + - no deletion 1
Unknown 11 Unknown 4 + + - no deletion 1
Unknown 12 Unknown 4 + + - no deletion 1
Unknown 13 Unknown 3 + + + 39-bp 1
Unknown 14 Unknown 4 + + - no deletion 1
Unknown 15 Unknown 4 + + - no deletion 1
Unknown 16 Unknown 4 + + - no deletion 1
Unknown 17 Unknown 4 + + - no deletion 1
Total 271
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4.2.3 Comparison of molecular results between host species 
 
The majority of the isolates in the swine population and the human population 
shared the same characteristics.  In both populations, the most prevalent toxinotype was 
toxinotype V (Figure 13) and the most prevalent PFGE type was the variant pattern 
(Figure 14).  Isolates that were the variant PFGE pattern and toxinotype V all had a 39-
bp deletion in the tcdC gene, were positive for the binary toxin gene, and were positive 
for the toxin A and toxin B genes.  Between host species there was a significant 
difference in the size of the tcdC gene deletion (p<0.001), presence or absence of the 
binary toxin gene (p<0.001), and toxinotype (p<0.001).  No significant difference 
between host species was found for the PFGE patterns (p=0.15), presence or absence of 
the toxin A gene (p=0.69), and presence or absence of the toxin B gene (p=0.57). 
Overall, there was a larger diversity of PFGE patterns and toxinotypes in the human 
population; however, the majority of the combinations that were unique to the human 
population were only represented by a single isolate (Table 27).  Figure 15 is a 
dendrogram showing the 19 different PFGE patterns found in both the human and swine 
populations.  Unknown PFGE patterns 1 and 2 were unique to the swine population, 
whereas Unknown patterns 5 through 17 were unique to the human population.  
Unknown PFGE patterns 3 and 4 were found in both the human and swine population.  
Interestingly, the Unknowns that were found in both populations were most similar to an 
Unknown found in only one of the host species.   
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Unknown 4 was 91% similar to Unknown 11, which was only found in the 
human population while Unknown 3 was 69.9% similar to Unknown 1, which was found 
only in the swine population.  When comparing Unknown isolates 1, 2, 3 and 4 in the 
dendrogram with only swine patterns (Figure 7) to the dendrogram with all 19 patterns 
(Figure 15), it is evident these isolates were more closely related to isolates found only 
in human population than to isolates found only in the swine population.  As in the 
dendrogram of the human isolates, there were 2 main clusters and within these clusters 
the isolates were more than 80% similar.  Unknown PFGE patterns 1 and 3 were the 
outliers in a separate cluster.  These patterns were 69.9% similar to each other and were 
75.4% similar to the other two clusters.  This dendrogram is evidence that there was a 
high degree of similarity between our isolates and many of the 19 patterns were clonal, 
using 80% similarity as the cutoff for clonality. 
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 Figure 13.  Comparison of Clostridium difficile PCR toxinotyping results between the host species. 
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 Figure 14.  Comparison of Clostridium difficile pulsed-field gel electrophoresis results between the host species. 
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Table 27.  Comparison of Clostridium difficile PFGE/toxinotype combinations between 
the host species. 
 
 
 
 
 
 
 
 
PFGE Toxinotype # isolates PFGE Toxinotype # isolates
NAP7 V 60 NAP7 V 64
NAP7 V-like 3 NAP7 XI 1
NAP7 Unknown 3 1 NAP7 Unknown 1 1
Variant V 167 Variant V 163
Variant V-like 4 Variant V-like 7
Variant XI 5 Variant XI 3
Variant III 1 Unknown 1 XI 1
Variant Unknown 2 2 Unknown 2 XI 2
Variant Unknown 3 1 Unknown 2 V 1
Variant Unknown 4 1 Unknown 3 V 8
Unknown 3 Unknown 2 1 Unknown 4 Unknown 1 1
Unknown 3 Unknown 4 5
Unknown 4 Unknown 2 1 Total 252
Unknown 4 Unknown 4 1
Unknown 5 V 2
Unknown 6 Unknown 4 1
Unknown 7 Unknown 2 1
Unknown 7 Unknown 4 1
Unknown 8 Unknown 2 1
Unknown 8 Unknown 4 1
Unknown 9 Unknown 4 3
Unknown 10 Unknown 4 1
Unknown 11 Unknown 4 1
Unknown 12 Unknown 4 1
Unknown 13 Unknown 3 1
Unknown 14 Unknown 4 1
Unknown 15 Unknown 4 1
Unknown 16 Unknown 4 1
Unknown 17 Unknown 4 1
Total 271
SwineHuman
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Figure 15.  Dendrogram comparing all 19 PFGE patterns found in both the swine and human populations.
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4.3 Multivariable logistic regression models 
 
4.3.1 Multivariable and multilevel mixed-effects logistic regression models for 
 the swine population 
Using a multivariable logistic regression model we tested if there was an 
important association between the fixed effects of production group, month, year, and 
season (and the interaction of these terms) and C. difficile prevalence in the swine 
population.  The random effect in the model was the unit itself, in order to account for 
the inherent dependency of responses by location.  Production group was significant 
(p<0.001), while season (p=0.94) and month (p=0.37) were not significantly associated 
with prevalence of C. difficile.  Sampling year contributed significantly to the model as a 
fixed effect (p<0.001).  The final model including unit as a random effect retained 
production group and year as the significant fixed effects (Table 28).  The interaction of 
production group and year was not found to be significant (p=0.15).  Since sampling 
year was significant to the first multivariable model, a multilevel, mixed-effects logistic 
regression model was built that took into account both unit and year as random effects to 
account for the dependency of responses by location and over time.  Production group 
remained significant (p<0.001) when unit and year were included as random effects 
(Table 29).  As in the previous model, season (p=0.83) and month (p=0.31) were 
unimportant.   
 
A large component of the variance for C. difficile prevalence initially attributed 
to the units themselves was explained by the difference in production group types across 
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the units (i.e., farrow-to-finish versus grower-to-finisher).  Once these fixed effects were 
included in the models the variance component (i.e., random effect) associated with unit 
was diminished greatly.  In the intercept-only model 54.4% of the variance was 
attributed to the unit, whereas in the final model that included the production groups 
only 32.3% of the variance was attributed to the unit.  However, the addition of 
production group to the model did not help explain any variance in C. difficile 
prevalence between years.  In the intercept only model 34.3% of the variance was 
attributed to year, whereas in the final model with production groups 37.1% of the 
variance was attributed to year.  When comparing the models with year as a random 
effect versus as a fixed effect there was little meaningful difference between the 
estimated coefficients (and adjusted odds ratios) for the production group fixed effects. 
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Table 28.  Coefficients and odds ratios from multivariable logistic regression model of the swine population with unit as a 
random effect. 
LR test of random vs. fixed effect logistic regression: χ21 d.f. = 39.10; P<0.00001 
Intercept only model – 54.4% of variance attributed to random effect of the unit.  
Final model – 32.3% of variance attributed to random effect the unit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Odds Ratio
Risk factor P-value (LR test d.f.) Category Coefficient Adjusted Odds Ratio 95%  Confidence Interval
Intercept -0.093 - -
226.01; p<0.001
Swine production group (3 d.f) farrowing(referent category) - - -
grower/finisher -2.75 0.06 0.04--0.11
nursery -1.98 0.14 0.08--0.25
breeding -2.04 0.13 0.08--0.21
54.74; p<0.001
Year (2 d.f.) 2004 (referent category) - - -
2005 -1.00 0.37 0.24--0.56
2006 0.38 1.46 1.06--2.01
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Table 29.  Coefficients and odds ratios from the multilevel mixed-effects logistic regression model of the swine population 
with unit and year treated as random effects. 
 
LR test of random vs. fixed effect logistic regression: χ22 d.f = 67.72; P<0.00001 
Intercept only model – 54.4% of variance attributed to random effect of the unit and 34.3% attributed to random effect of the year. 
Final model – 32.3% of variance attributed to random effect of the unit and 37.1% attributed to random effect of the year.
Odds Ratio
Risk factor P-value (LR test d.f.) Category Coefficient Adjusted Odds Ratio 95%  Confidence Interval
Intercept -1.13 - -
225.28; p<0.001
Swine production group (3 d.f) farrowing(referent category) - - -
grower/finisher -2.74 0.06 0.04--0.11
nursery -1.96 0.14 0.08--0.25
breeding -2.06 0.13 0.08--0.20
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4.3.2 Multivariable and multilevel mixed-effects logistic regression models for 
the human population 
 
A multivariable logistic regression model was developed to test if there was an 
association between the fixed factors of occupational group cohort, month, season, year, 
and the 2-way interactions of these terms with the prevalence of C. difficile in the human 
population.  The random effect in the model was the unit to account for the dependency 
of responses by location.  The occupational group cohort in the human population was 
not significantly (p=0.81) associated with prevalence.  Season (p=0.002), month 
(p<0.001), and year (p<0.001) were all significant.  The variable season contained the 
same data as month, except it was collapsed into the four categories winter, spring, 
summer, and fall.  Winter included December, January, and February; spring included 
March, April, and May; summer included June, July, and August; and fall included 
September, October, and November.  Since season was significantly associated with 
prevalence in bivariable analyses, this variable was included in the final model, rather 
than month, because there would be a larger number of observations in each category 
and therefore would be fewer degrees of freedom employed in the fixed portion of the 
model.  The final multivariable logistic regression model with unit as the random effect 
included season and year as fixed factors (Table 30).   
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As with the swine population, sampling year was significantly associated with 
prevalence (p<0.001) and, therefore, a multilevel mixed-effects logistic regression model 
was run that took into account both unit and year as random effects in the model in order 
to account for the dependency of responses by location and repeated over time.  The 
occupational group cohort remained not significant (p=0.93); however, season (p=0.002) 
and month (p<0.001) were significant when unit and year were included as random 
effects in univariate analysis.  The final multilevel mixed-effects logistic regression 
model for the human population with unit and year as random effects included season as 
a fixed effect rather than month (Table 31).   The variance in C. difficile prevalence 
attributed to the unit (random effect) was small (< 1.0%) and was not greatly affected by 
adding the fixed effect of season to the model.  The variance in C. difficile attributed to 
the year (21.8%) was greater than that attributed to the unit, but was also not affected by 
adding season to the model (23.6%).
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Table 30.  Coefficients and odds ratios from multivariable logistic regression model of the human population with unit as a 
random effect. 
 
LR test of random vs. fixed effect logistic regression: χ21 d.f = 0.15; P<0.35 
Intercept only model – less than 1.0% of variance attributed to random effect of the unit. 
Final model – less than 1% of variance attributed to random effect of the unit. 
 
 
 
 
 
 
 
 
 
 
 
 
Odds Ratio
Risk factor P-value (LR test d.f.) Category Coefficient Adjusted Odds Ratio 95%  Confidence Interval
Intercept -2.31 - -
15.96; p=0.001
Season (3 d.f) winter (referent category) - - -
spring 0.51 1.67 1.17--2.38
summer -0.03 0.97 0.66--1.42
fall -0.13 0.88 0.60--1.29
63.57; p<0.001
Year (2 d.f.) 2004 (referent category) - - -
2005 0.74 2.09 1.56--2.79
2006 -0.60 0.55 0.37--0.82
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Table 31.  Coefficients and odds ratios from the multilevel mixed-effects logistic regression model of the human population 
with unit and year as the random effects. 
 
LR test of random vs. fixed effect logistic regression: χ22 d.f = 19.05; P=0.0001 
Intercept only model – less than 1.0% of variance attributed to random effect of the unit and 21.8% attributed to random effect of the year. 
Final model – less than 1% of variance attributed to random effect of the unit and 23.6% attributed to random effect of the year. 
 
 
 
 
 
Odds Ratio
Risk factor P-value (LR test d.f.) Category Coefficient Adjusted Odds Ratio 95%  Confidence Interval
Intercept -2.22 - -
15.47; p=0.002
Season (3 d.f) winter (referent category) - - -
spring 0.51 1.67 1.17--2.37
summer -0.02 0.98 0.67--1.43
fall -0.12 0.88 0.60--1.30
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4.3.3 Multilevel mixed effects model for phenotypes across host species 
 
A multilevel mixed-effects model was used to test the association between the 
fixed factors of either host species or swine production group/human occupational group 
cohort (collinear/nested with host species), season, and month and the interaction of 
these factors and C. difficile prevalence in this closed population.  Unit and year were 
included as random factors in the model to account for the dependency of responses by 
location and over time.  Host species (p=0.05) or swine production group/human 
occupational group cohort (p<0.001) were significant predictors of C. difficile 
prevalence.  Season (p=0.16) and month (p=0.08) individually were not significantly 
associated with C. difficile prevalence.  However, when season was added as a fixed 
factor with either host species or production group/group cohort we found that both 
factors were significantly associated with prevalence (p<0.001).  The interaction terms 
of host species and season were also significant (p<0.05).  On the other hand, the 
interaction terms of swine production group/ human occupational group cohort and 
season were not significant (p=0.06).  Host species and swine production group/ human 
occupational group cohort were not included in the same model, because of collinearity 
and, therefore, two different final models were presented.   
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From the models in the previous sections it is evident that season was significant 
in the human population, but not in the swine population.  Therefore, season was forced 
into the final models while month was omitted.  The first model included the fixed effect 
of host species, season, and the interaction of host species and season (Table 32).  The 
second model included the fixed effect of swine production group / human occupational 
group cohort and season with swine farrowing as the referent group for the cohort type 
and winter as the referent group for season (Table 33).  As in the multivariable logistic 
regression model for the swine population, the addition of the swine production 
group/human occupational group cohort reduced the variance attributed to the unit.  In 
the intercept only model, the variance attributed to the unit was 4.7% and in the final 
model with swine production group/human occupational group cohort as a fixed factor 
the variance associated with unit was 1.9%.   
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Odds Ratio
Risk factor P-value (LR test d.f.) Category Coefficient Adjusted Odds Ratio 95%  Confidence Interval
Intercept -2.57 - -
3.98; p=0.05
host species (1 d.f) swine (referent category) - - -
human 0.39 1.48 1.01--2.17
0.45; p=0.93
season (3 d.f.) winter (referent category) - - -
spring -0.04 0.96 0.67--1.38
summer -0.03 0.97 0.66--1.41
fall 0.07 1.07 0.74--1.56
9.14; p=0.03
host species and season interaction (3 d.f.) swine winter - - -
human winter - - -
swine spring - - -
human spring 0.56 1.75 1.06--2.91
swine summer - - -
human summer 0.06 1.06 0.62--1.81
swine fall - - -
human fall -0.15 0.86 0.50--1.46
Table 32.  Coefficients and odds ratios from the multilevel mixed-effects logistic regression model for both host species; with 
host species, season, and the interaction of host species and season as the fixed factors and unit and time treated as the random 
effects. 
 
LR test of random vs. fixed effect logistic regression: χ22 d.f = 37.62; P<0.00001 
Intercept only model – 4.7% of variance attributed to random effect of the unit and 7.4% attributed to random effect of the year. 
Final model – 7.9% of variance attributed to random effect of the unit and 9.3% attributed to random effect of the year. 
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Table 33.  Coefficients and odds ratios from the multilevel mixed-effects logistic regression model for both host species; with 
swine production group/human occupational group cohort and season as the fixed factors and unit and time treated as the 
random effects. 
 
LR test of random vs. fixed effect logistic regression: χ22 d.f = 13.50; P=0.001 
Intercept only model – 4.7% of variance attributed to random effect of the unit and 7.4% attributed to random effect of the year. 
Final model – 1.9% of variance attributed to random effect of the unit and 7.3% attributed to random effect of the year. 
 
 
 
 
 
 
 
 
 
Odds Ratio
Risk factor P-value (LR test d.f.) Category Coefficient Adjusted Odds Ratio 95%  Confidence Interval
Intercept -1.25 - -
270.34; p<0.001
group cohort (5 d.f) farrowing (referent category) - - -
grower/finisher -2.46 0.09 0.06--0.13
nursery -1.85 0.16 0.09--0.28
breeding -1.98 0.14 0.09--0.21
swine non-worker -0.87 0.42 0.32--0.55
swine worker -0.84 0.43 0.33--0.57
5.49; p=0.14
season (3 d.f.) winter (referent category) - - -
spring 0.25 1.29 1.00--1.67
summer 0.04 1.04 0.79--1.37
fall -0.01 0.99 0.75--1.30
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4.4  Antimicrobial resistance data 
  
4.4.1 Swine binary antimicrobial resistance data 
 
All 252 of the swine isolates were susceptible to amoxicillin/clavulanic acid, 
piperacillin/tazobactam, and vancomycin (100% susceptibility, 0% resistance).  The 
majority of the swine isolates were susceptible to ampicillin (84.9%), chloramphenical 
(99.2%), clindamycin (56.0%), metronidazole (91.7%), and tetracycline (98.0%) (Table 
34).  The majority had decreased susceptiblity to cefoxitin (95.6%), ciprofloxacin 
(86.5%), and imipenem (58.7%) (Table 34).  In unconditional associations, there was a 
significant difference in susceptibility levels between the swine production groups for 
ciprofloxacin (p<0.001) and tetracycline (p<0.01) (Table 35).  All of the isolates in the 
nursery production group had decreased susceptibility to ciprofloxacin and tetracycline, 
and all of the isolates in the grower/finisher group had decreased susceptibility to 
tetracycline.  There was no significant difference in susceptibility among production 
groups for ampicillin (p=0.69), cefoxitin (p=0.12), chloramphenical (p=0.09), 
clindamycin (p=0.29), imipenem (p=0.06), or metronidazole (p=0.21).  At the time of 
publication the interpretation of the results for metronidazole and imipenem was under 
review due to concern in the scientific community concerning the Etest readings at 24 
and 48 hour.  Thus, in future publications the interpreted binary endpoints may be 
presented differently than those reported in this publication. 
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4.4.2 Human binary antimicrobial resistance data 
All 271 of the human isolates were susceptible to amoxicillin/clavulanic acid, 
piperacillin/tazobactam, chloramphenical, and vancomycin (100% susceptibility, 0% 
resistance).  The majority of the human isolates were susceptible to ampicillin (91.5%), 
clindamycin (87.5%), imipenem (71.2%), metronidazole (86.7%), and tetracycline 
(95.9%) (Table 36).  The majority had decreased susceptibility to cefoxitin (96.3%) and 
ciprofloxacin (98.5%) (Table 36).  There was no significant difference in susceptibility 
levels between the occupational group cohorts for ampicillin (p=0.51), cefoxitin 
(p=0.21), ciprofloxacin (p=0.36), clindamycin (p=0.35), imipenem (p=0.89), 
metronidazole (p=0.28), or tetracycline (p=0.51).  At the time of publication the 
interpretation of the results for metronidazole and imipenem was under review due to 
concern in the scientific community concerning the Etest readings at 24 and 48 hour.  
Thus, in future publications the interpreted binary endpoints may be presented 
differently than those reported in this publication. 
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Table 34.  Prevalence of resistant Clostridium difficile swine isolates and 95% confidence interval for the  
11 different antimicrobials. 
 
 
 
 
Antimicrobial Prevalence of resistance (%) 95% Confidence Interval
Amoxicillin-clavulanic acid 0.0 0.0--1.5 *
Ampicillin 15.1 10.9--20.1
Cefoxitin 95.6 92.3--97.8
Chloramphenicol 0.8 0.1--2.8
Clindamycin 44.0 37.8--50.4
Imipenem 
1
58.7 52.4--64.9 
Metronidazole 
1
8.3 5.2--12.5 
Piperacillin-tazobactam 0.0 0--1.5 *
Tetracycline 2.0 0.6--4.6
Ciprofloxacin 86.5 81.7--90.5
Vancomycin 0.0 0.0--1.5 *
* one-sided 97.5% confidence interval
1
 interpretation of the results is still under review
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Table 35.  Prevalence of resistant Clostridium difficile swine isolates and 95% confidence interval among swine production 
groups for the 11 different antimicrobials. 
 
 
Antimicrobial Prev of res (%) 95% CI Prev of res (%) 95% CI Prev of res (%) 95% CI Prev of res (%) 95% CI
Amoxicillin-clavulanic acid 0.0 0.0--2.1 * 0.0 0.0--9.5 * 0.0 0.0--23.2 * 0.0 0.0--13.2 *
Ampicillin 14.3 9.5--20.4 18.9 8.0--35.2 7.1 0.2--33.9 19.2 6.6--39.4
Cefoxitin 96.6 92.7--98.7 89.2 74.6--97.0 92.9 66.1--99.8 100.0 86.8--100 *
Chloramphenicol 0.0 0.0--2.1 * 2.7 0.1--14.2 0.0 0.0--23.2 * 3.8 0.1--19.6
Clindamycin 46.3 38.7--54.0 29.7 15.9--47.0 50.0 23.0--77.0 46.2 26.6--66.6
Imipenem 
1
62.9 55.2--70.0 45.9 29.5--63.1 71.4 41.9--91.6 42.3 23.4--63.1
Metronidazole 
1
6.3 3.2--11.0 13.5 4.5--28.8 14.3 1.8--42.8 11.5 2.4--30.2
Piperacillin-tazobactam 0.0 0.0--2.1 * 0.0 0.0--9.5 * 0.0 0.0--23.2 * 0.0 0.0--13.2 *
Tetracycline 0.6 0.01--3.1 0.0 0.0--9.5 * 0.0 0.0--23.2 * 15.4 4.4--34.9
Ciprofloxacin 89.1 83.6--93.3 89.2 74.6--97.0 100.0 76.8--100 * 57.7 36.9--76.6
Vancomycin 0.0 0.0--2.1 * 0.0 0.0--9.5 * 0.0 0.0--23.2 * 0.0 0.0--13.2 *
* one-sided 97.5% confidence interval
1
 interpretation of the results is still under review
farrowing (n=175) grower/finisher (n=37) nursery (n=14) breeding (n=26)
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Table 36.  Prevalence of resistant Clostridium difficile human isolates and 95% confidence interval for the 11  
different antimicrobials. 
Antimicrobial Prevalence of resistance (%) 95% Confidence Interval
Amoxicillin-clavulanic acid 0.0 0.0--1.4 *
Ampicillin 8.5 5.5--12.5
Cefoxitin 95.9 92.9--98.0
Chloramphenicol 0.0 0.0--1.4 *
Clindamycin 12.5 8.8--17.1
Imipenem 
1
28.8 23.5--34.6
Metronidazole 
1
13.3 9.5--17.9
Piperacillin-tazobactam 0.0 0.0--1.4 *
Tetracycline 4.1 2.1--7.2
Ciprofloxacin 98.2 95.7--99.4
Vancomycin 0.0 0.0--1.4 *
* one-sided 97.5% confidence interval
1
 interpretation of the results is still under review
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4.4.3 Comparison of binary antimicrobial resistance data across host species 
All isolates in both the swine and human populations were susceptible to 
amoxicillin/clavulanic acid, piperacillin/tazobactam, and vancomycin (100% 
susceptibility, 0% resistance).  A majority of the isolates were susceptible to ampicillin 
(88.5%), chloramphenical (99.6%), clindamycin (72.5%), imipenem (57.0%), 
metronidazole (89.3%), and tetracycline (96.9%) (Table 37).  The majority of the 
isolates had decreased susceptiblity to cefoxitin (96.0%) and ciprofloxacin (92.7%) 
(Table 37).  In unconditional analyses (unadjusted for potential confounders), when 
comparing susceptibility between host species, there was significantly (p<0.05) 
decreased susceptiblity to ampicillin, clindamycin, and imipenem among the swine 
isolates and there was significantly (p<0.05) descreased susceptiblity to ciprofloxacin 
among the human isolates (Table 38).  There was a significant difference in 
susceptibility levels among swine production group/human occupational group cohorts 
for chloramphenical (p<0.05), ciprofloxacin (p<0.001), clindamycin (p<0.001), 
imipenem (p<0.001), and tetracycline (p<0.001) (Table 39).  There was a higher 
prevalence of decreased susceptibility to chloramphenical in the older swine production 
groups when compared to the younger swine production groups and human occupational 
group cohorts.   
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A higher prevalence of decreased susceptibility for imipenem was found in the 
younger swine production groups than in the older swine production groups and human 
occupational group cohorts.  Interestingly, the highest percentage of decreased 
susceptibility to tetracycline was found in the swine breeding production group.  There 
was also a significant difference in susceptibility levels between seasons for clindamycin 
(p<0.05), imipenem (p<0.001), and tetracycline (p<0.001) (Table 40).  The highest 
percentage of decreased susceptibility for clindamycin and imipenem was found in the 
winter and the highest for tetracycline was found in the spring, although decreased 
susceptibility was low in four seasons.  At the time of publication the interpretation of 
the results for metronidazole and imipenem was under review due to concern in the 
scientific community concerning the Etest readings at 24 and 48 hour.  Thus, in future 
publications the interpreted binary endpoints may be presented differently than those 
reported in this publication. 
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Table 37.  Prevalence of resistant Clostridum difficile isolates and 95% confidence interval for all  
C. difficile isolates tested across both host species and across all production  
groups/cohorts for the 11 different antimicrobials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antimicrobial Prev of resistance (%) 95% CI
Amoxicillin / clavulanic acid (2:1) 0.0 0.0--1.1 *
Ampicillin 11.5 8.9--14.5
Cefoxitin 96.0 93.9--97.5
Chloramphenical 0.4 0.05--1.4
Ciprofloxacin 92.7 90.2--94.8
Clindamycin 27.5 23.7--31.6
Imipenen 
1
43.0 38.7--47.4
Metronidazole 
1
10.7 8.2--13.7
Piperacillin / tazobactam 0.0 0.0--1.1 *
Tetracycline 3.1 1.8--4.9
Vancomycin 0.0 0.0--1.1 *
* one-sided 97.5% confidence interval
1
 interpretation of the results is still under review
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Table 38.  Prevalence of resistant Clostridium difficile isolates and 95% confidence interval for C. difficile  
isolates compared between host species for the 11 different antimicrobials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antimicrobial Prev of resistance (%) 95% CI Prev of resistance (%) 95% CI
Amoxicillin-clavulanic acid 0.0 0.0--1.5 * 0.0 0.0--1.4 *
Ampicillin 15.1 10.9--20.1 8.5 5.5--12.5
Cefoxitin 95.6 92.3--97.8 95.9 92.9--98.0
Chloramphenicol 0.8 0.1--2.8 0.0 0.0--1.4 *
Clindamycin 44.0 37.8--50.4 12.5 8.8--17.1
Imipenem 
1
58.7 52.4--64.9 28.8 23.5--34.6
Metronidazole 
1
8.3 5.2--12.5 13.3 9.5--17.9
Piperacillin-tazobactam 0.0 0--1.5 * 0.0 0.0--1.4 *
Tetracycline 2.0 0.6--4.6 4.1 2.1--7.2
Ciprofloxacin 86.5 81.7--90.5 98.2 95.7--99.4
Vancomycin 0.0 0.0--1.5 * 0.0 0.0--1.4 *
* one-sided 97.5% confidence interval
1
 interpretation of the results is still under review
Swine Human
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Table 39.  Prevalence of resistant Clostridium difficile isolates and 95% confidence interval for C. difficile isolates compared 
across production group/occupational group cohorts for both host species for the 11 different antimicrobials. 
 
 
Antimicrobial Prev of res (%) 95% CI Prev of res (%) 95% CI Prev of res (%) 95% CI Prev of res (%) 95% CI Prev of res (%) 95% CI Prev of res (%) 95% CI
Amoxicillin-clavulanic acid 0.0 0.0--2.1 * 0.0 0.0--9.5 * 0.0 0.0--23.2 * 0.0 0.0--13.2 * 0.0 0.0--2.6 * 0 0.0--2.8 *
Ampicillin 14.3 9.5--20.4 18.9 8.0--35.2 7.1 0.2--33.9 19.2 6.6--39.4 10.0 5.6--16.2 6.9 3.2--12.6
Cefoxitin 96.6 92.7--98.7 89.2 74.6--97.0 92.9 66.1--99.8 100.0 86.8--100 * 97.1 92.8--99.2 94.7 89.3--97.8
Chloramphenicol 0.0 0.0--2.1 * 2.7 0.1--14.2 0.0 0.0--23.2 * 3.8 0.1--19.6 0.0 0.0--2.6 * 0 0.0--2.8 *
Clindamycin 46.3 38.7--54.0 29.7 15.9--47.0 50.0 23.0--77.0 46.2 26.6--66.6 15.0 9.5--22.0 9.9 5.4--16.4
Imipenem 
1
62.9 55.2--70.0 45.9 29.5--63.1 71.4 41.9--91.6 42.3 23.4--63.1 28.6 21.3--36.8 29 21.4--37.6
Metronidazole
 1
6.3 3.2--11.0 13.5 4.5--28.8 14.3 1.8--42.8 11.5 2.4--30.2 11.4 6.7--17.9 15.3 9.6--22.6
Piperacillin-tazobactam 0.0 0.0--2.1 * 0.0 0.0--9.5 * 0.0 0.0--23.2 * 0.0 0.0--13.2 * 0.0 0.0--2.6 * 0 0.0--2.8 *
Tetracycline 0.6 0.01--3.1 0.0 0.0--9.5 * 0.0 0.0--23.2 * 15.4 4.4--34.9 6.5 3.0--11.9 1.5 0.2--5.4
Ciprofloxacin 89.1 83.6--93.3 89.2 74.6--97.0 100.0 76.8--100 * 57.7 36.9--76.6 98.6 94.9--99.8 97.7 93.5--99.5
Vancomycin 0.0 0.0--2.1 * 0.0 0.0--9.5 * 0.0 0.0--23.2 * 0.0 0.0--13.2 * 0.0 0.0--2.6 * 0 0.0--2.8 *
* one-sided 97.5% confidence interval
1
 interpretation of the results is still under review
non-worker (n=140) worker (n=131)farrowing (n=175) grower/finisher (n=37) nursery (n=14) breeding (n=26)
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Table 40.  Prevalence of resistant Clostridium difficile isolates and 95% confidence interval for C. difficile isolates compared 
across seasons for both host species for the 11 different antimicrobials. 
Antimicrobial Prev of res (%) 95% CI Prev of res (%) 95% CI Prev of res (%) 95% CI Prev of res (%) 95% CI
Amoxicillin-clavulanic acid 0.0 0.0--3.0 * 0.0 0.0--2.3 * 0.0 0.0--3.1 * 0.0 0.0--3.0 *
Ampicillin 9.0 4.6--15.6 12.4 7.8--18.5 12.6 7.2--19.9 12.4 7.1--19.6
Cefoxitin 96.7 91.8--99.1 97.5 93.8--99.3 94.1 88.3--97.6 94.2 88.4--97.6
Chloramphenicol 0.0 0.0--3.0 * 1.2 0.2--4.4 0.0 0.0--3.1 * 0.0 0.0--3.0 *
Clindamycin 36.1 27.6--45.3 26.7 20.1--34.2 19.3 12.7--27.6 28.9 21.0--37.9
Imipenem 
1
55.7 46.5--64.7 46.6 38.7--54.6 35.3 26.8--44.6 33.9 25.5--43.0
Metronidazole 
1
17.2 11.0--25.1 8.1 4.4--13.4 9.2 4.7--15.9 9.9 5.2--16.7
Piperacillin-tazobactam 0.0 0.0--3.0 * 0.0 0.0--2.3 * 0.0 0.0--3.1 * 0.0 0.0--3.0 *
Tetracycline 1.6 0.2--5.8 3.8 1.4--8.0 4.2 1.4--9.5 2.5 0.5--7.1
Ciprofloxacin 94.3 88.5--97.7 93.2 88.1--96.5 89.9 83.0--94.7 92.6 86.3--96.5
Vancomycin 0.0 0.0--3.0 * 0.0 0.0--2.3 * 0.0 0.0--3.1 * 0.0 0.0--3.0 *
* one-sided 97.5% confidence interval
1
 interpretation of the results is still under review
winter (n=122) spring (n=161) summer (n=119) fall (n=121)
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4.4.4 Within and between host species differences in C. difficile minimum  
inhibitory concentrations (MIC) for 11 antimicrobials  
Non-parametric survival analysis was used to assess differences in the 
distribution of MIC values both within and between the host species.  Figures 16 through 
26 show the distribution of MIC values for the 11 different antimicrobials tested for all 
523 C. difficile isolates (i.e., across host species).  Obvious differences can be seen in the 
distribution of MIC values between the host species suggesting that a common 
parametric approach to these data would be inappropriate (Figures 16-26).  Non-
parametric approaches are robust to these differences.  Significant (p<0.05) differences 
(based on log-rank test) were found among host species with trends towards higher MIC 
values for imipenem, ampicillin, and clindamycin in the swine isolates compared to the 
human isolates (Figures 27-29).  Significant (p<0.05) trends towards higher MIC values 
for cefoxitin, ciprofloxacin, amoxicillin/clavulanic acid, piperacillin/tazobactam, 
metronidazole, and tetracycline were found in the human isolates compared to the swine 
isolates (Figures 30-35).   
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Key MIC values were expressed graphically as MIC50 and MIC90 respectively.  A 
significant (p<0.05) difference was found among swine production groups for MIC‟s for 
amoxicillin/clavulanic acid and clindamycin (Figures 36 and 37).  Reduced susceptibility 
to amoxicillin/clavulanic acid was found in the grower/finisher pigs and reduced 
susceptibility to clindamycin among pigs in the farrowing barn.  No significant 
differences (P > 0.05) were found in the resistance patterns of isolates arising from the 
different human occupational group cohorts.  At the time of publication the 
interpretation of the results for metronidazole and imipenem was under review due to 
concern in the scientific community concerning the Etest readings at 24 and 48 hour.  
Thus, in future publications the interpreted binary endpoints may be presented 
differently than those reported in this publication. 
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Figure 16.  Distribution of MIC values for ampicillin among Clostridium difficile isolated from human (n=271)  
and swine (n=252); MIC cutoff values (Susceptible≤0.5, Resistant≥2). 
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Figure 17.  Distribution of MIC values for ciprofloxacin among Clostridium difficile isolated from human  
(n=271) and swine (n=252); MIC cutoff values (Susceptible≤2, Resistant≥8). 
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Figure 18.  Distribution of MIC values for chloramphenical among Clostridium difficile isolated from human (n=271)  
and swine (n=252); MIC cutoff values (Susceptible≤8, Resistant≥32). 
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Figure 19.  Distribution of MIC values for clindamycin among Clostridium difficile isolated from human  
(n=271) and swine (n=252); MIC cutoff values (Susceptible≤2, Resistant≥8). 
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Figure 20.  Distribution of MIC values for cefoxitin among Clostridium difficile isolated from human (n=271)  
and swine (n=252); MIC cutoff values (Susceptible≤16, Resistant≥64). 
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Figure 21.  Distribution of MIC values for imipenem among Clostridium difficile isolated from human (n=271)  
and swine (n=252); MIC cutoff values (Susceptible≤4, Resistant≥16). Interpretation of results under review. 
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Figure 22.  Distribution of MIC values for metronidazole among Clostridium difficile isolated from human  
(n=271) and swine (n=252); MIC cutoff values (Susceptible≤8, Resistant≥32).  Interpretation of results is under  
review. 
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Figure 23.  Distribution of MIC values for piperacillin/tazobactam among Clostridium difficile isolated from  
human (n=271) and swine (n=252); MIC cutoff values (Susceptible≤32, Resistant≥128). 
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Figure 24.  Distribution of MIC values for tetracycline among Clostridium difficile isolated from human  
(n=271) and swine (n=252); MIC cutoff values (Susceptible≤4, Resistant≥16). 
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Figure 25.   Distribution of MIC values for vancomycin among Clostridium difficile isolated from human  
(n=271) and swine (n=252); MIC cutoff values (Susceptible≤4, Resistant≥32). 
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Figure 26.  Distribution of MIC values for amoxicillin/clavulanic acid among Clostridium difficile isolated from  
human (n=271) and swine (n=252); MIC cutoff values (Susceptible≤4, Resistant≥16). 
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Figure 27.  Non-parametric survival analysis graph of Clostridium difficile isolate MIC values for imipenem by 
 host species (p<0.001; log-rank test). 
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Figure 28.  Non-parametric survival analysis graph of Clostridium difficile isolate MIC values for ampicillin by host  
species (p<0.001; log-rank test). 
 
 
  
 
1
6
2
 
MIC50
MIC90
0
.0
0
0
.2
0
0
.4
0
0
.6
0
0
.8
0
1
.0
0
P
ro
p
o
rt
io
n
 o
f 
C
. 
d
if
fi
c
ile
 i
s
o
la
te
s
 g
ro
w
in
g
 a
t 
ln
(M
IC
) 
+
 4
0 1 2 3 4 5 6 7 8 9 10
ln(MIC) + 4
Swine Human
C. difficile MIC for clindamycin by host species
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29.  Non-parametric survival analysis graph of Clostridium difficile isolate MIC values for clindamycin  
by host species (p<0.001; log-rank test). 
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Figure 30.  Non-parametric survival analysis graph of Clostridium difficile isolate MIC values for cefoxitin by  
host species (p=0.001; log-rank test). 
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Figure 31.  Non-parametric survival analysis graph of Clostridium difficile isolate MIC values for ciprofloxacin  
by host species (p<0.001; log-rank test). 
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Figure 32.  Non-parametric survival analysis graph of Clostridium difficile isolate MIC values for  
amoxicillin/clavulanic acid by host species (p=0.003; log-rank test). 
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Figure 33.  Non-parametric survival analysis graph of Clostridium difficile isolate MIC values for  
piperacillin/tazobactam by host species (p<0.001; log-rank test). 
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Figure 34.  Non-parametric survival analysis graph of Clostridium difficile isolate MIC values for metronidazole  
by host species (p=0.03; log-rank test). 
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Figure 35.  Non-parametric survival analysis graph of Clostridium difficile isolate MIC values for tetracycline  
by host species (p=0.02; log-rank test). 
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Figure 36.  Non-parametric survival analysis graph of Clostridium difficile isolate MIC values for  
amoxicillin/clavulanic acid by swine production group (p=0.04; log-rank test). 
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Figure 37.  Non-parametric survival analysis graph of Clostridium difficile isolate MIC values for clindamycin by 
swine production group (p=0.04; log-rank test).
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5.  DISCUSSION 
 
5.1 Discussion of results 
The objectives of this study were to compare the prevalence and genotypic 
characteristics of Clostridium difficile from 2004 to 2006 in a closed and integrated 
human and swine population in Texas.  The prevalence of C. difficile in the various 
swine production groups was compared to the prevalence in the human populations to 
explore the possibility of human infections occurring due to food-borne exposure; the 
prevalence and strain types in the swine worker cohort were compared to the non-worker 
cohort to explore possible occupational exposure; and isolates from the swine and 
human samples were compared to determine genotypic similarity of isolate carriage 
among the two host species overall.   
The study population used to explore these hypotheses is unique, because it was 
a closed population, with little movement of host species (swine or human) in or out of 
the system, and contains an integrated population of both humans and swine.  Previously 
published studies regarding transmission of C. difficile between food animals and 
humans have compared isolates from separate populations (54, 100-102, 122).  It is 
difficult to make comparisons and inferences concerning transmission between species 
from separate populations, because each population has a different set of risk factors, 
and more importantly, potentially different distributions of confounders.  Differences in 
strain carriage may simply be due to geography or demographics, and carriage of similar 
strains may be a result of a common point source rather than transmission between the 
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species; indeed, this latter hypothesis bears further exploration in all closely situated 
populations given the spore-forming ability of this organism.  This is the first study to 
explore the potential transmission of C. difficile between food animals and humans in the 
same closed population of food animals and humans.  
Previous studies evaluating the transmission of C. difficile from food animals to 
humans have focused on transmission via infected food animals (53, 54, 101, 102, 122, 
123) or contamination of retail meat (48, 50, 56, 103, 123, 134-136).  Studies of 
occupational risks of C. difficile have been limited to testing clinicians in health care 
facilities (49).  Studies have investigated C. difficile strains found in food animals (54, 
100-102, 122), therapeutic dogs (125, 126), and companion animals (dogs, horses, and 
cats) (100-102, 127, 128); however, no studies have investigated the risk of direct 
occupational exposure to food animals.   
This is the first study to assess the occupational risk of C. difficile infection from 
food animals; specifically, from exposure to swine.  The unique design of this study 
allowed the investigation of C. difficile in both a swine worker group cohort and swine 
non-worker group cohort.  The swine worker and non-worker cohorts were housed 
separately, facilitating the collection of wastewater samples for each cohort and valid 
comparisons between the cohorts.  Although the cohorts were housed separately, each 
matched pair was co-located within the same unit location, and experienced similar 
living conditions.  Indeed, the food source was common to both groups.  Importantly, 
there was little to no difference between the swine workers and non-workers other than 
their occupation.    
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 Twelve of the human units sampled during the study contained a corresponding 
swine population; and the thirteenth human unit sampled was associated with the swine 
slaughter facility.  All of the swine were born, raised, and slaughtered within the system, 
except for some purebred boars that entered the system for breeding purposes.  These 
were held in quarantine for several months before being sent to each of the farrow-to-
finish facilities.   
The majority of published studies investigating C. difficile in swine have focused 
on piglets.  Clostridium difficile is known to cause diarrhea, pseudomembranous colitis, 
and enteritis in piglets (87, 96-99); however, there are few data on the prevalence of C. 
difficile in older, slaughter-age swine.  It is not known whether piglets with C. difficile 
continue to harbor the bacterium as they age or if, similar to human infants, the 
bacterium is replaced by other natural gut flora.  The prevalence of C. difficile in 
grower/finisher pigs needed to be determined in order to more fully evaluate the 
potential risks due to food-borne exposure.  The current study compared the prevalence 
of C. difficile in different production groups including farrowing barn inhabitants (sows 
and their suckling piglets), nursery (weaners), breeding (boars and dry sows), and 
grower/finisher swine.  Ours is the first study to compare C. difficile among production 
groups and especially to determine the prevalence of C. difficile among asymptomatic 
grower/finisher swine. 
 This was a longitudinal study with repeated measurements of the outcome and 
exposure variables for samples repeatedly arising from the same group cohorts over the 
3-year study period.  This differs from a traditional cohort study, because of the 
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unknown status of the outcome of interest among the study subjects at the start of the 
study, and the cohort was not simply followed until some change in disease status 
occurred.  If study subjects are known to not harbor the outcome of interest at the start of 
the investigation then the outcome measurement is incidence.  In the current study, the 
status of C. difficile in the human and swine populations was not known at the 
beginning, nor could it be reliably inferred between sample periods, so the outcome at 
each time point is instead a repeated measurement of point prevalence.  One of the 
advantages of cross-sectional studies is that multiple hypotheses regarding „risk‟ factors 
or associations can be investigated.  In the current study, the prevalence of C. difficile 
was observed in the different swine production groups and human occupational group 
cohorts as well as any seasonal trends in C. difficile prevalence.  Cross-sectional studies 
are also well-suited for time-invariant exposure measures such as the swine production 
group and human occupational group cohort, and the random effect of unit location.  The 
two major limitations of a cross-sectional study are that prevalence is the only 
measureable outcome and it is difficult to determine if the exposure (risk factor) of 
interest actually occurred before the outcome was measured (for time-variant exposures 
only).  Due to these limitations it is very difficult to prove causation using a cross-
sectional study (144).  The current study was not designed to prove causation; instead, it 
was intended to assess the prevalence of C. difficile among swine production groups and 
human occupational group cohorts and determine if associations existed that would 
warrant concern for occupational or food-borne exposure to the bacterium.  Finding 
trends in C. difficile carriage among the swine production groups or human occupational 
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group cohorts would necessitate further individual-level follow-up studies into the direct 
measure of transmission of C. difficile from swine to humans through food-borne or 
occupational exposure.   
 The samples in the current study were collected and analyzed at the group level 
rather than the individual level.  These aggregated samples were collected at the pen 
level in the swine population and at the occupational group cohort level for the human 
population (by unit).  Swine samples were classified as farrowing, nursery, breeding, or 
grower/finisher based on the barn and pen from which they were collected.  Human 
wastewater samples were classified as swine worker or swine non-worker based on the 
location of the manhole from which they were collected.  Studies in which samples are 
collected and the results are analyzed at the group level are classified as ecologic studies.  
There are several reasons for conducting ecologic studies including: measurement 
constraints at the individual level, homogeneity of the exposure, interest in group-level 
effects, and simplicity of analysis (144).  Studying C. difficile at the group level was 
preferred in this study because of several of these factors: 1) there were ethical and legal 
problems with sampling humans at the individual level, 2) the relative variability within 
the swine production groups and human occupational group cohorts was expected to be 
small and, therefore, the exposure (group cohorts) would be fairly homogenous, 3) food-
borne or occupational C. difficile infections were likely to be population-based problems, 
especially in our integrated population,  and 4) based on preliminary data, the prevalence 
of C. difficile in non-farrowing production groups was likely to be low and therefore 
analyzing at a group level would help increase the statistical power in the analysis (145).   
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Ecological fallacy occurs when inferences are made at the individual level using 
data that have been collected and analyzed at the group level (144).  Ecological fallacy is 
not a problem in the current study because the objective was to compare the prevalence 
between production group cohorts in the swine population and the occupational group 
cohorts in the human population, without inferring association at the individual-animal 
or human level.  However, care must be taken in the presentation of the results and 
understanding that from these data the effects for individual swine or humans cannot be 
inferred.  This results, from among many issues, the fact that a single positive result 
arising from a composite sample could be the result of one positive pig/human, several, 
or even all of them. 
The highest prevalence of C. difficile was found in samples from the farrowing 
barn (Table 6).  Samples from the farrowing barns were made up primarily (>95%) of 
feces from suckling piglets, but also may have contained traces of lactating sow feces.  
The swine veterinarian tasked with collecting these samples was instructed to collect 
piglet feces; however, we cannot be absolutely certain that there was never any 
contamination from the lactating sow in each of the farrowing crates.  These results are 
consistent with other studies that have found a high prevalence of C. difficile among 
piglets.  Two studies conducted in Iowa each detected C. difficile in the colon of 29% 
(97) and 42% (117) of piglets with symptoms of diarrhea, respectively.  C. difficile was 
detected in 24.9% of the farrowing barn composite fecal samples in the current study.  
The prevalence reported from the current study is slightly lower than those found in the 
studies in Iowa; however, this may be entirely attributable to the different types of 
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samples used.  Fecal samples were used in the current study whereas the authors of the 
other studies used samples from the colon obtained during necropsy of clinically ill 
piglets.  Both of the studies mentioned above sampled piglets with symptoms of diarrhea 
and in the current study asymptomatic piglets were sampled.  Interestingly, one of the 
studies conducted in Iowa also found C. difficile in the colon of 79.3% of asymptomatic 
piglets (117).  The prevalence of C. difficile found in the colon of asymptomatic piglets 
in their study was once again much higher than the 24.9% prevalence we found in the 
feces, and this difference remains unexplained.   
Alvarez-Perez et al. (2009) isolated C. difficile from 28.6% of the rectal swabs 
taken from asymptomatic piglets (1 to 7 days old) and 22.8% of the rectal swabs taken 
from symptomatic piglets (118).  Their study is more comparable to the current study 
because the authors generated their prevalence estimates from rectal swabs of 
asymptomatic piglets.  The 28.6% prevalence they found is very close to the 24.9% 
found in the current study.  The study by Alvarez-Perez also evaluated the prevalence of 
C. difficile in both symptomatic and asymptomatic piglets that were 1 to 2 months old.  
They did not detect C. difficile in any of the rectal swabs from the 1 to 2 month old 
piglets.  This is also consistent with the results in the current study that showed the 
prevalence of C. difficile declined significantly in older swine.  In the current study, the 
prevalence declined from 24.9% in the farrowing barn to 5.1% in the nursery, 4.3% in 
the breeding barn, and 2.7% in the grower/finisher swine (Table 6).  The 1 to 2 month 
old piglets mentioned in Alvarez-Perez et al. (2009) would be similar to the nursery 
production group in the current study (118).  A total of 276 fecal samples were collected 
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from the nurseries in the current study and Alvarez-Perez et al. (2009) collected 239 
rectal swab samples (118).  Although the sample size numbers are comparable, the 
samples in the current study are aggregated and therefore account for more piglets 
overall.  This may be one of the reasons a higher prevalence was found among the 
nursery piglets; however, it clearly is not the only reason.  Increasing the number of 
piglets sampled may increase the probability of detecting a lower prevalence of C. 
difficile; however this is not necessarily the case.  Another reason for detection of C. 
difficile in the nursery piglets in the current study is the culturing techniques used to 
isolate the bacterium.  Alvarez et al. (2009) used an alcohol-shock treatment followed by 
plating on selective media (118).  In the current study an alcohol-shock treatment was 
used, followed by a 7 day enrichment procedure, a second alcohol-shock treatment, and 
then plating to selective media.  The enrichment procedure used in the current study 
should increase the probability of detection (i.e., increases the test sensitivity of the 
culture method).  The study conducted by Alvarez et al. (2009) included both 
asymptomatic and symptomatic piglets; whereas the current study only included 
asymptomatic animals (118).  We would expect the inclusion of symptomatic piglets in 
the Alavarez et al. study to increase the detection probability for C. difficile; however, 
another study in calves isolated C. difficile from 14.9% of asymptomatic and 7.6% of 
symptomatic calves (95); hence, assumptions about the relationship between clinical 
illness and probability of recovery of  C. difficile may not hold true in all circumstances. 
During an initial pilot study a significantly (p<0.05) higher prevalence of C. 
difficile was found arising from swine composite fecal samples during the fall and winter 
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months (September, October, November; December, January, February) (145).  The 
estimated prevalence was 16.2% during the fall and winter months and 10.3% during the 
spring and summer months (March through August).  That pilot study included 1,008 
swine fecal samples from 2006 only.  When the additional swine samples were included 
from 2004 and 2005 a significant difference in the prevalence of C. difficile was not 
found during either the winter months (p=0.65; compared to summer) or among the four 
separate seasons (p=0.96) when adjusting for the random effects of unit and year (Table 
29).  There have been no other published studies suggesting that there are seasonal 
trends in the prevalence of C. difficile in swine; however, one study reported a 
significantly (p<0.05) increased prevalence of C. difficile in retail meat sampled during 
the months of January and February when compared to March through August (50).  
Finding an increased prevalence of C. difficile in retail meat during the winter months 
would suggest that similar trends should be found among food animals if they are, in 
fact, the source of the meat contamination.  A small sample size and disproportionate 
monthly sampling could be responsible for the differences in monthly prevalence in the 
aforementioned retail meat study (46) and further studies are needed to confirm or refute 
any reported seasonal trends of C. difficile in retail meat, as well as in feces.  Seasonal 
trends in enteric pathogen-carriage among food animals are not uncommonly reported; 
however, most studies have found an increase in prevalence during the warmer months.  
As very limited and brief illustrative examples, one study reported that cattle shed 
Campylobacter spp. more heavily in the spring and autumn (146) while another found an 
increased prevalence of E. coli O157:H7 in cattle feces during the summer months (147).   
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 Clostridium difficile has not previously been studied in human wastewater 
samples.  An overall C. difficile prevalence of 11.8% was estimated in all of the human 
wastewater samples (Table 10).  A study on the levels of human pathogens in biosolids 
from wastewater facilities detected C. difficile in 25 to 38% of their sludge samples 
(106).  Biosolids are domestic sewer sludge that have been treated for pathogen removal 
and are then used for agricultural purposes.  It is not known whether the high prevalence 
of C. difficile found in the biosolids was due to removal of other competing pathogens or 
whether biosolids provided a favorable environment for C. difficile; however, the latter 
hypothesis may be more plausible, perhaps due to the bacterium‟s spore-forming 
capacity.  It is difficult to compare the findings from the current study on human 
wastewater samples (almost entirely water with little organic matter) to those arising 
from biosolids; however, both studies found a surprisingly high prevalence of C. difficile 
in human-sourced fecal matter.  It has been estimated that 3% of healthy adults are 
asymptomatic carriers of C. difficile (2).  The human population sampled in the current 
study was comprised of asymptomatic individuals and the individual-level prevalence in 
human wastewater samples (were that achievable) would be expected to be closer to the 
prevalence in asymptomatic adults.  However since the samples in the current study 
were aggregated samples, rather than individual samples, this may help explain the 
higher prevalence.  Another reason that the prevalence in the wastewater samples may 
have been higher than expected is that the contribution of each individual‟s feces to the 
whole is unknown, as well as the subsequent dynamics of bacteria growth in the contents 
of a wastewater sample.  Wastewater samples may contain components that can either 
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enhance or hinder the survival of C. difficile.  Alcohol-shock treatment has been shown 
to enhance the recovery of C. difficile spores (133).  Wastewater samples may contain 
alcohol or other cleaning agents that promote the sporulation of C. difficile.  The 
wastewater samples may also contain bleach, which will kill vegetative C. difficile and 
its spores and therefore may be a reason for the lowered prevalence found in the 
wastewater samples as compared to the biosolids.   
 Studies on asymptomatic carriers of C. difficile have tended to focus on patients 
in hospitals and nursing homes.  One study found that 47.9% of the individuals sampled 
in a long-term care facility were asymptomatic carriers of C. difficile (105).  Another 
study found that 11.9% of the infants (< 12 months old) and 21.1% of the children (1-11 
yrs. old) sampled at a hospital in Thailand were asymptomatic carriers (104).  It is 
difficult to compare the results from the current study with the results from the 
previously mentioned studies because their study subjects were in a hospital where there 
is an increased risk of acquiring C. difficile.  The samples were also collected from 
individuals, compared to the aggregate samples used in the current study.  Also, fecal 
samples were used to test for asymptomatic carriers in the hospital studies and fecal 
samples likely have a different diagnostic sensitivity than wastewater samples. 
 A significantly (p<0.05) increased prevalence of C. difficile in the wastewater 
samples was found during the spring, which included the months of March, April, and 
May (Table 12).  There have been conflicting results regarding seasonal trends of C. 
difficile in humans while in hospitals.  A study conducted in Denmark found no seasonal 
difference in the carriage of C. difficile in hospitalized children (81), similarly another 
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study found no seasonal trends in a teaching hospital in Australia (148).  In contrast, a 
study conducted at the Veteran Administration Puget Sound Health Care System 
(VAPSHCS) in Seattle, Washington found that C. difficile followed a biannual seasonal 
pattern with an increased incidence both in the fall and spring (149).  The results from 
the current study are somewhat similar to the results found at the VAPSHCS in that the 
highest prevalence of 16.3% was found in the spring; however, a higher prevalence in 
the fall was not found.  The prevalence in the fall, winter, and summer months were all 
approximately 10.0% (Table 12).  The difference in seasonal trend results may be due to 
the study population or even the geography (i.e, the Pacific Northwest versus southeast 
Texas).  The study populations for the Denmark, Australia, and VAPSHCS studies were 
all hospitalized patients whereas our study population is likely more representative of the 
general population-at-large in the community.  Finally, all 4 of the studies were 
conducted in different geographical regions and unmeasured but varying conditions may 
be entirely responsible for the observed seasonal pattern differences in C. difficile 
carriage. 
 No significant (p=0.42) difference was found in the prevalence of C. difficile in 
wastewater samples arising from swine worker and swine non-worker housing (Table 
11).  This is the first study to assess the risk of occupational exposure to swine and C. 
difficile infection.  It has been shown that there is an increased risk of occupational 
exposure to C. difficile for health care workers in the human clinical setting (124).  C. 
difficile was isolated from 23% of health care workers in wards that contained patients 
infected with C. difficile, and 6% of workers in wards without patients infected with C. 
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difficile.  Although occupational exposure to C. difficile appears to be a concern in 
clinical settings, evidence that occupational exposure to swine is a risk factor for C. 
difficile in human wastewater samples was not found in the current study.  A reason that 
occupational exposure to C. difficile may have been found in the clinical setting is that 
study did not adjust for the statistical dependence of results for staff assigned within 
ward (124).  In the current study, multi-level mixed logistic regression was used to 
adjust for statistical dependence of wastewater samples by unit.  In the clinical study, 
there may have been other differences among the wards that caused the increase in C. 
difficile prevalence, other than the presence of patients infected with C. difficile; 
adjustment for these differences were not included in the analysis.  A second reason a 
difference in prevalence between workers and non-workers may not have been observed 
is that the farms may adhere to biosecurity measures that limit the exposure of workers 
to harmful pathogens.  Another reason a difference may not have been observed is that 
human wastewater samples from representative manholes were utilized to compare the 
worker and non-worker populations.  C. difficile prevalence in human wastewater 
samples is likely not representative of the prevalence within the individuals comprising 
the study population.  It is more likely that the prevalence from aggregated samples is 
higher than individual prevalences, because the wastewater samples from non-carriers 
may be contaminated with C. difficile by wastewater samples from carriers.  As 
discussed previously, it is also not known whether wastewater samples contain items that 
may hinder or promote the detection of C. difficile.   
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 At the farm level, the highest prevalence of C. difficile in swine was found in the 
farrow-to-finish units (Table 9).  The prevalence among the farrow-to-finish units (1, 6, 
7, 5, and 3) was 14.6%, 14.5%, 11.6%, 10.9%, and 1.9%, respectively.  It is not known 
why Unit 3 had a much lower prevalence than the other 4 farrow-to-finish units.  Some 
of the reasons for the lower prevalence may be different management practices, 
differences in antibiotic use, or (perhaps, though unlikely) geographical location.  C. 
difficile is an environmental contaminant and spores from infected swine could easily be 
spread by workers and equipment in the barns.  Biosecurity measures to restrict 
contamination of pathogens such as E. coli and Salmonella in the units may also be 
effective for controlling the spread of C. difficile.  No studies have been conducted to 
assess the risk of antibiotic use in swine and C. difficile infection; however, antibiotic 
use is the largest risk factor for infection in humans.  Swine and humans share similar 
anatomical and physiological features; therefore, antibiotic use may plausibly be 
explored as an important risk factor for C. difficile infection in swine.  The current study 
did not pursue this hypothesis; however, future studies should consider assessing 
antibiotic use, even if aggregated at the group level over longer periods such as a month 
or season.  
 There were no apparent differences in the prevalence of C. difficile in the human 
wastewater samples when comparing units (Table 14) as might be expected due to 
obvious differences such as swine farm type.  The highest prevalence in humans (17.2%) 
was observed in Unit 7 (grower-finisher unit).  Interestingly, Unit 3, which had the 
lowest prevalence among the farrow-to-finish units for swine, had the second highest 
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prevalence for the human wastewater samples.  It was also found that units with a high 
prevalence of C. difficile in swine did not necessarily have a high prevalence in humans 
(Table 15).  A difference in prevalence between swine workers and non-workers was not 
found and this could explain why a significant correlation between swine and human 
prevalence was not observed when comparing units. 
 The most prevalent toxinotype among the swine isolates was toxinotype V.  
Toxinotype V isolates are characterized by a 39-bp deletion in the tcdC gene, are 
positive for the binary toxin gene, and are positive for both the toxin A and toxin B 
genes.  A total of 93.7% of the isolates were toxinotype V and there was no significant 
difference in toxinotype prevalence in the swine isolates between units (p=0.18) or 
season (p=0.07).  However, there was a significant (p<0.05) difference in toxinotype 
prevalence between swine production groups (Figure 5).  Toxinotype V was found in all 
4 of the production groups; however, other toxinotypes were found in only 2 or 3 of the 
production groups.  The finding of toxinotype V as the dominant toxinotype in the swine 
isolates is consistent with other reports (53, 122).  A study conducted in the Netherlands 
observed that all C. difficile isolates sampled from the swine farms were toxinotype V 
(122), while a study in Slovenia estimated 76.7% (102/133) of swine isolates to be 
toxinotype V (53).   The study in Slovenia, limited in scope and scale, sampled only 
three different farms and found that toxinotype V was found exclusively on two of the 
farms; whereas toxinotype 0 was found exclusively on another of the farms.  In the 
current study, evidence of a difference in toxinotype carriage among units was not 
apparent.  Since this is the first study to assess C. difficile across swine production 
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groups the findings of toxinotype differences between production groups cannot be 
compared with other studies.  One of the reasons for the difference in toxinotypes may 
be due to the culturing techniques used in the current study.  The culturing technique 
may favor the isolation of a specific toxinotype because it may have an unknown fitness 
advantage over the other toxinotypes during the enrichment procedure.  There was also a 
large variation in the number of C. difficile isolates between production groups.  The 
highest number of C. difficile isolates was found in the farrowing production group and 
this is the only production group to exhibit all 4 toxinotypes that were found in this 
study.  At the other end of the spectrum, the nursery production group had the fewest 
number of C. difficile isolates and all of the isolates were found to be toxinotype V.  
Another reason a difference in toxinotypes may have been seen across production types 
is because of the small number of toxinotypes other than toxinotype V found in the 
study.  The 3 toxinotypes other than toxinotype V only comprised 6.3% of the isolates.   
 Overall, 6 different PFGE patterns were identified among the swine isolates.  The 
two most common PFGE patterns were NAP7 and a variant pattern that varied from 
NAP7 by only one band.  The variant pattern was 90.5% similar to the NAP7 pattern 
(Figure 6).  This pattern was actually more prevalent than NAP7, accounting for 68.7% 
of the isolates (Table 19).  The NAP7 pattern accounted for 26.2% of the isolates.  The 
remaining 4 PFGE patterns accounted for only 5.2% of the isolates.  Combining type 
taxonomies (PFGE and toxinotype), the majority of our isolates belonged to the 
toxinotype V, PFGE NAP7-variant pattern, or else the toxinotype V, PFGE NAP7 
pattern combination.  These results are consistent with other studies that have observed 
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that the majority of C. difficle isolates from swine are of toxinotype V and PFGE type 
NAP7 (personal communication Angela Thompson, CDC).  One study comparing 
toxinotype V isolates from humans and food animals reported that 6 of 14 swine isolates 
were NAP7 (54).  The remaining isolates were NAP8 and were more than 70% similar 
to the NAP7 isolates.   As in the study of toxinotype V isolates from humans and food 
animals (54), the current study found a high degree of similarity between the swine 
isolates.  All of the isolates were more than 60% similar (Figure 7).  A significant 
(p<0.05) difference in PFGE patterns was found across units and production groups 
when all the unknown PFGE patterns were collapsed into a single category (Figure 9 and 
10).  There are no published data concerning differences in PFGE patterns between 
farms or production groups; however, a previously mentioned study reported a 
difference in toxinotypes across three farms in Slovenia (53).  Another study in Slovenia 
also found the majority of their swine isolates to be toxinotype V, ribotype 066 (53), 
whereas studies in the United States have found that the majority of swine isolates are 
toxinotype V, ribotype 078 (personal communication, Angela Thompson, CDC).  These 
studies provide evidence that there may be very large geographical differences in strain 
carriage.  Ribotyping analysis was not performed in our study so we do not know which 
ribotypes are among the swine isolates.  The majority of the isolates are likely to be 
ribotype 078 based on a previous swine study conducted in the United States (101).  
Although a significant difference in strain carriage was found between swine units, this 
was largely due to the small number of strains that were not NAP7 (or its variant) and 
also the high degree of variability in detection across units.  The remaining four 
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unknown PFGE patterns accounted for only 5.2% of the isolates.  Even when all the 
unknown PFGE patterns were collapsed into a single category, there were PFGE patterns 
that were not found in many of the units.  In addition, there was a high degree of 
variability in the number of isolates found in each unit.  Only 1 or 2 isolates were 
detected in some of the units, whereas other units had close to 60 isolates each.  A far 
greater number of isolates were isolated from the farrow-to-finish units compared to the 
grower-finisher units.  Most of the difference in PFGE patterns across units can best be 
explained by the differences in the production groups. 
 The dominant toxinotype found among the human wastewater samples was also 
toxinotype V (Table 24).  Although there was a greater diversity of toxinotypes among 
the human samples, 84.5% were toxinotype V.  In addition to the toxinotypes found 
among the swine isolates, toxinotype III and three other unknown toxinotypes were 
found in the human samples.  Toxinotype III strains are responsible for the recent severe 
outbreaks in hospitals in North America and Europe (33).  Toxinotype V is not a strain 
that has been recognized as a major cause of disease in U.S. hospitals; however, it has 
been isolated from humans (150) and some studies have suggested that the rate of 
toxinotype V isolation is increasing (54).  A significant difference in toxinotypes was not 
observed across season, unit, or occupational group cohort.  In a study in the 
Netherlands, 14% of isolates from patients with CDAD were toxinotype V, 64% were 
toxinotype 0, and 16% were toxinotype III (150).  This is very different than results of 
the current study which found that 84.5%, if isolates from wastewater draining housing 
representing healthy asymptomatic humans, were toxinotype V and 0.4% were 
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toxinotype III.  No toxinotype 0 isolates were found; however, one of the three unknown 
toxinotypes may have been toxinotype 0.  One of the reasons a higher prevalence of 
toxinotype V isolates may have been found is because the samples came from 
asymptomatic individuals and the samples from the Netherlands came from patients with 
CDAD.  It has been suggested that certain strains of C. difficile may be responsible for 
community-acquired infection (130) and these may be the strains are found more 
commonly among the general public in the community.  A study conducted in the 
Netherlands found that ribotype 078 (toxinotype V) was more often associated with 
community-acquired cases than ribotype 027 (toxinotype III) (130) and this finding 
could have important implications for understanding our data.     
 Among the human wastewater isolates, 17 different PFGE patterns were found; 
however, the majority of the isolates were NAP7 and the aforementioned NAP7-like 
variant pattern (Table 25).  The variant pattern accounted for 66.8% of the isolates and 
23.6% were NAP7.  The remaining 15 unknown patterns only accounted for 26 (10.0%) 
of the isolates.  There was a high degree of pulse-type similarity among the human 
wastewater isolates.  There were two major phylogenic clusters that were more than 80% 
similar and all of the isolates were more than 75% similar.  There was no significant 
difference in prevalence of PFGE pattern types among seasons, units, or between 
occupational group cohorts.  It is difficult to compare the results from the current study 
to other studies is because most other studies have compared isolates from clinical 
human cases in health care facilities.  Studies in human health care facilities have found 
PFGE type NAP1 (toxinotype III) to be the virulent strain responsible for recent 
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outbreaks in North America and Europe (151).  While no studies of human clinical 
studies have made explicit mention of NAP7, studies have found ribotype 078, 
toxinotype V isolates among human cases and this is the strain most commonly 
associated with PFGE pattern NAP7 (130).  Thus, the lack of reporting of NAP7 may 
simply reflect differences in typing preference, which does vary greatly around the 
world.  As with toxinotype V isolates, it is unusual to find reports of a high prevalence of 
PFGE NAP7 isolates in human isolates; however, this may simply be due to the fact that 
the isolates from the current study are from asymptomatic individuals. 
 There were 29 unique combinations of PFGE pattern and toxinotype among the 
human wastewater samples (Table 26).  Although there was a large diversity of strains, 
the majority of the strains were PFGE variant pattern and toxinotype V or PFGE NAP7 
and toxinotype V combination.  The PFGE NAP7-like variant pattern and toxinotype V 
combination accounted for 61.6% of the isolates and a further 22.1% were the NAP7 and 
toxinotype V.  The remaining 27 combinations accounted for less than 2% of the isolates 
in total.  It is common in studies of human clinical cases to find limited diversity of 
strains with one or two predominant strains; however, most often the dominant strain in 
human cases is not NAP7/toxinotype V (54, 101, 115, 130).  A study conducted in the 
United States comparing animal and human isolates found that 12 different ribotypes 
among the human clinical cases and ribotype 078 (NAP7/toxinotype V) isolates 
accounted for only 4.4% of the isolates (101). Another study found that the most 
common ribotypes among human cases were 027 (NAP1/toxinotype III), ribotype 014, 
ribotype 078 (NAP7/toxinotype V), and ribotype 001; further, only 9% of the isolates 
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were ribotype 078 (NAP7/toxinotype V) (130).  Finally, a study investigating toxinotype 
V isolates in the United States found 7 toxinotype V isolates among 6,000 isolates in VA 
hospitals from 1984 to 2001 and another 8 isolates out of 620 from hospital outbreaks 
from 2001 to 2007 (54).  All of these studies provide evidence that while 
NAP7/toxinotype V strains have been found in humans; they are not at the high 
prevalence found in the current study.  Contrary to previously mentioned studies, a study 
researching CA-CDAD found NAP1/toxinotype III isolates were the most prominent 
strain and the second most prominent strain was NAP7/toxinotype V (115).  This latter 
study is likely more comparable to the results of the current study because the samples 
were from community-acquired cases rather than hospital-aquired cases.  We propose 
that one of the reasons the current study may have found a high prevalence of 
NAP7/toxinotype V strains is because this strain is more commonly associated with CA-
CDAD and asymptomatic carriers. 
 A high degree of similarity was found between swine and human strains.  The 
majority of both the swine and human isolates were the variant or NAP7 PFGE pattern 
and toxinotype V (Table 27).  All of the isolates in both populations were more than 
70% similar.  When comparing a dendrogram of the swine isolates (Figure 7) to a 
dendrogram with both host species (Figure 15), it was found that the swine isolates with 
an unknown PFGE pattern were more similar to human isolates than they were to other 
unknown PFGE swine isolates.  However, there was a significant difference in the 
presence of binary toxin gene, tcdC gene deletion size, and toxinotype among the 
isolates across host species.  The reason for the differences between host species is likely 
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because of the greater diversity of strains among the human isolates.  All of the swine 
isolates were positive for the binary toxin, whereas only 90% of the human isolates were 
positive for the binary toxin.  Isolates with a 39-bp deletion and no deletion in the tcdC 
gene were found among the swine isolates.  These two deletions were found in the 
human isolates as well, along with an 18-bp deletion.  A total of 4 toxinotypes were 
found among the swine isolates and 7 toxinotypes were found among the human isolates.  
Three of the toxinotypes found in the swine isolates were also found in the human 
isolates.  This is not the first study to find similarities between human and swine strains 
of C. difficile.  A study conducted on human clinical cases from VA hospitals and recent 
hospital outbreaks found toxinotype V human isolates that were 100% similar to swine 
isolates (54).  Another study conducted in the Netherlands compared human clinical 
isolates to those from asymptomatic and symptomatic piglets.  They compared 11 piglet 
and 21 human strains using MLVA and found that all of the strains were genetically 
related.  The researchers also found that two pairs of human and swine isolates were 
100% homologous (122, 129).  The biggest difference between our study and the 
previously mentioned studies is that our swine and human populations were both 
contained within the same closed system and in close geographical proximity.  The 
previously published studies in the United States and the Netherlands were each 
comparing human and swine strains that arose from completely different study 
populations and this makes it difficult to interpret any association between C. difficile 
infection in humans and food animal sources (54, 122, 129).  Similar strain carriage 
between host species in the same study population provides some evidence for possible 
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transmission between species; equally plausible, the evidence suggests that a common 
point source may exist for both host species within the same geographical region. 
 Although similar strain carriage was found between the two host species in the 
present study, evidence of a low risk of infection via occupational and foodborne 
exposures was found.  One reason for this may be that infection can occur from a 
common environmental source.  C. difficile spores can survive in the environment for 
long periods of time under adverse conditions.  C. difficile may be a ubiquitous 
environmental contaminant, and the more places we look for it, the more places we will 
find it.  Until recently, C. difficile research has largely been confined to clinical settings.  
As research continues outside these clinical settings we continue to find C. difficile in 
new places.  It is unknown whether C. difficile has always occurred in these places or if 
evolution of the bacterium has led to its expansion outside of the clinical setting. 
 Another reason for apparently similar strain carriage between the two host 
species it that our isolation methods may select for certain strains, making them appear 
similar even if the ratio of strains within hosts difers.  There are no standardized 
protocols for the isolation of C. difficile and a variety of different methods have been 
previously published for isolation from animal fecal samples (95) and retail meat(48, 
56).  Methods differ by the media used, enrichment times, and alcohol or heat shock 
treatments.  It is also not known if wastewater samples select for specific strains of C. 
difficile.  Even if using wastewater to sample the human population selects for specific 
strains, this would likely not affect the degree of similarity found between the 
occupational group cohorts.  Isolation of C. difficile from animal feces has been well 
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documented; however this is the first study to assess C. difficile from human wastewater 
samples.  There is no reason to believe wastewater samples select for specific strains of 
C. difficile given the higher degree of variability found in the strains from the wastewater 
samples than from the swine samples. 
 Multilevel mixed-effects logistic regression models are essential tools in 
performing data analysis where aggregation of samples occurs.  Mixed-effects models 
allow independent variables to be classified as either fixed or random effects.  Random 
effect variables may have an effect on the dependent variable; however, the nature of 
this effect is often considered a nuisance rather than an estimated factor.  Data were 
collected from 12 swine units and one additional human unit.  There are most likely 
unmeasured differences that exist between these units; for example, differing 
management techniques in the swine units.  It is unknown how such differences in the 
units may affect the prevalence of C. difficile; however, it is necessary to take into 
account the potential for clustering of (or, correlation among) responses at the unit level.  
Thus, a random-intercept model suffices for these purposes to account for dependence 
among responses and adjust for unknown or unmeasured unit-level effects.  Prevalence 
data varied significantly between years for both host species; therefore, in the multilevel 
mixed-effects model, year was also included as a random effect.  Including unit and year 
as random effects in the models accounted for the dependency of responses both by 
location and over time.   
 Multivariable and multilevel mixed-effects logistic regression models for the 
swine population illustrated that production group added significantly (p<0.001) to the 
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model when unit and year were included as random effects (Table 29).  However, season 
and month were not found to be significant (p>0.05).  A large component of the variance 
in C. difficile prevalence that was attributed to the unit in an intercept-only model could 
later be explained by the production group differences.  In the intercept only model, 
54.4% of the variance was attributed to the unit, while in the final model that included 
the production groups only 32.3% of the variance was attributed to the unit.  The units 
with the highest prevalence of C. difficile were the farrow-to-finish units; on the other 
hand, the grower-finisher unit samples typically had much lower prevalence.  As 
previously mentioned, the high prevalence of C. difficile in piglets has been well 
documented.  The finding that there is a significant difference in production groups in 
models predicting C. difficile prevalence provides potential evidence of a lowered food 
safety risk in older slaughter-aged animals. 
 In the human population, multivariable and multilevel mixed-effects logistic 
regression models suggested that season was significantly associated with prevalence 
(p=0.002),when unit and year were included as random effects (Table 31).  Occupational 
group cohort and month were unimportant.  No studies have been published concerning 
the occupational risk of C. difficile infection and exposure to swine in the workplace.  
The finding that occupational group cohort was not significant in models estimating C. 
difficile prevalence provides evidence that occupational exposure is not likely to be a 
risk factor for C. difficile infection. 
Multilevel mixed-effects logistic regression models across host species found 
that the fixed effects of host species and swine production group/human occupational 
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group cohort were significantly associated with C. difficile prevalence (p<0.05).  Note, 
however, that the major factor differences were between host species rather than within 
host species, especially as regards human samples.  Season did not contribute 
significantly to the model; however, the interaction of host species and season were 
important contributions to the model, hence season was also included in the model.  
Season was important in the human population but not significant (p<0.05) for the swine 
population; therefore, it was important to include season and the interaction of season 
and host species in the two-host model (Table 32).  Since swine production group/human 
occupational group cohort is a more exhaustive version of the host species variable, 
swine production group/human occupational group cohort were included in a separate 
model with season (Table 33).  Somewhat surprisingly, higher overall C. difficile 
prevalence was found in the human population, rather than the swine population.  Some 
speculative reasons for this may be the type of samples collected or the methods used to 
isolate the bacterium.  Both the swine fecal samples and the human wastewater samples 
were aggregated samples that represent a group of individuals.  The big difference in the 
sample collection is that isolation of C. difficile from swine fecal samples has been well 
documented (118, 123, 152), whereas the current study is the first to broadly quantify C. 
difficile isolated from upstream human wastewater sources.   
The nature of any chemicals or other compounds present in wastewater 
samples that may have hindered or promoted the growth, preservation, or detection of C. 
difficile is not known.  There was also a difference in the plating step of the isolation 
methods used for the swine and wastewater samples.  For the swine samples, 600 µl of 
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sterile de-ionized water was added to the enriched sediment before plating; for the 
human wastewater samples, only 200 µl of sterile de-ionized water was added to the 
sediment.   Less water was added to the wastewater samples because a small pellet of 
sediment resulted from the sample, whereas the swine samples resulted in a larger pellet 
that needed to be diluted with more water in order to pipette the sample onto selective 
agar.  The increased dilution to the swine samples could also be responsible for the 
lower prevalence resulting when compared with the human wastewater samples. 
 Analysis of the binary antimicrobial data found that all of the human and swine 
isolates were susceptible to amoxicillin/clavulanic acid, piperacillin/tazobactam, and 
vancomycin (Tables 34 and 36); in addition, all of the human isolates were susceptible to 
chloramphenical (Table 36).  The majority of swine isolates was susceptible to 
ampicillin, chloramphenical, clindamyacin, metronidazole, and tetracycline (Table 34); 
whereas the majority had decreased susceptibility to cefoxitin, ciprofloxacin, and 
imipenem (Table 34).  The majority of the human isolates were susceptible to ampicillin, 
clindamycin, imipenem, metronidazole (interpretation of results for metronidazole are 
under review) and tetracycline (Table 36); and the majority had decreased susceptibility 
to cefoxitin and ciprofloxacin (Table 36).  There were significantly more swine isolates 
with decreased susceptibility to ampicillin, clindamycin, and imipenem and significantly 
(p<0.05) more human isolates with decreased susceptibility to ciprofloxacin when 
comparing between host species (Table 38).   
 Comparing swine production groups, a significant (p<0.05) difference in 
susceptibility was found for ciprofloxacin and tetracycline (Table 35).  All swine isolates 
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arising from the nursery production group had decreased susceptibility to ciprofloxacin 
and tetracycline, while all isolates from the grower/finisher swine had decreased 
susceptibility to tetracycline.  No significant difference was found between human 
occupational group cohorts.  The antimicrobial usage data for the swine and human 
populations were not assessed in this study; however, varying rates of usage between 
and within the two populations may be responsible for the differences between and 
within host species (153).  The finding of differences in susceptibility patterns between 
host species and the finding of no difference between human occupational group cohorts 
would provide evidence that transmission between host species is unlikely. 
 A study in the Netherlands comparing human and animal C. difficile strains 
found both similar as well as contrasting results (122).  In contrast to the results of the 
current study, they found similar patterns for clindamycin between host species; similar 
to the results of the current study, they found patterns for metronidazole and vancomycin 
to be consistent between species.  Another study conducted in the Netherlands also 
found no significant difference in antimicrobial resistance patterns between humans and 
swine (130).  This latter study found that 94% of 49 isolates were resistant to 
ciprofloxacin and 57% were susceptible to clindamycin.  The percentage of 
ciprofloxacin resistance reported in that study is similar to the 96% resistance we found 
among our human isolates.  The majority of the isolates (77.6%) in the study from the 
Netherlands were human strains and this may be why the percent resistant to 
clindamycin more closely resembles our human results, rather than the 86.5% resistance 
we found in the swine isolates.  However, this would not explain why the 57% 
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susceptible to clindamycin in the Dutch study more closely resembles the 56% 
susceptible in the swine isolates from the current study, rather than the 87.8% 
susceptible in the human isolates.  Both of the studies conducted in the Netherlands had 
a much smaller sample size than the current study and this may be an additional reason 
why they did not find a statistically significant difference between host species.  It is also 
important to note that the human and swine populations compared in the two studies 
from the Netherlands did not arise from the same integrated system.   
 Valuable data may be lost when collapsing antimicrobial data into binary 
categories.  In addition to analyzing the binary data, survival analysis was used to assess 
the data across the actual MIC values.  Similar to results from the binary analysis, a 
significantly (p<0.05) decreased susceptibility was found among swine to ampicillin, 
clindamycin, and imipenem and significantly (p<0.05) decreased susceptibility to 
ciprofloxacin in the human isolates when comparing between host species.  In addition, 
through the MIC analysis, which includes coverage of the sub-breakpoint or cut-off 
values, significantly (p<0.05) increased levels of MIC were found in the human isolates 
to cefoxitin, amoxicillin/clavulanic acid, piperacillin/tazobactam, metronidazole, and 
tetracycline.  Significant (p<0.05) MIC differences were also found among swine 
production groups for amoxicillin/clavulanic acid and clindamycin.  As with the binary 
data analysis, no significant differences were observed across human occupational group 
cohorts.  Using survival analysis to analyze the antimicrobial data resulted in similar 
results to analysis of the binary data; however, additional findings below the cutpoints 
were also noted that would have been missed if only the binary data was analyzed.  
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These latter findings are most important in assessing the emergence of resistance (i.e., 
beyond the established breakpoint) before it becomes widespread. 
 The most common risk factor for C. difficile is antibiotic use (154).  This 
relationship with antibiotic use makes it difficult to both prevent and treat C. difficile 
infections.  In the 1970‟s C. difficile first was linked to the use of clindamycin.  Health 
care practitioners began to decrease the use of clindamycin and in the 1980‟s and 1990‟s 
cephalosporins were more heavily prescribed (35).  Fluoroquinolone use began in the 
late 1980‟s, and in 2001 a study linked ciprofloxacin use to CDAD (155).  The high 
level of ciprofloxacin resistance in the human isolates in our study is not surprising 
because the problem of fluoroquinolone resistance in health care facilities has been well 
documented (156-159).  One of these studies assessed the antimicrobial resistance of C. 
difficile strains found in European hospitals and found a high level of resistance to a 
variety of fluoroquinolones, including ciprofloxacin (156).  Clindamycin resistance in C. 
difficile is often associated with the virulent strain (NAP1/ribotype 027/toxinotype III) 
responsible for recent outbreaks (160, 161).  The finding of low levels of resistance to 
clindamycin in the human samples in our study is encouraging and most likely relates to 
fact that we only found one toxinotype III isolate.  The antibiotics most commonly 
prescribed to treat CDAD are metronidazole and vancomycin.  Treatment of CDAD will 
be complicated by the discovery of strains resistant to these antibiotics.  All of our 
human isolates were susceptible to vancomycin; on the other hand, 12.9% of our isolates 
were resistant to metronidazole.  Resistance to metronidazole appears to be increasing; 
often, initial treatment with metronidazole is unsuccessful in treating CDAD and 
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subsequent vancomycin treatment is needed (162).  Despite this, the majority of reported 
studies have found no resistance to either vancomycin or metronidazole (163, 164).  It is 
important to note that at the time of publication the interpretation of the results for 
metronidazole and imipenem was under review.  Many of the isolates classified as 
resistant to metronidazole or imipenem based on the CLSI breakpoints, showed vastly 
different results between 24 and 48 hours.  Many of the isolates had MIC values that 
were classified as susceptible (based on CLSI breakpoints) at 24 hours, but at 48 hours 
there would be additional hazy growth on the plate, resulting in MIC values that would 
then be classified as resistant.  Differing results for metronidazole or imipenem between 
24 and 48 hours has not previously been reported in the C. difficile literature.  A random 
sample of isolates classified as resistant to metronidazole, will be tested again using a 
new batch of Etest strips, to ensure the previous results are accurate.  One of the reasons 
we may have found decreased susceptibility to metronidazole in the isolates of the 
current study may be due to the strains found in this population.  The toxinotype V 
strains found in this study are not one of the strains typically isolated from patients in a 
clinical setting.  One hypothesis may be that toxinotype V strains have a decreased 
susceptibility to metronidazole in comparison to strains found in the clinical setting. 
5.2 Future Work 
 The isolates from the current study are currently undergoing ribotyping analysis 
and MLVA analysis through collaborative agreements with the Ohio State University 
and the University of Pittsburgh, respectively.  This will allow the comparison of PFGE, 
ribotyping, and MLVA results.  It will also allow for the comparison of results from the 
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current study to other studies that have used ribotyping, and not PFGE, to determine 
similarity of strains.  In addition, investigation into the antimicrobial susceptibility 
results for metronidazole and imipenem will continue.  Researchers are currently 
sequencing isolates resistant to metronidazole and it will be interesting to determine 
similarities or differences between those isolates and the isolates from the current study. 
Further research is needed to investigate the possible sources of community-
acquired C. difficile infection.  The current study provides evidence that occupational 
and food-borne exposures are less likely sources of these community-acquired 
infections.  Continuing to research C. difficile outside of the health care facility setting 
will help further the understanding of community-acquired infections and may lead to 
new hypotheses on possible sources of infection.   
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6.  CONCLUSIONS 
 
 The objectives of this study were to assess the possible food-borne and 
occupational exposure risks of C. difficile in an integrated human and swine population.  
This is the first study to explore the risk of C. difficile infection in humans arising from 
occupational exposure to swine.  It is also the first study to examine the varied 
prevalence of C. difficile across different swine production groups.  There have been 
several studies that have explored the potential transmission of C. difficile from food 
animals to humans, often focusing on food animal products in the form of retail meats 
(e.g., ready-to-eat, frozen, and fresh meats).  Many of these studies have focused on 
comparing strains between the host species, then drawing conclusions on the direction of 
flow for strains exhibiting shared carriage.  Generally, the limitations of those studies are 
1) the strains from the different host species have originated from separate study 
populations and 2) when the food animals are swine, the study population has focused 
only on piglets.  The current study is different from previous studies in that samples 
were collected from a closed population that contained both a human and swine 
population.  The human population consisted of a swine worker group cohort and a 
swine non-worker group cohort that were housed separately from one another on each of 
13 units.  The swine population flowed vertically from the farrowing barn to the 
grower/finisher slabs and all swine were slaughtered and then pork products were 
consumed entirely within the system.   
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 The prevalence of C. difficile among the swine production groups was assessed 
in order to determine the potential for risk of human infection due to food-borne 
exposure.  C. difficile is a known cause of diarrhea and psuedomembranous colitis in 
piglets; however, little is known about the bacteria in the other swine production groups.  
Consistent with other studies, the highest prevalence of C. difficile was found in the 
farrowing barn.  The prevalence of C. difficile declined significantly in the other 
production groups with the lowest prevalence in the grower/finisher swine.  The lowered 
prevalence of C. difficile in the grower/finisher swine may be indicative of a diminished 
risk of food-borne exposure than was previously assumed.  No seasonal trends in C. 
difficile carriage were found in the swine population. 
The risk of C. difficile infection from occupational exposure to swine was 
assessed by comparing the prevalence of C. difficile in human wastewater samples 
arising from each of the swine worker and non-worker cohorts.  No significant 
difference was found in the prevalence of C. difficile between the occupational group 
cohorts; this should be indicative of a low risk of human C. difficile infection specifically 
arising from occupational exposure to swine.  However, a significant seasonal difference 
in the carriage of C. difficile was found among the human population, with a higher 
prevalence of C. difficile during the spring (March, April, and May).  Seasonal patterns 
in bacteria carriage are not unusual and there have been conflicting results about the 
seasonal trends of C. difficile in hospitals.  While a seasonal difference in carriage was 
found in samples arising from the human population, no seasonal trends were found in 
samples arising from the swine population.  Exposure to environmental sources of C. 
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difficile and differences in these environments among host species also may explain 
variations in seasonal carriage.   
Although no evidence of transmission of C. difficile via occupational or food-
borne exposure was found, very similar strain carriage was found between the two host 
species.  Many studies have found similar C. difficile strains in human and swine 
populations; however, the isolates arising from each of those host species were from 
different study populations, or else not formally sampled from the same targeted 
population.  The results from the current study suggest that rather than focusing on the 
„flow‟ of C. difficile between hosts, identifying a common environmental point source 
for this spore-forming gram negative bacterium might be a more prudent approach.  
Indeed, it is quite possible that food (and feed) could be a quite suitable fomite or 
delivery mechanism for the spores to reach both humans and swine, respectively.  
However, since this does not fit the classic public health construct of a foodborne 
pathogen, perhaps the term „food vectored‟ pathogen would be better suited to this 
situation. 
 The results from our swine population are consistent with other studies that have 
found that the majority of swine isolates are toxinotype V, PFGE NAP7 (or else a 
variant pattern that is 90.5% similar).  The finding that the majority of our human 
isolates were also of this same strain is surprising.  Toxinotype V, PFGE NAP7 strains 
have been found in humans; however, not nearly at as high prevalence as found in our 
study.  One reason similar strains may have been found in both host species is the 
isolation method used to culture the bacteria.  The isolation method we used to culture C. 
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difficile may select for certain strains.  Another reason for the similar strain carriage is 
that our human isolates came from asymptomatic individuals.  It has been suggested that 
the strains responsible for community-acquired C. difficile are different than those in 
hospital-acquired cases.  If asymptomatic carriers are responsible for community-
acquired infections then they will share similar strain carriage.  A third reason for the 
similar strain carriage between the two host species is that infection can occur from a 
common environmental source.  C. difficile spores can survive in the environment for 
long periods of time under adverse conditions.  C. difficile may be a ubiquitous 
environmental contaminant, and the more places we look for it, the more places we will 
find it. 
Further research is needed to investigate the possible sources of community-
acquired C. difficile infection and the component causes needed to propagate the strains 
associated with CDAD.  The current study provides evidence that occupational and 
food-borne exposures are less likely sources of these community-acquired bacteria.  
Continuing to research C. difficile outside of the health care facility setting will help 
further the understanding of community-acquired infections and may lead to new 
hypotheses on possible sources of infection (necessary causes), and their relative 
contributions to CA-CDAD when compared to the other component (if insufficient) 
cuases of disease.   
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